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COMPOSITIONS AND METHODS OF 
MODULATING 15-PGDH ACTIVITY 
RELATED APPLICATION 
This application claims priority from U.S. Provisional 
Application No. 61/624,670, filed Apr. 16, 2012, the subject 
matter of which is incorporated herein by reference in its 
entirety. 10 
GOVERNMENT FUNDING 
This invention was made with govermnent support under 15 
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BACKGROUND 
15-hydroxy-prostaglandin dehydrogenase (15-PGD H)
represents the key enzyme in the inactivation of a number of 
25 
active prostaglandins, leukotrienes and hydroxyeicosatetra­
enoic acids (HETEs) (e.g., by catalyzing oxidation of PGE2 
to 15-keto-prostaglandin E2, 15k-PGE). The human enzyme 
is encoded by the HPGD gene and consists of a homodimer 
with subunits of a size of 29 kDa. The enzyme belongs to the 30 
evolutionarily conserved superfamily of short-chain dehy­
drogenase/reductase enzymes (SDRs), and according to the 
recently approved nomenclature for human enzymes, it is 
named SDR36Cl. Thus far, two forms of 15-PGDH have 
been identified, NAD+-dependent type I 15-PGDH and the 35 
type II NADP-dependent 15-PGDH, also known as carbonyl 
reductase 1 (CBRl, SDR21Cl). However, the preference of 
CBRl for NADP and the high Km values of CBRl for most 
prostaglandin suggest that the majority of the in vivo activity 
can be attributed to type I 15-PGDH. 40 
Recent studies suggest that inhibitors of 15-PGDH and 
activators of 15-PGDH could be therapeutically valuable. It 
has been shown that there is an increase in the incidence of 
colon tumors in 15-PGDH knockout mouse models. A more 
recent study implicates increased 15-PGDH expression in 45 
the protection of thrombin-mediated cell death. It is well 
known that 15-PGDH is responsible for the inactivation of 
prostaglandin E2 (PGE2), which is a downstream product of 
COX-2 metabolism. PGE2 has been found to be neurotoxic 
both in vitro and in vivo; thus, COX-2 specific inhibitors, 50 
which decrease PGE2 release, exhibit neuroprotective 
effects. PGE2 has also been shown to be beneficial in a 
variety of biological processes, such as hair density, dermal 
wound healing, and bone formation. 
55 
SUMMARY 
Embodiments described herein relate to compounds and 
methods of modulating 15-PGDH activities, modulating 60 
tissue prostaglandin levels, and/or treating diseases, disor­
ders, or conditions in which it is desired to modulate 
15-PGDH activity and/or prostaglandin levels.
In some embodiments, a 15-PGDH inhibitor can be
administered to a tissue of a subject at an amount effective 65 
to increase prostaglandin levels in the tissue. The 15-PGDH 
inhibitor can include formula (I): 
2 
(I) 
wherein n is 0-2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted (e.g., R1 can be a 
C2_6 alkyl, C2_4 alkyl, or C4 alkyl, which is linear, 
branched, or cyclic and which is unsubstituted or 
substituted); 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)niOR' (wherein nl=l, 2, or 3), CF3, CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is H or a lower alkyl group); 
R4 and Rs are the same or different and are each selected 
from the group consisting of hydrogen, C1 -C24 alkyl, 
C2-C24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, CcC24 
alkaryl, C6-C24 aralkyl, halo, silyl, hydroxyl, sulfhy­
dryl, C1 -C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alky­
nyloxy, Cs-C20 aryloxy, acyl (including C2-C24 alkyl­
carbonyl (-CO-alkyl) and CcC20 arylcarbonyl 
(-CO-aryl)), acyloxy (-0-acyl), C2-C24 alkoxycar­
bonyl (-(C0)---0-alkyl), C6-C20 aryloxycarbonyl 
(-(C0)---0-aryl), C2-C24 alkylcarbonato (-O­
(C0)---0-alkyl), CcC20 arylcarbonato (---0-(CO)­
O-aryl), carboxy (-COOH), carboxylato (-Coo-), 
carbamoyl (-(CO)-NH2), C1 -C24 alkyl-carbamoyl 
(-(CO)-NH(C1 -C24 alkyl)), arylcarbamoyl 
(-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), 
carbamido (-NH-(CO)-NH2), cyano(----CN), iso­
cyano (-N+c-), cyanato (---0-CN), isocyanato
(-0-N+=C-), isothiocyanato (-S----CN), azido
(-N W W), formyl (-(CO)-H), thioformyl 
(-(CS)-H), amino (-NH2), C1-C24 alkyl amino, 
Cs-C20 aryl amino, C2-C24 alkylamido (-NH-(CO)­
alkyl), C6-C20 arylamido (-NH-(CO)-aryl), imino
(-CR NH where R is hydrogen, C1-C24 alkyl, 
Cs-C20 aryl, C6-C24 alkaryl, C6-C24 aralkyl, etc.), alky­
limino (----CR=N(alkyl), where R= hydrogen, alkyl, 
aryl, alkaryl, aralkyl, etc.), arylimino (----CR=N(aryl), 
where R= hydrogen, alkyl, aryl, alkaryl, etc.), nitro 
(-N02), nitroso (-NO), sulfa (-S02-0H), sul­
fonato (-S02---0-), C1-C24 alkylsulfanyl (-S-alkyl; 
also termed "alkylthio"), arylsulfanyl (-S-aryl; also 
termed "arylthio"), C1 -C24 alkylsulfinyl (-(SO)­
alkyl), Cs-C20 arylsulfinyl (-(SO)-aryl), C1-C24 alkyl­
sulfonyl (-S02-alkyl), Cs-C20 arylsulfonyl (-S02-
aryl), phosphono (-P(O)(OH)2), phosphonato (-P 
(0)(0-)2), phosphinato (-P(O)(O-)), phospho 
(-P02), phosphino (-PH2), combinations thereof, 
and wherein R4 and Rs may be linked to form a cyclic 
or polycyclic ring, wherein the ring is a substituted or 
unsubstituted aryl, a substituted or unsubstituted het­
eroaryl, a substituted or unsubstituted cycloalkyl, and a 
substituted or unsubstituted heterocyclyl; and pharma­
ceutically acceptable salts thereof. 
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In other embodiments, the 15-PGDH inhibitor can i) at 
2.5 µM concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 70 (using a scale on 
which a value of 100 indicates a doubling of reporter output 
over baseline); ii) at 2.5 µM concentration stimulate a V9m 
reporter cell line expressing a 15-PGDH luciferase fusion 
construct to a luciferase output level of greater than 75; iii) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to a 10 
luciferase output level of greater than 70; iv) at 7.5 µM 
concentration, does not activate a negative control V9m cell 
line expressing TK-renilla luciferase reporter to a level 
greater than 20; and v) inhibits the enzymatic activity of 15 
recombinant 15-PGDH protein at an IC50 of less than 1 µM. 
In other embodiments, the 15-PGDH inhibitor can i) at 
2.5 µM concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; ii) at 2.5 µM concentration stimu- 20 
late a V9m reporter cell line expressing a 15-PGDH 
luciferase fusion construct to increase luciferase output; iii) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; iv) at 7.5 µM concentration, does 25 
not activate a negative control V9m cell line expressing 
TK-renilla luciferase reporter to a luciferase level greater 
than 20% above background; and v) inhibits the enzymatic 
activity of recombinant 15-PGDH protein at an IC50 of less 
than 1 µM. 30 
In other embodiments, the 15-PGDH inhibitor can inhibit 
the enzymatic activity of recombinant 15-PGDH at an IC50 
of less than 1 µM, or preferably at an IC50 of less than 250 
nM, or more preferably at an IC50 of less than 50 nM, or 
more preferably at an IC50 of less than 5 nM. 35 
In still other embodiments, the 15-PGDH inhibitor can be 
applied to skin of a subject to promote and/or stimulate 
pigmentation of the skin and/or hair growth and/or inhibit 
hair loss. The 15-PGDH inhibitor can also be administered 
to a subject to promote wound healing, regenerate tissue, 40 
and/or treat at least one of oral ulcers, ulcerative colitis, 
gastrointestinal ulcers, inflammatory bowel disease, vascu-
lar insufficiency, colitis, Raynaud's disease, Buerger's dis­
ease, diabetic neuropathy, pulmonary artery hypertension, 
cardiovascular disease, diabetic ulcers, renal disease, and 45 
erectile dysfunction. The 15-PGDH inhibitor can further be 
administered to a subject in combination with a prostanoid 
agonist for the purpose of enhancing the therapeutic effect of 
the agonist in prostaglandin responsive conditions. 
In some embodiments, the 15-PGDH inhibitor can be 50 
administered to tissue of a subject to increase tissue stem 
cells. The 15-PGDH inhibitor can also be administered to a 
bone marrow graft donor or a hematopoietic stem cell donor 
to increase the fitness of a donor bone marrow graft or a 
donor hematopoietic stem cell graft. The 15-PGDH inhibitor 55 
can be administered to bone marrow of a subject to increase 
stem cells in the subject. The 15-PGDH inhibitor can further 
be administered to bone marrow of a subject to increase the 
fitness of the marrow as a donor graft. 
In other embodiments the 15-PGDH inhibitor can be 60 
administered to a preparation of hematopoietic stem cells of 
a subject to increase the fitness of the stem cell preparation 
as a donor graft. The 15-PGDH inhibitor can also be 
administered to a preparation of peripheral blood 
hematopoietic stem cells of a subject to increase the fitness 65 
of the stem cell preparation as a donor graft. The 15-PGDH 
inhibitor can further be administered to a preparation of 
4 
umbilical cord stem cells to increase the fitness of the stem 
cell preparation as a donor graft. 
In yet other embodiments, the 15-PGDH inhibitor can be 
administered to a subject to mitigate bone marrow graft 
rejection, to enhance bone marrow graft engraftment, and/or 
to enhance engraftment of a hematopoietic stem cell graft, or 
an umbilical cord stem cell graft. 
In still other embodiment, the 15-PGDH inhibitor can be 
administered to a subject or to a tissue graft of a subject to 
mitigate graft rejection or to enhance graft engraftment. 
In other embodiments, the 15-PGDH inhibitor can be 
administered to a subject or to tissue of the subject to confer 
resistance to toxic or lethal effects of exposure to radiation. 
In other embodiments, the 15-PGDH inhibitor can be 
administered to a subject for the treatment of osteoporosis, 
bone fractures, or promoting healing after bone injury or 
joint replacement. 
In an alternative example, the 15-PGDH inhibitor can be 
administered to a subject or to the liver of a subject to 
promote liver regeneration following liver resection or fol­
lowing toxic injury to the liver. In one instance, toxic injury 
to the liver may be caused by overdose of acetaminophen or 
related hepatotoxic compounds. 
In still other embodiments of the application, a 15-PGDH 
activator can be administered to a tissue of a subject at an 
amount effective to increase 15-PGDH levels and decrease 
prostaglandin levels in the tissue. The 15-PGDH activator 
can include formula (IV): 
R11 
I 
O Y2 =0 
II I 
U R10 
/X3YN' 
R12 
wherein X3 and Y 2 are independently C or SO; 
(IV) 
U is OR" (wherein R" is H, a substituted or unsubstituted 
alkyl group, or substituted or unsubstituted aryl group) 
or 
Rs, R9, R10, Ru, and R12 are each selected from the group 
consisting of H, F, Cl, Br, I, an alkyl group, (CH2)niOR' 
(wherein nl=l, 2, or 3), CF3, CH2----CH2X, O----CH2-
CH2X, CH2----CH2----CH2X, O-CH2----CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
N02, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is H or a lower alkyl group), a substituted 
or unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, a substituted or unsubstituted heterocyclyl, 
and Rs and R9 may be linked to form a cyclic or 
polycyclic ring; and pharmaceutically acceptable salts 
thereof. 
In some embodiments, the activator can i) at 7.5 µM 
concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 50 (using a scale on 
which a value of 100 indicates a doubling of reporter output 
US 9,790,233 B2 
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over baseline); ii) at 7 .5 µM concentration stimulate a V9m 
reporter cell line expressing a 15-PGDH luciferase fusion 
construct to a luciferase output level of greater than 50; iii) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to a 5 
luciferase output level of greater than 50; iv) at 7.5 µM 
concentration, does not activate the negative control V9m 
cell line expressing TK-renilla luciferase reporter to a level 
any greater than 25; and v) against recombinant 15-PGDH 
protein the compound shows an IC50 concentration for 10 
inhibiting 15-PGDH enzyme activity of greater than or equal 
to 2.5 µM. 
In some embodiments, the activator can i) at 7.5 µM 
concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to 15 
increase luciferase output; ii) at 7.5 µM concentration stimu­
late a V9m reporter cell line expressing a 15-PGDH 
luciferase fusion construct to increase luciferase output; iii) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to 20 
increase luciferase output; iv) at 7.5 µM concentration, does 
not activate the negative control V9m cell line expressing 
TK-renilla luciferase reporter to a luciferase level any 
greater than 25% above; and v) against recombinant 
15-PGDH protein the compound shows an IC50 concentra- 25 
tion for inhibiting 15-PGDH enzyme activity of greater than
or equal to 2.5 µM.
6 
FIGS. 7(A-C) illustrate graphs showing 15-PGDH mRNA 
levels in colon cancer cell lines treated with SW033291. 
FIGS. S(A-C) illustrate graphs showing 15-PGDH mRNA 
levels in colon cancer cell lines treated with SW054384 and 
SW145753. 
FIGS. 9(A-I) illustrate graphs showing 15-PGDH mRNA 
levels in colon cancer cell lines treated with 5 µM 
SW124531. 
FIGS. lO(A-C) illustrate graphs showing 15-PGDH activ­
ity in cell lines treated with SW033291, SW054384, and 
SW145753. Activity is measured as pmol PGE2/min/million 
cells. 
FIGS. ll(A-D) illustrates a table and plots showing 
activity of recombinant 15-PGDH protein (a 15-PGDH-GST 
fusion protein) incubated with varying concentrations of the 
test compounds. 
FIGS. 12(A-D) illustrate plots showing the activity of 
recombinant 15-PGDH protein treated with SW033291 and 
SW054384, with panels 12A and C measuring transfer of 
tritium from a radiolabeled PGE2 substrate and panels 12 B 
and D measuring generation of NADH by fluorescence. 
FIG. 13 illustrates a table and plot showing 15-PGDH 
activity measured by following transfer of tritium from a 
radiolabeled PGE2 substrate in cells treated with SW124531 
(upper panel) and in recombinant 15-PGDH protein treated 
with SW124531 (lower panel). 
FIGS. 14(A-B) illustrate melt curves and a table showing 
different compound's ability to directly bind to recombinant 
15-PGDH protein as measured by shifting the melting
temperature of the protein.
In other embodiments, the 15-PGDH activator can be 
administered to a subject to treat a neoplasia, such as a colon 
neoplasia. The 15-PGDH activator can also be administered 30 
to a subject to prevent neoplasia, such as a colon neoplasia. 
The 15-PGDH activator can also be administered to a FIGS. 15(A-B) illustrate melt curves temperature of cata­
lytically inactive mutant 15-PGDH protein treated with the 
35 
test compounds. 
subject to reduce inflammation and/or pain. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. l(A-C) illustrate graphs showing luciferase activity 
FIGS. 16(A-B) illustrates graphs showing PGE2 levels 
that are assayed in the medium of A549 cells that have been 
stimulated by ILi-beta for 23 hours, with the test com­
pounds. 
FIG. 17 illustrates a graph showing the dose response 
effect of SW033291 on PGE2 production from ILi-beta 
treated A549 cells. 
of cells that express a 15-PGDH luciferase fusion construct 
created by targeted gene knock-in of renilla luciferase into 
the last coding exon of 15-PGDH treated with the com- 40 
pounds SW033291, SW054384, and SW145753 at various 
concentrations. The activity is demonstrated in three differ­
ent colon cancer cell lines all engineered to contain the 
15-PGDH-luciferase fusion. These cell lines are Vaco-9m
(V9m), LSI 74T, Vaco503 (V503).
FIGS. 18(A-B) illustrate graphs showing the in vivo 
modulations by compounds (2.5 µM) of PGDH activity as 
45 reflected in PGE2 levels following addition of PGE2 into the 
medium of Vaco-503 cells. FIG. 2 illustrates western blots demonstrating the levels 
of 15-PGDH protein in cell lines V9M, LS174T, and V503 
treated with 7.5 µM of SW033291, SW054384, and 
SW145753 for 48 hours. Untreated FET cells provide a 
positive control for 15-PGDH expression. 
FIG. 19 illustrates images showing the activity of 
SW033291 in speeding the healing of a model wound 
consisting of a scratch in a monolayer of HaCaT cells 
50 observed over 48 hours of treatment. 
FIGS. 3(A-C) illustrate western blots demonstrating 
15-PGDH protein levels in colon cell lines treated with
SW124531 (FET cells treated with TGF-� (10 ng/ml for 48 
hours) are used as a positive control for 15-PGDH expres­
sion in certain panels).
FIG. 4 illustrates western blots demonstrating the levels 
55 
of 15-PGDH protein (wt-PGDH) expressed from a cDNA 
expression vector in V400-S3-2-32 cells treated with 5 µM 
SW! 24531, and protein levels of a catalytically dead mutant 
15-PGDH (mu-PGDH) also expressed from a cDNA expres- 60 
sion vector in V 400-M3-2-72 cells treated with SW124531.
FIGS. S(A-C) illustrate 15-PGDH protein levels in V503 
cells treated with SW124531 as assayed by immuno-fluo­
rescence (upper two rows) and by western blot (lower 
panel). 
FIGS. 6(A-F) illustrate graphs showing 15-PGDH mRNA 
levels in colon cancer cell lines treated with SW033291. 
65 
FIG. 20 illustrates graphs showing the quantitation of 
scratch width at O and 48 hours in the control, SW033291 
(2.5 µM) treated cells, and the TGF-beta (1 ng/ml) treated 
cells. 
FIGS. 21(A-B) illustrate plots showing: (A) percent inhi-
bition of PGDH using titrations of 15-PGDH inhibitor 
SW033291 run at different 15-PGDH concentrations; and 
(B) the 1050 of 15-PGDH inhibitor SW033291 versus
15-PGDH concentration.
FIGS. 22(A-B) illustrate graphs showing: (A) 15-PGDH 
enzyme inhibiting activity and (B) percent inhibition of 
activity due to of SW033291 as measured before and after 
dialysis of the 15-PGDH and SW033291 mixture. 
FIGS. 23(A-B) illustrate a plot showing reaction rates and 
relative reaction velocity of 15-PGDH at varying concen­
trations of SW033291. 
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FIGS. 24(A-B) illustrate plots showing: (A) inhibition of 
15-PGDH by SW033291 in the presence of PGE-2; and (B)
1050 of SW033291 against 15-PGDH versus PGE2 concen­
tration.
8 
FIG. 47 illustrates a graph showing CFU counts in wild 
type bone marrow treated with SW033291 and PGE-2. 
FIG. 25 illustrates a schematic diagram showing the 5 
structure activity relationships of analogues of SW033291 
versus their IC50 against 15-PGDH. 
FIGS. 48(A-C) illustrate graphs showing: (A) bone mar­
row cellularity of mice treated with SW033291; (B) SKL % 
in whole bone marrow of mice treated with SW033291; and 
(C) CFU counts in mice treated SW033291.
FIGS. 49(A-B) illustrate: (A) a schematic diagram fol­
lowing CD45.2 antigen marked cells in lethally irradiated 
C57BL/6J mice rescued with a bone marrow transplant from 
donor mice treated with SW033291 or with vehicle; and (B) 
graphs showing chimerism, of donor B-Cells, myeloid cells, 
and T-Cells after such treatment. 
FIG. 26 illustrates a schematic diagram showing addi­
tional analogues of SW033291. 
FIGS. 27(A-C) illustrate graphs showing luciferase activ- 10 
ity of colon cancer cell lines V503, LS174T, and V503 
treated with 2.5 µMand 7 .5 µM the compounds of FIG. 26. 
FIG. 28 illustrates a graph showing percent inhibition of 
15-PGDH activity by the compounds of FIG. 26.
FIGS. 29(A-B) illustrate plots showing the 1050 against
15-PGDH of SW033291 and SW0206980.
FIGS. 30(A-B) illustrate plots showing melting profiles of
SW0206890 and SW033291 binding to 15-PGDH. 
FIGS. 31(A-C) illustrate plots showing percent inhibition 
of 15-PGDH activity by SW033291, SW206980, and 
SW206992. 
FIGS. 32(A-C) illustrate graphs showing luciferase activ­
ity of colon cancer cell lines V503, LS174T, and V503 
treated with various concentrations of SW033291. 
FIG. 33(A-C) illustrate graphs showing luciferase activity 
of colon cancer cell lines V503, LSI 74T, and V503 treated 
with various concentrations of SW0206980. 
FIG. 34(A-C) illustrate graphs showing luciferase activity 
of colon cancer cell lines V503, LSI 74T, and V503 treated 
with various concentrations of SW0206992. 
FIGS. 35(A-B) illustrate plots showing melting profiles of 
SW206992, SW0206890 and SW033291 binding to 
15-PGDH.
FIG. 50 illustrates a schematic diagram showing schema 
15 of a study in which C57BL/61 mice are irradiated with 11 
GY on day O and followed by treatment with SW033291. 
FIG. 51 illustrates a schematic diagram of a partial 
hepatectomy. 
FIGS. 52(A-D) illustrate photographs showing preopera-
20 tive and post-operative view of mouse liver. 
FIGS. 53(A-D) illustrate photographs showing post-he­
patectomy views of the mouse liver ( at left) and regeneration 
of mouse liver on post-operative day 7 (at right). 
FIGS. 54(A-B) illustrate micrographs of post-hepatec-
25 tomy mouse livers of mouse administered SW033291 and 
control vehicle, with arrows designating mitotic figures. 
FIG. 55 illustrates a graph showing mitosis in liver of 
SW033291 treated mouse versus the control mouse. 
FIG. 56 illustrates a graph showing the liver to body 
30 weight ratios attained following partial hepatectomy in 
control versus SW033291 treated C57Bl/6J mice. 
FIGS. 36(A-B) illustrate plots showing melting profiles of 35 
SW206992, SW0206890 and SW033291 binding to 
15-PGDH.
FIG. 57 illustrates a graph showing the liver to body 
weight ratios attained following partial hepatectomy in 
control versus SW033291 twice daily treated C57Bl/6J 
mice. 
FIG. 58 illustrates a graph reprising the liver to body 
weight ratios attained following partial hepatectomy in 
control versus SW033291 treated C57Bl/6J mice. 
FIGS. 37(A-C) illustrate graphs showing the effect of
SW206992, SW0206890 and SW033291 on the regulation 
of PGE-2 in A549 cells stimulated with ILi-Beta. 
FIGS. 38(A-C) illustrate graphs showing the effect of 
SW206992, SW0206890 and SW033291 on cell numbers in 
A549 cells after stimulated with ILi-Beta. 
FIG. 39 illustrates a schematic diagram of additional 
analogues of SW033291. 
FIGS. 40(A-C) illustrate graphs showing luciferase activ­
ity of colon cancer cell lines V9M, LS174T, and V503 
treated with 2.5 µMand 7.5 µM the compounds of FIG. 39. 
FIG. 41 illustrates a graph showing percent inhibition of 
15-PGDH activity by the compounds of FIG. 40.
FIG. 42 illustrates a graph showing percent inhibition of
15-PGDH activity by the compounds of FIG. 40.
40 FIGS. 59(A-B) illustrate a graph and plot showing ALT 
levels following partial hepatectomy in one mouse control 
versus one mouse treated with SW033291. 
FIG. 60 illustrates a graph showing serum bilirubin levels 
following partial hepatectomy in a control mouse and a 
45 mouse treated with SW033291. 
FIG. 61 illustrates a graph showing the liver to body 
weight ratios attained following partial hepatectomy in 
control versus SW033291 treated FVB mice. 
FIG. 62 illustrates a graph showing preoperative body 
50 weights in control versus SW033291 treated FVB mice. 
FIG. 43 shows the dose response curve for induction of a
15-PGDH-luciferase fusion gene reporter in the V9m cell
line background of SW033291, SW208064, SW208065, 55 
SW208066, and SW208067. 
FIG. 63 illustrates a graph showing the weight of the 
resected liver segment from mice treated with either 
SW033291 or vehicle control and assayed for liver regen­
eration. 
FIG. 64 illustrates a graph showing liver weights attained 
post partial heptatectomy in SW033291 and control mice. 
FIG. 44 illustrates titration curves of 15-PGDH inhibitor 
compounds in an assay measuring effects on PGE2 levels in 
the medium of A549 cells that have been stimulated with 
ILi-beta. 
FIG. 45 is a plot showing weight change of FVB mice 
treated with SW033291. 
FIGS. 46(A-C) illustrate graphs showing: (A) total bone 
marrow cellularity; (B) SKL population of wild type versus 
PGDH-/- mice; and (C) average CFU counts in wild type 
versus PGDH-/- mice (designated as either PGDH -/- or as 
PGDH). 
60 
FIG. 65 illustrates a graph showing the liver to body 
weight ratios obtained post partial hepatectomy in 
SW033291 treated and control mice. 
FIG. 66 illustrates a "box and whisker" plot comparing 
liver to body weight ratio following partial hepatectomy of 
SW033291 treated and control FVB mice at post-operative 
day 4. 
FIG. 67 illustrates a "box and whisker" plot comparing 
65 liver to body weight ratio following partial hepatectomy of 
SW033291 treated and control FVB mice at post-operative 
day 7. 
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FIG. 68 illustrates a "box and whisker" plot comparing 
liver to body weight ratio following partial hepatectomy of 
SW033291 treated and control FVB mice at post-operative 
day 4. 
FIG. 69 illustrates photographs ofS-phase cells following 5 
partial hepatectomy on post-operative day 2 in livers of 
SW033291 treated and vehicle treated control mice. 
FIG. 70 illustrates a photograph showing high powered 
( 40x) views of representative fields from the study of FIG. 
69. 10 
10 
FIG. 87 illustrates a schematic diagram of analogues of 
SW054384. 
FIG. 88 illustrates a graph showing luciferase activity of 
colon cancer cell V 9m treated with 2.5 µMand 7.5 µM the 
compounds of FIG. 87. 
FIG. 89 illustrates a graph showing luciferase activity of 
colon cancer LS174T cells treated with 2.5 µMand 7.5 µM 
the compounds of FIG. 87. 
FIG. 90 illustrates a graph showing luciferase activity of 
colon cancer cell V 503 treated with 2.5 µMand 7.5 µM the 
compounds of FIG. 87. 
FIG. 91 illustrates a graph showing percent inhibition of 
15-PGDH activity by the compounds of FIG. 87.
FIG. 92 is a schematic illustration showing the structures
FIG. 71 illustrates a "box and whiskers" plot comparing 
percent of BrdU positive cells in livers of SW033291 treated 
versus vehicle control treated mice on post-operative day 2 
following partial hepatectomy. 
FIG. 72 illustrates a graph showing the average changes 
from baseline weight of the cohort of control versus 
SW033291 treated mice all treated with 2% dextran sulfate 
sodium (DSS) in the drinking water. 
15 of 15-PGDH activators SW054384, SW125991, 
SW207997, SW207998, and SW207999. 
FIG. 73 illustrates a graph of the daily disease activity 
index of the cohort of control versus SW033291 treated 
mice all treated with 2% DSS in the drinking water. 
FIG. 93 illustrates a graph showing the activities of 
SW054384, SW125991, SW207997, SW207998, 
SW207999 in lowering PGE2 levels in medium of A549 
20 cells that have been treated with 2.5 µM of each compound 
along with addition of 2.5 ng/ml ILi-beta. 
FIG. 74 illustrates a graph showing the average changes 
from baseline weight of the cohort of DSS treated mice 
receiving a control vehicle versus SW033291. 
FIG. 94 illustrates titration curves of 15-PGDH activator 
compounds in an assay measuring effects on PGE2 levels in 
the medium of A549 cells that have been stimulated with 
25 ILi-beta. 
FIGS. 75(A-B) illustrates: (A) a graph showing the num­
ber of ulcers in a colon of DSS treated mice receiving a 
control vehicle versus SW033291; and (B) photographs 
showing ulcers of DSS treated mice receiving control (left) 
or SW033291 (right). 
FIG. 76 illustrates a graph showing quantitation of ulcer 
burden on day 15 of DSS treated mice. 
30 
FIGS. 77(A-B) illustrate photographs showing colono­
scopic findings and mouse endoscopic index of colitis 
severity (MEICs) for a DSS treated mouse receiving a 35 
control vehicle or SW033291. 
FIG. 95 illustrates a photograph showing assessment of 
toxicity of SW125991 by testing effect of increasing doses 
on colony formation of A549 cells, Vaco9M (V9m) cells, 
LSI 74T cells, and Vaco503 (V503) cells. 
FIG. 96 illustrates a photograph showing assessment of 
toxicity of SW207997 by testing effect of increasing doses 
on colony formation of A549 cells, Vaco9M (V9m) cells, 
LSI 74T cells, and Vaco503 (V503) cells. 
FIG. 97 illustrates a photograph showing assessment of 
toxicity of SW207998 by testing effect of increasing doses 
on colony formation of A549 cells, Vaco9M (V9m) cells, 
LSI 74T cells, and Vaco503 (V503) cells. FIG. 78 illustrates a graph showing MEICS score ofDSS 
treated mice receiving a control vehicle or SW033291. 
FIG. 79 illustrates photomicrographs of high powered 
fields from the mid-colon on day 8 of the DSS protocol from 
control mice, SW033291 treated mice (treatment) and 
15-PGDH knockout mice (KO) and a graph depicting sum
FIG. 98 illustrates a photograph showing assessment of 
toxicity of SW207999 by testing effect of increasing doses 
40 on colony formation of A549 cells, Vaco9M (V9m) cells, 
LSI 74T cells, and Vaco503 (V503) cells. 
of the average number of BrdU positive cells per crypt in the
distal plus middle colons of control (Cn), SW033219 treated
mice (Tx), and 15-PGDHknockout mice (KO) on day 1, day 45 
8, and day 15 of the DSS treatment protocol. 
FIG. 80 illustrates a graph showing colon length at day 22 
of DSS treated mice receiving a control vehicle or 
SW033291. 
FIG. 81 illustrates a schematic diagram of analogues of 50 
SW054384. 
FIGS. 82(A-C) illustrate graphs showing luciferase activ­
ity of colon cancer cell lines V 9M, LS174T, and V503 
treated with 2.5 µMand 7 .5 µM the compounds of FIG. 81. 
FIG. 83 illustrates a graph showing percent inhibition of 55 
15-PGDH activity by the compounds of FIG. 74.
FIGS. 84(A-C) illustrate: (A) a graph showing activity in
lowering PGE2 levels in media of A549 cells that are 
stimulated to produce PEG2 by treatment using ILi-beta 
using compounds of FIG. 81; (B) a graph showing toxicity 60 
of A549 cells administered the compounds of FIG. 81; and 
(C) photographs of A549 cells treated with compounds of
FIG. 81.
DETAILED DESCRIPTION 
For convenience, certain terms employed in the specifi­
cation, examples, and appended claims are collected here. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly under­
stood by one of ordinary skill in the art to which this 
application belongs. 
The articles "a" and "an" are used herein to refer to one 
or to more than one (i.e., to at least one) of the grammatical 
object of the article. By way of example, "an element" 
means one element or more than one element. 
The terms "comprise," "comprising," "include," "includ­
ing," "have," and "having" are used in the inclusive, open 
sense, meaning that additional elements may be included. 
The terms "such as", "e.g.", as used herein are non-limiting 
and are for illustrative purposes only. "Including" and 
"including but not limited to" are used interchangeably. 
The term "or" as used herein should be understood to 
mean "and/or", unless the context clearly indicates other­
wise. 
It will be noted that the structure of some of the com-FIG. 85 illustrates a plot showing metabolic stability of 
SW054384 by incubation with murine liver S9 microsomes. 
FIG. 86 illustrates a plot showing metabolic stability of 
SW0125991 by incubation with murine liver S9 microsomes 
65 pounds of the application include asymmetric (chiral) car­
bon atoms. It is to be understood accordingly that the 
isomers arising from such asymmetry are included herein, 
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unless indicated otherwise. Such isomers can be obtained in 
substantially pure form by classical separation techniques 
and by stereochemically controlled synthesis. The com­
pounds of this application may exist in stereoisomeric form, 
therefore can be produced as individual stereoisomers or as 
mixtures. 
The term "isomerism" means compounds that have iden­
tical molecular formulae but that differ in the nature or the 
sequence of bonding of their atoms or in the arrangement of 
their atoms in space. Isomers that differ in the arrangement 
of their atoms in space are termed "stereoisomers". Stereoi­
somers that are not mirror images of one another are termed 
"diastereoisomers", and stereoisomers that are non-super­
imposable mirror images are termed "enantiomers", or 
sometimes optical isomers. A carbon atom bonded to four 
nonidentical substituents is termed a "chiral center". 
The term "chiral isomer" means a compound with at least 
one chiral center. It has two enantiomeric forms of opposite 
chirality and may exist either as an individual enantiomer or 
as a mixture of enantiomers. A mixture containing equal 
amounts of individual enantiomeric forms of opposite chi­
rality is termed a "racemic mixture". A compound that has 
more than one chiral center has 2n-1 enantiomeric pairs, 
where n is the number of chiral centers. Compounds with 
more than one chiral center may exist as either an individual 
diastereomer or as a mixture of diastereomers, termed a 
"diastereomeric mixture". When one chiral center is present, 
a stereoisomer may be characterized by the absolute con­
figuration (R or S) of that chiral center. Alternatively, when 
one or more chiral centers are present, a stereoisomer may 
be characterized as ( +) or (-). Absolute configuration refers 
to the arrangement in space of the substituents attached to 
the chiral center. The substituents attached to the chiral 
center under consideration are ranked in accordance with the 
Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al, 
Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et 
al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. 
Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 
81; Cahn, J., Chem. Educ. 1964, 41, 116). 
The term "geometric Isomers" means the diastereomers 
that owe their existence to hindered rotation about double 
bonds. These configurations are differentiated in their names 
by the prefixes cis and trans, or Z and E, which indicate that 
the groups are on the same or opposite side of the double 
bond in the molecule according to the Cahn-Ingold-Prelog 
rules. Further, the structures and other compounds discussed 
in this application include all atropic isomers thereof. 
The term "atropic isomers" are a type of stereoisomer in 
which the atoms of two isomers are arranged differently in 
space. Atropic isomers owe their existence to a restricted 
rotation caused by hindrance of rotation of large groups 
about a central bond. Such atropic isomers typically exist as 
a mixture, however as a result of recent advances in chro­
matography techniques, it has been possible to separate 
mixtures of two atropic isomers in select cases. 
The terms "crystal polymorphs" or "polymorphs" or 
"crystal forms" means crystal structures in which a com­
pound ( or salt or solvate thereof) can crystallize in different 
crystal packing arrangements, all of which have the same 
elemental composition. Different crystal forms usually have 
different X-ray diffraction patterns, infrared spectral, melt­
ing points, density hardness, crystal shape, optical and 
electrical properties, stability and solubility. Recrystalliza­
tion solvent, rate of crystallization, storage temperature, and 
other factors may cause one crystal form to dominate. 
Crystal polymorphs of the compounds can be prepared by 
crystallization under different conditions. 
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The term "derivative" refers to compounds that have a 
common core structure, and are substituted with various 
groups as described herein. 
The term "bioisostere" refers to a compound resulting 
from the exchange of an atom or of a group of atoms with 
another, broadly similar, atom or group of atoms. The 
objective of a bioisosteric replacement is to create a new 
compound with similar biological properties to the parent 
compound. The bioisosteric replacement may be physico-
10 chemically or topologically based. Examples of carboxylic 
acid bioisosteres include acyl sulfonimides, tetrazoles, sul­
fonates, and phosphonates. See, e.g., Patani and LaVoie, 
Chem. Rev. 96, 3147-3176 (1996). 
The phrases "parenteral administration" and "adminis-
15 tered parenterally" are art-recognized terms, and include 
modes of administration other than enteral and topical 
administration, such as injections, and include, without 
limitation, intravenous, intramuscular, intrapleural, intravas­
cular, intrapericardial, intraarterial, intrathecal, intracapsu-
20 lar, intraorbital, intracardiac, intradermal, intraperitoneal, 
transtracheal, subcutaneous, subcuticular, intra-articular, 
subcapsular, subarachnoid, intraspinal and intrastemal injec­
tion and infusion. 
The term "treating" is art-recognized and includes inhib-
25 iting a disease, disorder or condition in a subject, e.g., 
impeding its progress; and relieving the disease, disorder or 
condition, e.g., causing regression of the disease, disorder 
and/or condition. Treating the disease or condition includes 
ameliorating at least one symptom of the particular disease 
30 or condition, even if the underlying pathophysiology is not 
affected. 
The term "preventing" is art-recognized and includes 
stopping a disease, disorder or condition from occurring in 
a subject, which may be predisposed to the disease, disorder 
35 and/or condition but has not yet been diagnosed as having it. 
Preventing a condition related to a disease includes stopping 
the condition from occurring after the disease has been 
diagnosed but before the condition has been diagnosed. 
The term "pharmaceutical composition" refers to a for-
40 mulation containing the disclosed compounds in a form 
suitable for administration to a subject. In a preferred 
embodiment, the pharmaceutical composition is in bulk or in 
unit dosage form. The unit dosage form is any of a variety 
of forms, including, for example, a capsule, an IV bag, a 
45 tablet, a single pump on an aerosol inhaler, or a vial. The 
quantity of active ingredient ( e.g., a formulation of the 
disclosed compound or salts thereof) in a unit dose of 
composition is an effective amount and is varied according 
to the particular treatment involved. One skilled in the art 
50 will appreciate that it is sometimes necessary to make 
routine variations to the dosage depending on the age and 
condition of the patient. The dosage will also depend on the 
route of administration. A variety of routes are contem­
plated, including oral, pulmonary, rectal, parenteral, trans-
55 dermal, subcutaneous, intravenous, intramuscular, intraperi­
toneal, intranasal, inhalational, and the like. Dosage forms 
for the topical or transdermal administration of a compound 
described herein includes powders, sprays, ointments, 
pastes, creams, lotions, gels, solutions, patches, nebulized 
60 compounds, and inhalants. In a preferred embodiment, the 
active compound is mixed under sterile conditions with a 
pharmaceutically acceptable carrier, and with any preserva­
tives, buffers, or propellants that are required. 
The term "flash dose" refers to compound formulations 
65 that are rapidly dispersing dosage forms. 
The term "immediate release" is defined as a release of 
compound from a dosage form in a relatively brief period of 
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time, generally up to about 60 minutes. The term "modified 
release" is defined to include delayed release, extended 
release, and pulsed release. The term "pulsed release" is 
defined as a series of releases of drug from a dosage form. 
The term "sustained release" or "extended release" is 
defined as continuous release of a compound from a dosage 
form over a prolonged period. 
The phrase "pharmaceutically acceptable" is art-recog­
nized. In certain embodiments, the term includes composi­
tions, polymers and other materials and/or dosage forms 
which are, within the scope of sound medical judgment, 
suitable for use in contact with the tissues of human beings 
and animals without excessive toxicity, irritation, allergic 
response, or other problem or complication, commensurate 
with a reasonable benefit/risk ratio. 
The phrase "pharmaceutically acceptable carrier" is art­
recognized, and includes, for example, pharmaceutically 
acceptable materials, compositions or vehicles, such as a 
liquid or solid filler, diluent, excipient, solvent or encapsu­
lating material, involved in carrying or transporting any 
subject composition from one organ, or portion of the body, 
to another organ, or portion of the body. Each carrier must 
be "acceptable" in the sense of being compatible with the 
other ingredients of a subject composition and not injurious 
to the patient. In certain embodiments, a pharmaceutically 
acceptable carrier is non-pyrogenic. Some examples of 
materials which may serve as pharmaceutically acceptable 
carriers include: (1) sugars, such as lactose, glucose and 
sucrose; (2) starches, such as corn starch and potato starch; 
(3) cellulose, and its derivatives, such as sodium carboxym­
ethyl cellulose, ethyl cellulose and cellulose acetate; (4)
powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8)
excipients, such as cocoa butter and suppository waxes; (9)
oils, such as peanut oil, cottonseed oil, sunflower oil, sesame
oil, olive oil, corn oil and soybean oil; (10) glycols, such as
propylene glycol; (11) polyols, such as glycerin, sorbitol,
mannitol and polyethylene glycol; (12) esters, such as ethyl
oleate and ethyl laurate; (13) agar; (14) buffering agents,
such as magnesium hydroxide and aluminum hydroxide; 
(15) alginic acid; (16) pyrogen-free water; (17) isotonic
saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phos­
phate buffer solutions; and (21) other non-toxic compatible
substances employed in pharmaceutical formulations.
The compounds of the application are capable of further 
forming salts. All of these forms are also contemplated 
herein. 
"Pharmaceutically acceptable salt" of a compound means 
a salt that is pharmaceutically acceptable and that possesses 
the desired pharmacological activity of the parent com­
pound. For example, the salt can be an acid addition salt. 
One embodiment of an acid addition salt is a hydrochloride 
salt. The pharmaceutically acceptable salts can be synthe­
sized from a parent compound that contains a basic or acidic 
moiety by conventional chemical methods. Generally, such 
salts can be prepared by reacting the free acid or base forms 
of these compounds with a stoichiometric amount of the 
appropriate base or acid in water or in an organic solvent, or 
in a mixture of the two; generally, non-aqueous media like 
ether, ethyl acetate, ethanol, isopropanol, or acetonitrile 
being preferred. Lists of salts are found in Remington's 
Pharmaceutical Sciences, 18th ed. (Mack Publishing Com­
pany, 1990). 
The compounds described herein can also be prepared as 
esters, for example pharmaceutically acceptable esters. For 
example, a carboxylic acid function group in a compound 
can be converted to its corresponding ester, e.g., a methyl, 
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ethyl, or other ester. Also, an alcohol group in a compound 
can be converted to its corresponding ester, e.g., an acetate, 
propionate, or other ester. 
The compounds described herein can also be prepared as 
prodrugs, for example pharmaceutically acceptable prod­
rugs. The terms "pro-drug" and "prodrug" are used inter­
changeably herein and refer to any compound, which 
releases an active parent drug in vivo. Since prodrugs are 
known to enhance numerous desirable qualities of pharma-
lO ceuticals ( e.g., solubility, bioavailability, manufacturing, 
etc.) the compounds can be delivered in prodrug form. Thus, 
the compounds described herein are intended to cover 
prodrugs of the presently claimed compounds, methods of 
15 delivering the same and compositions containing the same.
"Prodrugs" are intended to include any covalently bonded 
carriers that release an active parent drug in vivo when such 
prodrug is administered to a subject. Prodrugs are prepared 
by modifying functional groups present in the compound in 
20 such a way that the modifications are cleaved, either in 
routine manipulation or in vivo, to the parent compound. 
Prodrugs include compounds wherein a hydroxy, amino, 
sulfhydryl, carboxy, or carbonyl group is bonded to any 
group that may be cleaved in vivo to form a free hydroxyl, 
25 free amino, free sulfhydryl, free carboxy or free carbonyl 
group, respectively. 
Examples of prodrugs include, but are not limited to, 
esters (e.g., acetate, dialkylaminoacetates, formates, phos­
phates, sulfates, and benzoate derivatives) and carbamates 
30 (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional 
groups, ester groups ( e.g., ethyl esters, morpholinoethanol 
esters) of carboxyl functional groups, N-acyl derivatives 
(e.g., N-acetyl) N-Marmich bases, Schiff bases and enam­
inones of amino functional groups, oximes, acetals, ketals 
35 and enol esters of ketone and aldehyde functional groups in 
compounds of Formula I, and the like, See Bundegaard, H. 
"Design of Prodrugs" p 1-92, Elesevier, New York-Oxford 
(1985). 
The term "protecting group" refers to a grouping of atoms 
40 that when attached to a reactive group in a molecule masks, 
reduces or prevents that reactivity. Examples of protecting 
groups can be found in Green and Wuts, Protective Groups 
in Organic Chemistry, (Wiley, 2.sup.nd ed. 1991); Harrison 
and Harrison et al., Compendium of Synthetic Organic 
45 Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996); and 
Kocienski, Protecting Groups, (Verlag, 3rd ed. 2003). 
The term "amine protecting group" is intended to mean a 
functional group that converts an amine, amide, or other 
nitrogen-containing moiety into a different chemical group 
50 that is substantially inert to the conditions of a particular 
chemical reaction. Amine protecting groups are preferably 
removed easily and selectively in good yield under condi­
tions that do not affect other functional groups of the 
molecule. Examples of amine protecting groups include, but 
55 are not limited to, formyl, acetyl, benzyl, t-butyldimethyl­
silyl, t-butyldiphenylsilyl, t-butyloxycarbonyl (Boe), 
p-methoxybenzyl, methoxymethyl, tosyl, trifluoroacetyl,
trimethylsilyl (TMS), fluorenyl-methyloxycarbonyl, 2-trim­
ethylsilyl-ethyoxycarbonyl, l-methyl-1-( 4-biphenylyl)
60 ethoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl 
(CBZ), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and 
substituted trityl groups, 9-fluorenylmethyloxycarbonyl 
(FMOC), nitro-veratryloxycarbonyl (NV OC), and the like. 
Those of skill in the art can identify other suitable amine 
65 protecting groups. 
Representative hydroxy protecting groups include those 
where the hydroxy group is either acylated or alkylated such 
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as benzyl, and trityl ethers as well as alkyl ethers, tetrahy­
dropyranyl ethers, trialkylsilyl ethers and ally! ethers. 
Additionally, the salts of the compounds described herein, 
can exist in either hydrated or unhydrated (the anhydrous) 
form or as solvates with other solvent molecules. Nonlim­
iting examples of hydrates include monohydrates, dihy­
drates, etc. Nonlimiting examples of solvates include etha­
nol solvates, acetone solvates, etc. 
The term "solvates" means solvent addition forms that 
16 
or more of the subject compositions. If it is administered 
prior to clinical manifestation of the unwanted condition 
(e.g., disease or other unwanted state of the host animal) 
then the treatment is prophylactic, i.e., it protects the host 
against developing the unwanted condition, whereas if it is 
administered after manifestation of the unwanted condition, 
the treatment is therapeutic (i.e., it is intended to diminish, 
ameliorate, or stabilize the existing unwanted condition or 
side effects thereof). 
The terms "therapeutic agent", "drug", "medicament" and 
"bioactive substance" are art-recognized and include mol­
ecules and other agents that are biologically, physiologically, 
or pharmacologically active substances that act locally or 
systemically in a patient or subject to treat a disease or 
contain either stoichiometric or non stoichiometric amounts 10 
of solvent. Some compounds have a tendency to trap a fixed 
molar ratio of solvent molecules in the crystalline solid state, 
thus forming a solvate. If the solvent is water the solvate 
formed is a hydrate, when the solvent is alcohol, the solvate 
formed is an alcoholate. Hydrates are formed by the com­
bination of one or more molecules of water with one of the 
substances in which the water retains its molecular state as 
H20, such combination being able to form one or more 
hydrate. 
15 condition. The terms include without limitation pharmaceu­
tically acceptable salts thereof and prodrugs. Such agents 
may be acidic, basic, or salts; they may be neutral molecules, 
polar molecules, or molecular complexes capable of hydro­
gen bonding; they may be prodrugs in the form of ethers, 
The compounds, salts and prodrugs described herein can 
exist in several tautomeric forms, including the enol and 
imine form, and the keto and enamine form and geometric 
isomers and mixtures thereof. Tautomers exist as mixtures of 
a tautomeric set in solution. In solid form, usually one 
tautomer predominates. Even though one tautomer may be 
described, the present application includes all tautomers of 
the present compounds. A tautomer is one of two or more 
structural isomers that exist in equilibrium and are readily 
converted from one isomeric form to another. This reaction 
results in the formal migration of a hydrogen atom accom­
panied by a switch of adjacent conjugated double bonds. In 
solutions where tautomerization is possible, a chemical 
equilibrium of the tautomers will be reached. The exact ratio 
of the tautomers depends on several factors, including 
temperature, solvent, and pH. The concept oftautomers that 
are interconvertable by tautomerizations is called tautomer-
1sm. 
Of the various types oftautomerism that are possible, two 
are commonly observed. In keto-enol tautomerism a simul­
taneous shift of electrons and a hydrogen atom occurs. 
Tautomerizations can be catalyzed by: Base: 1. deproto­
nation; 2. formation of a delocalized anion ( e.g., an enolate ); 
3. protonation at a different position of the anion; Acid: 1.
protonation; 2. formation of a delocalized cation; 3. depro­
tonation at a different position adjacent to the cation.
The term "analogue" refers to a chemical compound that 
is structurally similar to another but differs slightly in 
composition (as in the replacement of one atom by an atom 
of a different element or in the presence of a particular 
functional group, or the replacement of one functional group 
by another functional group). Thus, an analogue is a com­
pound that is similar or comparable in function and appear­
ance, but not in structure or origin to the reference com­
pound. 
20 esters, amides and the like that are biologically activated 
when administered into a patient or subject. 
The phrase "therapeutically effective amount" or "phar­
maceutically effective amount" is an art-recognized term. In 
certain embodiments, the term refers to an amount of a 
25 therapeutic agent that produces some desired effect at a 
reasonable benefit/risk ratio applicable to any medical treat­
ment. In certain embodiments, the term refers to that amount 
necessary or sufficient to eliminate, reduce or maintain a 
target of a particular therapeutic regimen. The effective 
30 amount may vary depending on such factors as the disease 
or condition being treated, the particular targeted constructs 
being administered, the size of the subject or the severity of 
the disease or condition. One of ordinary skill in the art may 
empirically determine the effective amount of a particular 
35 compound without necessitating undue experimentation. In 
certain embodiments, a therapeutically effective amount of 
a therapeutic agent for in vivo use will likely depend on a 
number of factors, including: the rate of release of an agent 
from a polymer matrix, which will depend in part on the 
40 chemical and physical characteristics of the polymer; the 
identity of the agent; the mode and method of administra­
tion; and any other materials incorporated in the polymer 
matrix in addition to the agent. 
The term "ED50" is art-recognized. In certain embodi-
45 ments, ED50 means the dose of a drug, which produces 50% 
of its maximum response or effect, or alternatively, the dose, 
which produces a pre-determined response in 50% of test 
subjects or preparations. The term "LD50" is art-recognized. 
In certain embodiments, LD50 means the dose of a drug, 
50 which is lethal in 50% of test subjects. The term "therapeutic 
index" is an art-recognized term, which refers to the thera­
peutic index of a drug, defined as LD50/ED50. 
The terms "IC50," or "half maximal inhibitory concentra­
tion" is intended to refer to the concentration of a substance 
55 ( e.g., a compound or a drug) that is required for 50% 
inhibition of a biological process, or component of a pro­
cess, including a protein, subunit, organelle, ribonucleopro­
tein, etc. 
A "patient," "subject," or "host" to be treated by the 
subject method may mean either a human or non-human 
animal, such as a mammal, a fish, a bird, a reptile, or an 
amphibian. Thus, the subject of the herein disclosed meth­
ods can be a human, non-human primate, horse, pig, rabbit, 
dog, sheep, goat, cow, cat, guinea pig or rodent. The term 60 
does not denote a particular age or sex. Thus, adult and 
newborn subjects, as well as fetuses, whether male or 
female, are intended to be covered. In one aspect, the subject 
With respect to any chemical compounds, the present 
application is intended to include all isotopes of atoms 
occurring in the present compounds. Isotopes include those 
atoms having the same atomic number but different mass 
numbers. By way of general example and without limitation, 
isotopes of hydrogen include tritium and deuterium, and is a mammal. A patient refers to a subject afflicted with a 
disease or disorder. 
The terms "prophylactic" or "therapeutic" treatment is 
art-recognized and includes administration to the host of one 
65 isotopes of carbon include C-13 and C-14. 
When a bond to a substituent is shown to cross a bond 
connecting two atoms in a ring, then such substituent can be 
US 9,790,233 B2 
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bonded to any atom in the ring. When a substituent is listed 
without indicating the atom via which such substituent is 
bonded to the rest of the compound of a given formula, then 
such substituent can be bonded via any atom in such 
substituent. Combinations of substituents and/or variables 
are permissible, but only if such combinations result in 
stable compounds. 
18 
When an atom or a chemical moiety is followed by a 
subscripted numeric range ( e.g., C1_6), it is meant to encom­
pass each number within the range as well as all intermediate 10 
ranges. For example, "C1 _6 alkyl" is meant to include alkyl 
groups with 1, 2, 3, 4, 5, 6, 1-6, 1-5, 1-4, 1-3, 1-2, 2-6, 2-5, 
2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, and 5-6 carbons.
having 5 to 8 carbon atoms. The term "substituted alkenyl" 
refers to alkenyl substituted with one or more substituent 
groups, and the terms "heteroatom-containing alkenyl" and 
"heteroalkenyl" refer to alkenyl or heterocycloalkenyl ( e.g., 
heterocylcohexenyl) in which at least one carbon atom is 
replaced with a heteroatom. If not otherwise indicated, the 
terms "alkenyl" and "lower alkenyl" include linear, 
branched, cyclic, unsubstituted, substituted, and/or heteroa-
tom-containing alkenyl and lower alkenyl, respectively. 
The term "alkynyl" refers to a linear or branched hydro-
carbon group of 2 to 24 carbon atoms containing at least one 
triple bond, such as ethynyl, n-propynyl, and the like. 
Generally, although again not necessarily, alkynyl groups 
can contain 2 to about 18 carbon atoms, and more particu-The term "alkyl" is intended to include both branched
15 larly can contain 2 to 12 carbon atoms. The term "lower 
alkynyl" intends an alkynyl group of 2 to 6 carbon atoms. 
The term "substituted alkynyl" refers to alkynyl substituted 
with one or more substituent groups, and the terms "het­
eroatom-containing alkynyl" and "heteroalkynyl" refer to 
( e.g., isopropyl, tert-butyl, isobutyl), straight-chain e.g., 
methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, 
nonyl, decyl), and cycloalkyl (e.g., alicyclic) groups (e.g., 
cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooc­
tyl), alkyl substituted cycloalkyl groups, and cycloalkyl 
substituted alkyl groups. Such aliphatic hydrocarbon groups 
have a specified number of carbon atoms. For example, C1_6 
alkyl is intended to include Ci, C2, C3, C4, C5, and C6 alkyl 
groups. As used herein, "lower alkyl" refers to alkyl groups 
having from 1 to 6 carbon atoms in the backbone of the 
carbon chain. "Alkyl" further includes alkyl groups that 25 
have oxygen, nitrogen, sulfur or phosphorous atoms replac­
ing one or more hydrocarbon backbone carbon atoms. In 
certain embodiments, a straight chain or branched chain 
alkyl has six or fewer carbon atoms in its backbone (e.g., 
20 alkynyl in which at least one carbon atom is replaced with 
a heteroatom. If not otherwise indicated, the terms "alkynyl" 
and "lower alkynyl" include linear, branched, unsubstituted, 
substituted, and/or heteroatom-containing alkynyl and lower 
alkynyl, respectively. 
The terms "alkyl", "alkenyl", and "alkynyl" are intended 
to include moieties which are diradicals, i.e., having two 
points of attachment. A nonlimiting example of such an alkyl 
moiety that is a diradical is ----CH2CH2-, i.e., a C2 alkyl 
group that is covalently bonded via each terminal carbon 
C1 -C6 for straight chain, C3-C6 for branched chain), for 
example four or fewer. Likewise, certain cycloalkyls have 
from three to eight carbon atoms in their ring structure, such 
as five or six carbons in the ring structure. 
The term "substituted alkyls" refers to alkyl moieties 
having substituents replacing a hydrogen on one or more 
carbons of the hydrocarbon backbone. Such substituents can 
include, for example, alkyl, alkenyl, alkynyl, halogen, 
hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbo­
nyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, 
arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylamin­
ocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, 
alkoxyl, phosphate, phosphonato, phosphinato, cyano, 
amino (including alkylamino, dialkylamino, arylamino, dia­
rylamino, and alkylarylamino ), acylamino (including alky­
lcarbonylamino, arylcarbonylamino, carbamoyl and ureido ), 
amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxy­
late, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfona­
mido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, 
alkylaryl, or an aromatic or heteroaromatic moiety. 
Cycloalkyls can be further substituted, e.g., with the sub­
stituents described above. An "alkylaryl" or an "aralkyl" 
moiety is an alkyl substituted with an aryl (e.g., phenylm­
ethyl (benzyl)). If not otherwise indicated, the terms "alkyl" 
and "lower alkyl" include linear, branched, cyclic, unsub­
stituted, substituted, and/or heteroatom-containing alkyl or 
lower alkyl, respectively. 
The term "alkenyl" refers to a linear, branched or cyclic 
hydrocarbon group of 2 to about 24 carbon atoms containing 
at least one double bond, such as ethenyl, n-propenyl, 
isopropenyl, n-butenyl, isobutenyl, octenyl, decenyl, tetra­
decenyl, hexadecenyl, eicosenyl, tetracosenyl, cyclopente­
nyl, cyclohexenyl, cyclooctenyl, and the like. Generally, 
although again not necessarily, alkenyl groups can contain 2 
to about 18 carbon atoms, and more particularly 2 to 12 
carbon atoms. The term "lower alkenyl" refers to an alkenyl 
group of 2 to 6 carbon atoms, and the specific term 
"cycloalkenyl" intends a cyclic alkenyl group, preferably 
30 atom to the remainder of the molecule. 
The term "alkoxy" refers to an alkyl group bound through 
a single, terminal ether linkage; that is, an "alkoxy" group 
may be represented as -0-alkyl where alkyl is as defined 
above. A "lower alkoxy" group intends an alkoxy group 
35 containing 1 to 6 carbon atoms, and includes, for example, 
methoxy, ethoxy, n-propoxy, isopropoxy, t-butyloxy, etc. 
Preferred substituents identified as "C1 -C6 alkoxy" or 
"lower alkoxy" herein contain 1 to 3 carbon atoms, and 
particularly preferred such substituents contain 1 or 2 carbon 
40 atoms (i.e., methoxy and ethoxy). 
The term "aryl" refers to an aromatic substituent contain­
ing a single aromatic ring or multiple aromatic rings that are 
fused together, directly linked, or indirectly linked (such that 
the different aromatic rings are bound to a common group 
45 such as a methylene or ethylene moiety). Ary! groups can 
contain 5 to 20 carbon atoms, and particularly preferred aryl 
groups can contain 5 to 14 carbon atoms. Examples of aryl 
groups include benzene, phenyl, pyrrole, furan, thiophene, 
thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, 
50 oxazole, isooxazole, pyridine, pyrazine, pyridazine, and 
pyrimidine, and the like. Furthermore, the term "aryl" 
includes multicyclic aryl groups, e.g., tricyclic, bicyclic, 
e.g., naphthalene, benzoxazole, benzodioxazole, benzothi­
azole, benzoimidazole, benzothiophene, methylenedioxy-
55 phenyl, quinoline, isoquinoline, napthridine, indole, benzo­
furan, purine, benzofuran, deazapurine, or indolizine. Those 
aryl groups having heteroatoms in the ring structure may 
also be referred to as "aryl heterocycles", "heterocycles," 
"heteroaryls" or "heteroaromatics". The aromatic ring can 
60 be substituted at one or more ring positions with such 
substituents as described above, as for example, halogen, 
hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, 
alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alky­
lcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alk-
65 enylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcar­
bonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, 
alkylthiocarbonyl, phosphate, phosphonato, phosphinato, 
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cyano, amino (including alkylamino, dialkylamino, ary­
lamino, diary! amino, and alkylaryl amino), acylamino (in­
cluding alkylcarbonylamino, arylcarbonylamino, carbamoyl 
and ureido ), amidino, imino, sulfhydryl, alkylthio, arylthio, 
thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfa- 5 
moyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, 
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic 
moiety. Ary! groups can also be fused or bridged with 
alicyclic or heterocyclic rings, which are not aromatic so as 
to form a multicyclic system ( e.g., tetralin, methylenedioxy- 10 
phenyl). If not otherwise indicated, the term "aryl" includes 
unsubstituted, substituted, and/or heteroatom-containing 
aromatic substituents. 
The term "alkaryl" refers to an aryl group with an alkyl 
substituent, and the term "aralkyl" refers to an alkyl group 15 
with an aryl substituent, wherein "aryl" and "alkyl" are as 
defined above. Exemplary aralkyl groups contain 6 to 24 
carbon atoms, and particularly preferred aralkyl groups 
contain 6 to 16 carbon atoms. Examples of aralkyl groups 
include, without limitation, benzyl, 2-phenyl-ethyl, 3-phe- 20 
nyl-propyl, 4-phenyl-butyl, 5-phenyl-pentyl, 4-phenylcyclo­
hexy I, 4-benzylcyclohexy I, 4-phenylcyclohexy lmethy I, 
4-benzylcyclohexylmethyl, and the like. Alkaryl groups
include, for example, p-methylphenyl, 2,4-dimethylphenyl,
p-cyclohexylphenyl, 2, 7-dimethylnaphthyl, 7-cyclooctyl- 25 
naphthyl, 3-ethyl-cyclopenta-1,4-diene, and the like.
The terms "heterocyclyl" or "heterocyclic group" include 
closed ring structures, e.g., 3- to 10-, or 4- to 7-membered 
rings, which include one or more heteroatoms. "Heteroa­
tom" includes atoms of any element other than carbon or 30 
hydrogen. Examples of heteroatoms include nitrogen, oxy­
gen, sulfur and phosphorus. 
Heterocyclyl groups can be saturated or unsaturated and 
include pyrrolidine, oxolane, thiolane, piperidine, pipera­
zine, morpholine, lactones, lactams, such as azetidinones 35 
and pyrrolidinones, sultams, and sultones. Heterocyclic 
groups such as pyrrole and furan can have aromatic char­
acter. They include fused ring structures, such as quinoline 
and isoquinoline. Other examples of heterocyclic groups 
include pyridine and purine. The heterocyclic ring can be 40 
substituted at one or more positions with such substituents as 
described above, as for example, halogen, hydroxyl, alkyl­
carbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy­
carbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, 
aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, 45 
phosphonato, phosphinato, cyano, amino (including alkyl 
amino, dialkylamino, arylamino, diarylamino, and alkylary­
lamino ), acylamino (including alkylcarbonylamino, arylcar­
bonylamino, carbamoyl and ureido ), amidino, imino, sulf­
hydryl, alkylthio, arylthio, thiocarboxylate, sulfates, 50 
sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, 
cyano, azido, heterocyclyl, or an aromatic or heteroaromatic 
moiety. Heterocyclic groups can also be substituted at one or 
more constituent atoms with, for example, a lower alkyl, a 
lower alkenyl, a lower alkoxy, a lower alkylthio, a lower 55 
alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, 
-CF3 , or -CN, or the like.
The term "halo" or "halogen" refers to fluoro, chloro,
bromo, and iodo. "Counterion" is used to represent a small, 
negatively charged species such as fluoride, chloride, bro- 60 
mide, iodide, hydroxide, acetate, and sulfate. 
The terms "substituted" as in "substituted alkyl," "sub­
stituted aryl," and the like, as alluded to in some of the 
aforementioned definitions, is meant that in the alkyl, aryl, 
or other moiety, at least one hydrogen atom bound to a 65 
carbon (or other) atom is replaced with one or more non­
hydrogen substituents. Examples of such substituents 
20 
include, without limitation: functional groups such as halo, 
hydroxyl, silyl, sulfhydryl, C1 -C24 alkoxy, C2-C24 alkeny­
loxy, C2-C24 alkynyloxy, C5-C20 aryloxy, acyl (including 
C2-C24 alkylcarbonyl (-CO-alkyl) and CcC20 arylcarbonyl 
(-CO-aryl)), acyloxy (---0-acyl), C2-C24 alkoxycarbonyl 
(-(C0)---0-alkyl), CcC20 aryloxycarbonyl (-(C0)-0-
aryl), C2-C24 alkylcarbonato (---0-(CO)---O-alkyl), 
C6-C20 arylcarbonato (---0-(CO)-O-aryl), carboxy
(-COOH), carboxylato (-COO-), carbamoyl (-(CO)­
NH2), mono-(C1 -C24 alkyl)-substituted carbamoyl 
(-(CO)-NH(C1-C24 alkyl)), di-(C1-C4 alkyl)-substituted 
carbamoyl (-(CO)-N(C1 -C24 alkyl)2), mono-substituted 
arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl 
(-(CS)-NH2), carbamido (-NH-(CO)-NH2), cyano 
(-CN), isocyano (-N+C-), cyanato (---0-CN), isocya­
nato (-ON+C-), isothiocyanato (-S-CN), azido
(-N W=W), formyl (-(CO)-H), thioformyl 
(-(CS)-H), amino (-NH2), mono- and di-(C1-C24 alkyl)­
substituted amino, mono- and di-(C5-C20 aryl)-substituted 
amino, C2-C24 alkylamido (-NH-(CO)-alkyl), C6-C20
arylamido (-NH-(CO)-aryl), imino (-CR NH where 
R= hydrogen, C1 -C24 alkyl, C5-C20 aryl, C6-C24 alkaryl, 
CcC24 aralkyl, etc.), alkylimino (-CR N(alkyl), where 
R= hydrogen, alkyl, aryl, alkaryl, etc.), arylimino (-CR N 
(aryl), where R= hydrogen, alkyl, aryl, alkaryl, etc.), nitro 
(-N02), nitroso (-NO), sulfa (-S02---0H), sulfonato 
(-S02-o-), C1 -C24 alkylsulfanyl (-S-alkyl; also termed 
"alkylthio"), arylsulfanyl (-S-aryl; also termed "arylthio"), 
C1-C24 alkylsulfinyl (-(SO)-alkyl), C5-C20 arylsulfinyl 
(-(SO)-aryl), C1 -C24 alkylsulfonyl (-S02-alkyl), C5-C20 
arylsulfonyl (-S02-aryl), phosphono (-P(O)(OH)2), 
phosphonato (-P(0)(0-)2), phosphinato (-P(O)(O-)), 
phospho (-P02), and phosphino (-PH2); and the hydro­
carbyl moieties C1 -C24 alkyl, C2-C24 alkenyl, C2-C24 alky­
nyl, C5-C20 aryl, CcC24 alkaryl, and CcC24 aralkyl. 
In addition, the aforementioned functional groups may, if 
a particular group permits, be further substituted with one or 
more additional functional groups or with one or more 
hydrocarbyl moieties such as those specifically enumerated 
above. Analogously, the above-mentioned hydrocarbyl moi­
eties may be further substituted with one or more functional 
groups or additional hydrocarbyl moieties such as those 
specifically enumerated. 
When the term "substituted" appears prior to a list of 
possible substituted groups, it is intended that the term apply 
to every member of that group. For example, the phrase 
"substituted alkyl, alkenyl, and aryl" is to be interpreted as 
"substituted alkyl, substituted alkenyl, and substituted aryl." 
Analogously, when the term "heteroatom-containing" 
appears prior to a list of possible heteroatom-containing 
groups, it is intended that the term apply to every member 
of that group. For example, the phrase "heteroatom-contain­
ing alkyl, alkenyl, and aryl" is to be interpreted as "heteroa­
tom-containing alkyl, substituted alkenyl, and substituted 
aryl. 
"Optional" or "optionally" means that the subsequently 
described circumstance may or may not occur, so that the 
description includes instances where the circumstance 
occurs and instances where it does not. For example, the 
phrase "optionally substituted" means that a non-hydrogen 
substituent may or may not be present on a given atom, and, 
thus, the description includes structures wherein a non­
hydrogen substituent is present and structures wherein a 
non-hydrogen substituent is not present. 
The terms "stable compound" and "stable structure" are 
meant to indicate a compound that is sufficiently robust to 
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survive isolation, and as appropriate, purification from a 
reaction mixture, and formulation into an efficacious thera­
peutic agent. 
The terms "free compound" is used herein to describe a 
compound in the unbound state. 
Throughout the description, where compositions are 
described as having, including, or comprising, specific com­
ponents, it is contemplated that compositions also consist 
essentially of, or consist of, the recited components. Simi­
larly, where methods or processes are described as having, 10 
including, or comprising specific process steps, the pro­
cesses also consist essentially of, or consist of, the recited 
processing steps. Further, it should be understood that the 
order of steps or order for performing certain actions is 
immaterial so long as the compositions and methods 15 
described herein remains operable. Moreover, two or more 
steps or actions can be conducted simultaneously. 
The term "small molecule" is an art-recognized term. In 
certain embodiments, this term refers to a molecule, which 
has a molecular weight of less than about 2000 amu, or less 20 
than about 1000 amu, and even less than about 500 amu. 
All percentages and ratios used herein, unless otherwise 
indicated, are by weight. 
The term "neoplasm" refers to any abnormal mass of cells 
or tissue as a result of neoplasia. The neoplasm may be 25 
benign, potentially malignant (precancerous), or malignant 
(cancerous). An adenoma is an example of a neoplasm. 
22 
double-stranded polynucleotides. In some embodiments, 
"nucleic acid" refers to inhibitory nucleic acids. Some 
categories of inhibitory nucleic acid compounds include 
antisense nucleic acids, RNAi constructs, and catalytic 
nucleic acid constructs. Such categories of nucleic acids are 
well-known in the art. 
Embodiments described herein relate to compounds and 
methods of modulating 15-PGDH activity, modulating tis­
sue prostaglandin levels, and/or treating diseases, disorders, 
or conditions in which it is desired to modulate 15-PGDH 
activity and/or prostaglandin levels "Inhibitors," "activa­
tors," and "modulators" of 15-PGDH expression or of 
15-PGDH activity are used to refer to inhibitory, activating,
or modulating molecules, respectively, identified using in
vitro and in vivo assays for 15-PGDH expression or
15-PGDH activity, e.g., ligands, agonists, antagonists, and 
their homologs and mimetics. The term "modulator"
includes inhibitors and activators. Inhibitors are agents that,
e.g., inhibit expression of 15-PGDH or bind to, partially or
totally block stimulation, decrease, prevent, delay activa­
tion, inactivate, desensitize, or down regulate the activity of
15-PGDH, e.g., antagonists. Activators are agents that, e.g.,
induce or activate the expression of a 15-PGDH or bind to,
stimulate, stabilize, increase, open, activate, facilitate, or
enhance activation, sensitize or up regulate the activity of
15-PGDH, e.g., agonists. Modulators include naturally
occurring and synthetic ligands, small chemical molecules,
and the like.
15-PGDH inhibitors described herein can provide a phar-
The terms "adenoma", "colon adenoma" and "polyp" are 
used herein to describe any precancerous neoplasm of the 
colon. 
The term "colon" as used herein is intended to encompass 
the right colon (including the cecum), the transverse colon, 
the left colon and the rectum. 
The terms "colorectal cancer" and "colon cancer" are 
used interchangeably herein to refer to any cancerous neo­
plasia of the colon (including the rectum, as defined above). 
30 macologic method for elevating prostaglandin levels in 
tissue. Known activities of prostaglandins include promot­
ing hair growth, promoting skin pigmentation, and promot­
ing skin darkening or the appearance of skin tanning. Known 
activities of prostaglandins also include ameliorating pul-
The terms "gene expression" or "protein expression" 
includes any information pertaining to the amount of gene 
transcript or protein present in a sample, as well as infor­
mation about the rate at which genes or proteins are pro­
duced or are accumulating or being degraded ( e.g., reporter 
gene data, data from nuclear runoff experiments, pulse-chase 
data etc.). Certain kinds of data might be viewed as relating 
35 monary artery hypertension. 15-PGDH inhibitors described 
herein may also be utilized to increase tissue stem cell 
numbers for purposes that would include increasing resis­
tance to tissue damage by radiation, increasing resistance to 
environmental exposures to radiation, increasing stem cell 
40 numbers to increase fitness of bone marrow or other types of 
transplantation (through either in vivo exposure to 
15-PGDH inhibitors described herein to increase stem cell
numbers prior to harvest of a transplanted tissue, or through
to both gene and protein expression. For example, protein 
levels in a cell are reflective of the level of protein as well 45 
as the level of transcription, and such data is intended to be 
included by the phrase "gene or protein expression infor­
mation". Such information may be given in the form of 
amounts per cell, amounts relative to a control gene or 
protein, in unitless measures, etc.; the term "information" is 50 
not to be limited to any particular means of representation 
and is intended to mean any representation that provides 
relevant information. The term "expression levels" refers to 
a quantity reflected in or derivable from the gene or protein 
expression data, whether the data is directed to gene tran- 55 
script accumulation or protein accumulation or protein syn­
thesis rates, etc. 
The terms "healthy" and "normal" are used interchange­
ably herein to refer to a subject or particular cell or tissue 
that is devoid (at least to the limit of detection) of a disease 60 
condition. 
The term "nucleic acid" refers to polynucleotides such as 
deoxyribonucleic acid (DNA), and, where appropriate, ribo­
nucleic acid (RNA). The term should also be understood to 
include analogues of either RNA or DNA made from nucleo- 65 
tide analogues, and, as applicable to the embodiment being 
described, single-stranded ( such as sense or anti sense) and 
ex vivo exposure of a harvested tissue prior to transplant into
a recipient host). 15-PGDH inhibitors described herein may
also be utilized for purposes that would include promoting
liver regeneration, including liver regeneration after liver
resection, and liver regeneration after toxic insults, which
for example may be the toxic insult of acetaminophen
overdose. Prostaglandin signaling is also known to promote
wound healing, protect the stomach from ulceration, and
promote healing of ulcers of stomach and intestines. Addi­
tionally, 15-PGDH inhibitors described herein can promote
activity of human keratinocytes in "healing" scratches
across cultures of keratinocyte cells. Hence, 15-PGDH
inhibitors described herein may be utilized to also heal 
ulcers of other tissues, including, but not limited to skin, and 
including but not limited to diabetic ulcers. Further, 
15-PGDH inhibitors described herein may be utilized for the 
treatment of erectile dysfunction.
15-PGDH activators described herein can increase levels
of 15-PGDH protein in cells and in increase levels of 
15-PGDH enzymatic activity in cells. Increasing tissue
levels of 15-PGDH can decrease tissue levels of prostaglan­
dins. Activities associated with compounds that decrease
tissue prostaglandins include decreasing development of
human tumors, particularly decreasing development of
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human colon tumors. Accordingly, compounds that increase 
tissue 15-PGDH activity can lower risk of development of 
colon and other tumors. Compounds that increase 15-PDGH 
activity can also be used to treat colon and other tumors. 
Compounds that increase 15-PDGH may be used to treat or 5 
to prevent tumors when given singly, or when given in 
combination with inhibitors of cyclooxygenase-1 and/or 
cyclooxygenase-2 enzymes, or when given in combination 
with other therapeutic agents. 
15-PGDH inhibitors and activators described herein can 10 
be identified using assays in which putative modulator 
compounds are applied to cells expressing 15-PGDH and 
then the functional effects on 15-PGDH activity are deter­
mined Samples or assays comprising 15-PGDH that are 
treated with a potential activator, inhibitor, or modulator are 15 
compared to control samples without the inhibitor, activator, 
or modulator to examine the extent of effect. Control 
samples (untreated with modulators) are assigned a relative 
15-PGDH activity value of 100% Inhibition of 15-PGDH is
achieved when the 15-PGDH activity value relative to the 20 
control is about 80%, optionally 50% or 25%, 10%, 5% or
1 %. Activation of l 5-PGDH is achieved when the 15-PGDH
activity or expression value relative to the control is 105%,
optionally 110%, optionally 125%, optionally 150%, option­
ally 200%, 300%, 400%, 500%, or 1000-3000% or more 25 
higher.
Agents tested as modulators of 15-PGDH can be any 
small chemical molecule or compound. Typically, test com­
pounds will be small chemical molecules, natural products, 
or peptides. The assays are designed to screen large chemical 
30 
libraries by automating the assay steps and providing com­
pounds from any convenient source to assays, which are 
typically run in parallel (e.g., in microtiter formats on 
microtiter plates in robotic assays). Modulators also include 
agents designed to increase the level of 15-PGDH mRNA or 
35 
the level of translation from an mRNA. 
In some embodiments, the modulator of 15-PGDH can be 
a 15-PGDH inhibitor that includes a compound having the 
following formula (I): 
40 
(I) 
45 
50 
wherein n is 0-2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted ( e.g., R 1 can be 
C2_6 alkyl, C2_4 alkyl, or C4 alkyl, which is linear, 55 
branched, or cyclic and which is unsubstituted or 
substituted); 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)niOR' (wherein nl=l, 2, or 3), CF 3, CH2- 60 
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=0)-R'(C=O)N(R')2, O(CO)R', COOR' (wherein 
R' is H or a lower alkyl group); 
R4 and Rs are the same or different and are each selected 65 
from the group consisting of hydrogen, C1 -C24 alkyl, 
C2-C24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, CcC24 
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alkaryl, CcC24 aralkyl, halo, silyl, hydroxyl, sulfhy­
dryl, C1 -C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alky­
nyloxy, Cs-C20 aryloxy, acyl (including C2-C24 alkyl­
carbonyl (-CO-alkyl) and CcC20 arylcarbonyl 
(-CO-aryl)), acyloxy (-0-acyl), C2-C24 alkoxycar­
bonyl (-(C0)---0-alkyl), CcC20 aryloxycarbonyl 
(-(C0)---0-aryl), C2-C24 alkylcarbonato (-O­
(C0)---0-alkyl), C6-C20 arylcarbonato (---0-(CO)­
O-aryl), carboxy (-COOH), carboxylato (-Coo-), 
carbamoyl (-(CO)-NH2), C1 -C24 alkyl-carbamoyl 
(-(CO)-NH(C1 -C24 alkyl)), arylcarbamoyl 
(-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), 
carbamido (-NH-(CO)-NH2), cyano(----CN), iso­
cyano (-N+c-), cyanato (---0-CN), isocyanato
(-0-N+=C-), isothiocyanato (-S----CN), azido
(-N W W), formyl (-(CO)-H), thioformyl 
(-(CS)-H), amino (-NH2), C1-C24 alkyl amino, 
Cs-C20 aryl amino, C2-C24 alkylamido (-NH-(CO)­
alkyl), CcC20 arylamido (-NH-(CO)-aryl), imino 
(-CR NH where R is hydrogen, C1-C24 alkyl, 
Cs-C20 aryl, CcC24 alkaryl, CcC24 aralkyl, etc.), alky­
limino (----CR=N(alkyl), where R = hydrogen, alkyl, 
aryl, alkaryl, aralkyl, etc.), arylimino (----CR=N(aryl), 
where R = hydrogen, alkyl, aryl, alkaryl, etc.), nitro 
(-N02), nitroso (-NO), sulfa (-S02-0H), sul­
fonato (-S02-0), C1-C24 alkylsulfanyl (-S-alkyl; 
also termed "alkylthio"), arylsulfanyl (-S-aryl; also 
termed "arylthio"), C1 -C24 alkylsulfinyl (-(SO)­
alkyl), Cs-C20 arylsulfinyl (-(SO)-aryl), C1-C24 alkyl­
sulfonyl (-S02-alkyl), Cs-C20 arylsulfonyl (-S02-
aryl), phosphono (-P(O)(OH)2), phosphonato (-P 
(0)(0-)2), phosphinato (-P(O)(O-)), phospho 
(-P02), phosphino (-PH2), combinations thereof, 
and wherein R4 and Rs may be linked to form a cyclic 
or polycyclic ring, wherein the ring is a substituted or 
unsubstituted aryl, a substituted or unsubstituted het­
eroaryl, a substituted or unsubstituted cycloalkyl, and a 
substituted or unsubstituted heterocyclyl; and pharma­
ceutically acceptable salts thereof. 
In other embodiments, the 15-PGDH inhibitor can include 
a compound having the following formula (II): 
(II) 
wherein n is 0-2; 
R 1 is a C1 _8 alkyl, which is linear, branched, or cyclic, and 
which is unsubstituted or substituted; 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)niOR' (wherein nl=l, 2, or 3), CF 3, CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is H or a lower alkyl group); 
Z1 is NR', 0 or S (wherein R' is H or a lower alkyl group); 
X1 and Y1 are the same or different and are each selected 
from the group consisting of hydrogen, C1 -C24 alkyl, 
C2-C24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, CcC24 
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alkaryl, CcC24 aralkyl, halo, silyl, hydroxyl, sulfhy­
dryl, C 1 -C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alky­
nyloxy, C5-C20 aryloxy, acyl (including C2-C24 alkyl­
carbonyl (-CO-alkyl) and CcC20 arylcarbonyl 
(-CO-aryl)), acyloxy (-0-acyl), C2-C24 alkoxycar- 5 
bony! (-(C0)---0-alkyl), CcC20 aryloxycarbonyl 
(-(C0)---0-aryl), C2-C24 alkylcarbonato (-O­
(C0)---0-alkyl), C6-C20 arylcarbonato (-0-(CO)­
O-aryl), carboxy (-COOR), carboxylato (-Coo-), 
carbamoyl (-(CO)-NH2), C 1 -C24 alkyl-carbamoyl 
10 
(-(CO)-NH(C 1-C24 alkyl)), arylcarbamoyl
(-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), 
carbamido (-NH-(CO)-NH2), cyano(-CN), iso­
cyano (-N+c-), cyanato (-0---CN), isocyanato 15 
(-0-N+=C-), isothiocyanato (-S---CN), azido
(-N W=W), formyl (-(CO)-H), thioformyl 
(-(CS)-H), amino (-NH2), C 1-C24 alkyl amino,
C5-C20 aryl amino, C2-C24 alkylamido (-NH-(CO)­
alkyl), CcC20 arylamido (-NH-(CO)-aryl), imino 20 
(-CR NH where R is hydrogen, C 1 -C24 alkyl,
C5-C20 aryl, CcC24 alkaryl, CcC24 aralkyl, etc.), alky­
limino (-CR=N(alkyl), where R = hydrogen, alkyl, 
aryl, alkaryl, aralkyl, etc.), arylimino (-CR N(aryl), 
where R = hydrogen, alkyl, aryl, alkaryl, etc.), nitro 25 
(-N02), nitroso (-NO), sulfa (-S02-0H), sul­
fonato (-S02---0-), C 1-C24 alkylsulfanyl (-S-alkyl; 
also termed "alkylthio"), arylsulfanyl (-S-aryl; also 
termed "arylthio"), C 1 -C24 alkylsulfinyl (-(SO)­
alkyl), C5-C20 arylsulfinyl (-(SO)-aryl), C 1 -C24 alkyl-
30 
sulfonyl (-S02-alkyl), C5-C20 arylsulfonyl (-S02-
aryl), phosphono (-P(O)(OH)2), phosphonato (-P 
(0)(0-)2), phosphinato (-P(O)(O-)), phospho 
(-P02), phosphino (-PH2), combinations thereof, 35 
and wherein X1 and Y1 may be linked to form a cyclic 
or polycyclic ring, wherein the ring is a substituted or 
unsubstituted aryl, a substituted or unsubstituted het­
eroaryl, a substituted or unsubstituted cycloalkyl, and a 
substituted or unsubstituted heterocyclyl; and pharma- 40 
ceutically acceptable salts thereof. 
Examples of 15-PGDH inhibitors having formulas (I) or 
(II) include the following compounds:
0 
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which a value of 100 indicates a doubling ofreporter output 
over baseline); iia) at 2.5 µM concentration stimulate a V9m 
reporter cell line expressing a 15-PGDH luciferase fusion 
construct to a luciferase output level of greater than 75; iiia) 
5 at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 70; and iva) at 7 .5 µM 
concentration, does not activate a negative control V9m cell 
line expressing TK-renilla luciferase reporter to a level 
10 greater than 20; and va) inhibits the enzymatic activity of 
recombinant 15-PGDH protein at an IC50 ofless than 1 µM 
In other embodiments, the 15-PGDH inhibitor can ib) at 
2.5 µM concentration, stimulate a Vaco503 reporter cell line 
15 expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; iib) at 2.5 µM concentration 
stimulate a V9m reporter cell line expressing a 15-PGDH 
luciferase fusion construct to increase luciferase output; iiib) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
20 line expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; ivb) at 7.5 µM concentration, 
does not activate a negative control V9m cell line expressing 
TK-renilla luciferase reporter to a luciferase level greater 
than 20% above background; and vb) inhibits the enzymatic 
25 activity ofrecombinant 15-PGDH protein at an IC50 ofless 
than 1 µM. 
In other embodiments, the 15-PGDH inhibitor can inhibit 
the enzymatic activity of recombinant 15-PGDH at: ic) an 
IC50 of less than 1 uM, or preferably iic) at an IC50 of less 
30 than 250 nM, or more preferably iiic) at an IC50 ofless than 
50 nM, or more preferably iv) at an IC50 ofless than 5 nM. 
An example of a 15-PGDH inhibitor having formula (I) 
that meets the above noted criteria (ia-va) includes a com­
pound having the formula (III): An example of a 15-PGDH 
35 inhibitor having formula (I) that meets the above noted 
criteria (ib-vb) includes a compound having the formula 
(III): An example of a 15-PGDH inhibitor having formula (I) 
that meets the above noted criteria ic, and/or iic, and or iiic, 
and or ivc, includes a compound having the formula (III): In 
40 still other embodiments, the 15-PGDH inhibitor can include 
a compound having the following formula (III): 
(III) 
45 
50 
wherein n is 0-2; CCN S�;
N=O 
CCN S�; 55
NH2 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted; 
R2 and R3 are the same or different and are each selected 
from the group consisting of a H, a lower alkyl group, 
(CH2)niOR' (wherein nl=l, 2, or 3), CF3, CH2-
CH2X, O---CH2---CH2X, CH2---CH2---CH2X, 
O---CH2---CH2X (wherein X=F, Cl, Br, or I), CN, 
(C=O)-R', (C=O)N(R')2, O(CO)R', COOR' 
(wherein R' is H or a lower alkyl group); 
II 
0 60 
and pharmaceutically acceptable salts thereof. 
In certain embodiments, the 15-PGDH inhibitor having 
formula (I) or (II) can be selected that can ia) at 2.5 µM 
concentration, stimulate a Vaco503 reporter cell line 65 
expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 70 (using a scale on 
Z1 is NR', 0 or S (wherein R' is H or a lower alkyl group); 
X2 is N or C; 
R6 and R7 are optional and if present are the same or 
different and are each selected from the group consist-
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ing of a H, F, Cl, Br, I, a lower alkyl group, (CH2)n1 OR' 
(wherein nl=l, 2, or 3), CF 3, CH2----CH2X, O----CH2-
CH2X, CH2-CH2-CH2X, O-CH2-CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
N02, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 5 
(wherein R' is H or a lower alkyl group); substituted or 
unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, and a substituted or unsubstituted hetero­
cyclyl; and pharmaceutically acceptable salts thereof. 
15-PGDH inhibitors having formula (III) can be synthe- 10 
sized as shown: 
30 
inhibitors having the formula III can be separated by a 
preparative HPLC using chromatography columns contain­
ing chiral stationary phases. 
Further, embodiments of this application include any 
modifications for the preparation method of the 15-PGDH 
inhibitors described above. In this connection, any interme­
diate product obtainable from any step of the preparation 
method can be used as a starting material in the other steps. 
Such starting material can be formed in situ under certain 
reaction conditions. Reaction reagents can also be used in 
the form of their salts or optical isomers. 
Depending on the kinds of the substituents to be used in 
the preparation of the 15-PGDH inhibitors, and the inter-
s O 
+ �CN ���"----
15 mediate product and the preparation method selected, novel
15-PGDH inhibitors can be in the form of any possible
isomers such as substantially pure geometrical ( cis or trans)
isomers, optical isomers (enantiomers) and racemates.
H2N 
s 
UCNc1�s, 
In some embodiments, a 15-PGDH inhibitor having for-
20 mula (III) can include a compound with the following 
formula: 
I 
R1 
Et3N 
R,; R1 
s)
Ri 
H202 ix AcOH 
I 
CN -
R,; R1 
25 
30 
35 
// 
s� 
and pharmaceutically acceptable salts thereof. 
Advantageously, the 15-PDGH inhibitor having formula 
(III) was found to: i) inhibit recombinant 15-PGDH at 1 nM
concentration; ii) inhibit 15-PGDH in cell lines at 100 nM
40 concentration, iii) increase PGE2 production by cell lines; 
iv) is chemically stable in aqueous solutions over broad pH
range; v) is chemically stable when incubated with hepato­
cyte extracts, vi) is chemically stable when incubated with
hepatocyte cell lines; vii) shows 253 minutes plasma half-
45 life when injected IP into mice; and viii) shows no imme­
diate toxicity over 24 hours when injected IP into mice at 0.6 
µmole/per mouse and at 1.2 µmole/per mouse and also no 
toxicity when injected IP into mice at 0.3 µmole/per mouse Any reaction solvent can be used in the above preparation 
process as long as it is not involved in the reaction. For 
example, the reaction solvent includes ethers such as diethyl 50 
ether, tetrahydrofuran and dioxane; halogenized hydrocar­
bons, such as dichloromethane and chloroform; amines such 
as pyridine, piperidine and triethylamine; alkylketones, such 
as acetone, methylethylketone and methylisobutyl; alcohols, 
such as methanol, ethanol and propanol; non-protonic polar 55 
solvent, such as N,N-dimethylformamide, N,N-dimethylac­
etamide, acetonitrile, dimethylsulfoxide and hexamethyl 
phosphoric acid triamide. Among non-reactive organic sol­
vents that are ordinarily used in the organic synthesis, 
preferable solvents are those from which water generated in 60 
the reaction can be removed by a Dean-Stark trap. The 
examples of such solvents include, but are not limited to 
benzene, toluene, xylene and the like. The reaction product 
thus obtained may be isolated and purified by condensation, 
extraction and the like, which is ordinarily conducted in the 65 
field of the organic synthesis, if desired, by silica gel column 
chromatography. The individual enantiomers of PGDH 
twice daily for 21 days. 
In other embodiments, a 15-PGDH inhibitor having for­
mula (III) can include a compound with the following 
formula: 
and pharmaceutically acceptable salts thereof. 
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In still other embodiments, a 15-PGDH inhibitor having 
formula (III) can include a compound with the following 
formula: 
and pharmaceutically acceptable salts thereof. 
In other embodiments, the 15-PDHG inhibitor can com­
prise a ( +) or (-) optical isomer of a 15-PGDH inhibitor 
having formula (III). In still other embodiments, the 
15-PDHG inhibitor can comprise a mixture at least one of a
32 
of prostaglandins in the various compartments of hair fol­
licles or their adjacent skin environments has been shown to 
be essential in maintaining and increasing hair density 
(Colombe Let. al, 2007, Exp. Dermatol, 16(9), 76 2-9). It has 
5 been reported that 15-PGDH, which is involved in the 
degradation of prostaglandins is present in the hair follicle 
dermal papillae, inactivates prostaglandins, especially, 
PGF 2a and PGE2, to cause scalp damage and alopecia 
(Michelet J F et. al., 2008, Exp. Dermatol, 17(10), 821-8). 
10 Thus, the compounds described herein, which have a sup­
pressive or inhibitory activity against 15-PGDH that 
degrades prostaglandins, can improve scalp damage, prevent 
alopecia and promote hair growth and be used in a pharma­
ceutical composition for the prevention of alopecia and the 
15 promotion of hair growth. 
In other embodiments, the 15-PGDH inhibitors described 
herein can be used in a pharmaceutical composition for 
promoting and/or inducing and/or stimulating pigmentation 
of the skin and/or skin appendages, and/or as an agent for 
20 preventing and/or limiting depigmentation and/or whitening 
of the skin and/or skin appendages, in particular as an agent 
for preventing and/or limiting canities. 
In still other embodiments, the 15-PGDH inhibitors 
described herein can be used in a pharmaceutical composi-
25 tion for the prevention or the treatment of cardiovascular 
disease and/or diseases of vascular insufficiency, such as 
Raynaud's disease, Buerger's disease, diabetic neuropathy, 
and pulmonary artery hypertension. Prostaglandins includ­
ing prostaglandin homologues produced in the body have 
( +) or (-) optical isomer of a 15-PGDH inhibitor having
formula (III). For example, the 15-PGDH inhibitor can
comprise a mixture of: less than about 50% by weight of the
(-) optical isomer of a 15-PGDH inhibitor having formula
(III) and greater than about 50% by weight of the ( +) optical
isomer of a 15-PGDH inhibitor having formula (III), less
than about 25% by weight of the (-) optical isomer of a
15-PGDH inhibitor having formula (III) and greater than
about 75% by weight of the ( +) optical isomer of a
15-PGDH inhibitor having formula (III), less than about
10% by weight of the(-) optical isomer of a 15-PGDH
inhibitor having formula (III) and greater than about 90% by
weight of the(+) optical isomer of a 15-PGDH inhibitor
having formula (III), less than about 1 % by weight of the (-)
optical isomer of a 15-PGDH inhibitor having formula (III)
and greater than about 99% by weight of the ( +) optical
isomer of a 15-PGDH inhibitor having formula (III), greater
than about 50% by weight of the (-) optical isomer of a
15-PGDH inhibitor having formula (III) and less than about
50% by weight of the ( +) optical isomer of a 15-PGDH 
inhibitor having formula (III), greater than about 75% by 
weight of the(-) optical isomer of a 15-PGDH inhibitor 
having formula (III) and less than about 25% by weight of 45 
the (+) optical isomer of a 15-PGDH inhibitor having 
formula (III), greater than about 90% by weight of the (-) 
optical isomer of a 15-PGDH inhibitor having formula (III) 
and less than about 10% by weight of the ( +) optical isomer 
30 been known to maintain the proper action of the blood vessel 
wall, especially to contribute to vasodilation for blood flow, 
preventing platelet aggregation and modulating the prolif­
eration of smooth muscle that surrounds blood vessel walls 
(Yan. Cheng et. al., 2006 , J. Clin., Invest). In addition, the 
35 inhibition of prostaglandins production or the loss of their 
activity causes the degeneration of the endothelium in the 
blood vessel walls, platelet aggregation and the dysfunction 
of cellular mechanism in the smooth muscle. Among others, 
the production of prostaglandins in blood vessels was shown 
40 to be decreased in hypertension patients, including pulmo­
nary artery hypertension. 
In other embodiments, the 15-PGDH inhibitors described 
herein can be used in a pharmaceutical composition for the 
prevention or the treatment of oral and/or gastrointestinal 
diseases, such as oral ulcers, gum disease, gastritis, colitis, 
ulcerative colitis, and gastric ulcers. Gastritis and gastric 
ulcer, representatives of the gastrointestinal diseases, are 
defined as the conditions where gastrointestinal mucus 
membrane is digested by gastric acid to form ulcer. In the 
of a 15-PGDH inhibitor having formula (III), or greater than 
about 99% by weight of the (-) optical isomer of a 
15-PGDH inhibitor having formula (III) and less than about
1 % by weight of the ( +) optical isomer of a 15-PGDH
inhibitor having formula (III).
In a still further embodiment, the 15-PDGH inhibitor can 
consist essentially of or consist of the ( +) optical isomer of 
a 15-PGDH inhibitor having formula (III). In yet another 
embodiment, the PDGH inhibitor can consist essentially of 
or consist of the (-) optical isomer of a 15-PGDH inhibitor 
having formula (III). 
The 15-PGDH inhibitors described herein can be used for 
the prevention or the treatment of diseases that are associ­
ated with 15-PGDH and/or decreased prostaglandin levels 
and/or where it desirable to increase prostaglandin levels in 
the subject. For example, as discussed above, it is known 
that prostaglandins play an important role in hair growth. 
Specifically, internal storage of various types (A2, F 2a, E2) 
50 stomach walls generally consisting of mucosa, submucosa, 
muscle layer and serosa, gastric ulcer even damages sub­
mucosa and muscle layer, while gastritis damages mucosa 
only. Although the morbidity rates of gastritis and gastric 
ulcer are relatively high, the causes thereof have not been 
55 clarified yet. Until now, they are known to be caused by an 
imbalance between aggressive factors and defensive factors, 
that is, the increase in aggressive factors such as the increase 
in gastric acid or pepsin secretion, or the decrease in 
defensive factors such as structural or morphological deficit 
60 of the gastric mucus membrane, the decrease in mucus and 
bicarbonate ion secretion, the decrease in prostaglandin 
production, or the like. 
Currently available therapeutic agents for gastritis and 
gastric ulcer comprise various drugs for strengthening the 
65 defensive factors such as an antacid, which does not affect, 
gastric acid secretion but neutralizes gastric acid that has 
been already produced, an inhibitor of gastric acid secretion, 
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a promoter of prostaglandin secretion, and a coating agent 
for stomach walls. Especially, prostaglandins are known to 
be essential in maintaining the mechanism for protecting and 
defending gastric mucus membrane (Wallace J L., 2008, 
Physiol Rev., 88(4), 1547-65, S. J. Konturek et al., 2005, 
Journal of Physiology and Pharmacology, 56(5)). In view of 
the above, since the 15-PGDH inhibitors described herein 
show a suppressive or inhibitory activity against 15-PGDH, 
which degrades prostaglandins that protect gastric mucus 
membrane, they can be effective for the prevention or the 
treatment of gastrointestinal diseases, inter alia, gastritis and 
gastric ulcer. 
In the kidney, prostaglandins modulate renal blood flow 
and may serve to regulate urine formation by both renovas­
cular and tubular effects. In clinical studies, PGE1 has been 
used to improve creatinine clearance in patients with chronic 
renal disease, to prevent graft rejection and cyclosporine 
toxicity in renal transplant patients, to reduce the urinary 
albumin excretion rate and N-acetyl-beta-D-glucosamini­
dase levels in patients with diabetic nephropathy ( see Porter, 
Am., 1989, J. Cardiol., 64: 22E-26E). In addition, U.S. Pat. 
No. 5,807,895 discloses a method of preventing renal dys­
function by intravenous administration of prostaglandins 
such as PGE1 , PGE2 and PGI2. Furthermore, it has been 
reported that prostaglandins serve as vasodilators in the 
kidney, and, thus, the inhibition of prostaglandin production 
in the kidney results in renal dysfunction (Hao. C M, 2008, 
Annu Rev Physiol, 70, 357.about.77). 
34 
wounds or burns, the inhibition of 15-PGDH activity can 
produce the treatment effect of the wounds or the burns by 
PGE2. 
Additionally, as discussed above, increased prostaglandin 
levels have been shown to stimulate signaling through the 
Wnt signaling pathway via increased beta-catenin mediated 
transcriptional activity. Wnt signaling is known to be a key 
pathway employed by tissue stem cells, and increasing 
PGE2 signaling has in model organisms been shown to 
10 increase numbers of hematopoietic stem cells. Hence, 
15-PGDH inhibitors described herein may be utilized to
increase tissue stem cell numbers for purposes that would
include increasing resistance to tissue damage by radiation,
increasing resistance to environmental exposures to radia-
15 tion, increasing stem cell numbers to increase fitness of bone 
marrow or other types of transplantation (through either in 
vivo exposure to 15-PGDH inhibitors described herein to 
increase stem cell numbers prior to harvest of a transplanted 
tissue, or through ex vivo exposure of a harvested tissue 
20 prior to transplant into a recipient host, or th rough treatment 
of the recipient host either before, during, or after receipt of 
the transplant). 
In some embodiments, the 15-PGDH inhibitor can be 
administered to a bone marrow graft donor or a hematopoi-
25 etic stem cell donor to increase the fitness of a donor bone 
marrow graft or a donor hematopoietic stem cell graft. 
In other embodiments, the 15-PGDH inhibitor can also be 
administered to bone marrow of a subject to increase stem 
cells in the subject or to increase the fitness of the marrow 
as a donor graft. 
In still other embodiments, the 15-PGDH inhibitor can be 
administered to a preparation of hematopoietic stem cells, 
peripheral blood hematopoietic stem cells, or umbilical cord 
stem cells of the subject to increase the fitness of the stem 
Thus, the 15-PGDH inhibitors described herein, which 30 
have a suppressive or inhibitory activity against 15-PGDH 
that degrades prostaglandins, may be effective in the pre­
vention or the treatment of renal diseases that are associated 
with renal dysfunction. 35 cell preparation as a donor graft or to decrease the number 
of units of umbilical cord blood required for transplantation. The term "renal dysfunction" as used herein includes such 
manifestations as follows: lower than normal creatinine 
clearance, lower than normal free water clearance, higher 
than normal blood urea, nitrogen, potassium and/or creati­
nine levels, altered activity of kidney enzymes such as 
gamma glutamyl synthetase, alanine phosphatidase, 
N-acetyl-beta-D-glucosaminidase, or beta-w-microglobulin;
and increase over normal levels of macroalbuminuria.
Prostaglandins including PGE1 , PGE2 and PGF2a have 
also been shown to stimulate bone resorption and bone 
formation to increase the volume and the strength of the 
bone (H. Kawaguchi et. al., Clinical Orthop. Rel. Res., 313, 
1995; J. Keller et al., Eur. Jr. Exp. Musculoskeletal Res., 1, 
1992, 8692). Considering that 15-PGDH inhibits the activi­
ties of prostaglandins as mentioned in the above, the inhi­
bition of 15-PGDH activity may lead to the promotion of 
bone resorption and bone formation that are inhibited by 
15-PGDH. Thus, the 15-PGDH inhibitors described herein
can be effective for the promotion of bone resorption and
bone formation by inhibiting 15-PGDH activity. 15-PGDH
inhibitors can also be used to increase bone density, treat
osteoporosis, promote healing of fractures, or promote heal­
ing after bone surgery or joint replacement.
In yet other embodiments, the 15-PGDH inhibitors 
described herein can effective for treating 15-PGDH 
expressing cancers Inhibition of 15-PGDH can inhibit the 
growth, proliferation, and metastasis of 15-PGDH express­
ing cancers. 
In still other embodiments, the 15-PGDH inhibitors 
described herein can be effective for wound healing. Among 
various prostaglandins, PGE2 is known to serve as a media­
tor for wound healing. Therefore, when skin is injured by 
In yet other embodiments, the 15-PGDH inhibitor can be 
administered to a subject to mitigate bone marrow graft 
rejection, to enhance bone marrow graft engraftment, to 
40 enhance engraftment of a hematopoietic stem cell graft, or 
an umbilical cord stem cell graft, to enhance engraftment of 
a hematopoietic stem cell graft, or an umbilical cord stem 
cell graft, and/or to decrease the number of units of umbili­
cal cord blood required for transplantation into the subject. 
45 The administration can be, for example, following treatment 
of the subject or the marrow of the subject with radiation 
therapy, chemotherapy, or immunosuppressive therapy. 
In other embodiments, the 15-PGDH inhibitor can be 
administered to a recipient of a bone marrow transplant, of 
50 a hematopoietic stem cell transplant, or of an umbilical cord 
stem cell transplant, in order to decrease the administration 
of other treatments or growth factors. 
In further embodiments, the 15-PGDH inhibitor can be 
administered to a subject or to a tissue graft of a subject to 
55 mitigate graft rejection, to enhance graft engraftment, to 
enhance graft engraftment following treatment of the subject 
or the marrow of the subject with radiation therapy, chemo­
therapy, or immunosuppressive therapy, to confer resistance 
to toxic or lethal effects of exposure to radiation, confer 
60 resistance to the toxic effect of Cytoxan, the toxic effect of 
fludarabine, the toxic effect of chemotherapy, or the toxic 
effect of immunosuppressive therapy, to decrease infection, 
and/or to decrease pulmonary toxicity from radiation. 
Additionally, in model organism PGE2 signaling stimu-
65 !ates liver regeneration and increase survival after exposure 
to hepatoxic agents, such as acetaminophen. Hence, 
15-PGDH inhibitors described herein may be utilized to 
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increase liver regeneration after liver resection, or to 
increase liver regeneration and increase survival after expo­
sures to hepatoxic agents, including but not limited to 
acetaminophen and similar compounds. 
PGEl analogues have also been used in the treatment of 
erectile dysfunction. Accordingly, in some embodiments, 
15-PGDH inhibitors described herein can used either alone
or combination with a prostaglandin for the treatment of
erectile dysfunction.
36 
and thiolactic acid. The topical anesthetics may be procaine 
HCl, lidocaine HCl and the like. The relaxants may be 
sodium chloride, glucose and the like. 
In other embodiments, the 15-PGDH inhibitors described 
herein may be incorporated into suppositories in accordance 
with conventional methods by adding thereto pharmaceuti­
cally acceptable carriers that are known in the art, for 
example, polyethylene glycol, lanolin, cacao butter or fatty 
acid triglycerides, if necessary, together with surfactants 
The 15-PGDH inhibitors described herein can be pro­
vided in a pharmaceutical composition or cosmetic compo­
sition depending on the pathological or cosmetic condition 
or disorder being treated. A pharmaceutical composition 
containing the 15-PGDH inhibitors described herein as an 
active ingredient may be manufactured by mixing the 
derivative with a pharmaceutically acceptable carrier(s) or 
an excipient(s) or diluting the 15-PGDH inhibitors with a 
diluent(s) in accordance with conventional methods. The 
pharmaceutical composition may further contain fillers, anti­
cohesives, lubricants, wetting agents, flavoring agents, 
emulsifying agents, preservatives and the like. The pharma­
ceutical composition may be formulated into a suitable 
formulation in accordance with the methods known to those 
10 such as Tween. 
The pharmaceutical composition may be formulated into 
various dosage forms as discussed above and then admin­
istered through various routes including an oral, inhala­
tional, transdermal, subcutaneous, intravenous or intramus-
15 cular route. The dosage can be a pharmaceutically effective 
amount. The pharmaceutically effective amount can be an 
amount of the 15-PGDH inhibitor to treat or improve 
alopecia, cardiovascular disease, gastrointestinal disease, 
wounds, and renal disease. The pharmaceutically effective 
20 amount of the compound will be appropriately determined 
depending on the kind and the severity of the disease to be 
treated, age, sex, body weight and the physical condition of 
the patients to be treated, administration route, duration of 
skilled in the art so that it can provide an immediate, 
controlled or sustained release of the 15-PGDH inhibitors 25 
after being administered into a mammal. 
therapy and the like. Generally, the effective amount of the 
compound may be in the range of about 1 to 1,000 mg in the 
oral administration, about 0.1 to 500 mg in the intravenous 
administration, about 5 to 1,000 mg in the rectal adminis­
tration. Generally, the daily dosage for adults is in the range 
of about 0.1 to 5,000 mg, preferably about to 1,000 mg but 
30 camiot be determined uniformly because it depends on age, 
sex, body weight and the physical condition of the patients 
to be treated. The formulation may be administered once a 
day or several times a day with a divided dose. 
In some embodiments, the pharmaceutical composition 
may be formulated into a parenteral or oral dosage form. The 
solid dosage form for oral administration may be manufac­
tured by adding excipient, if necessary, together with binder, 
disintegrants, lubricants, coloring agents, and/or flavoring 
agents, to the 15-PGDH inhibitors and shaping the resulting 
mixture into the form of tablets, sugar-coated pills, granules, 
powder or capsules. The additives that can be added in the 
composition may be ordinary ones in the art. For example, 
examples of the excipient include lactose, sucrose, sodium 
chloride, glucose, starch, calcium carbonate, kaolin, micro­
crystalline cellulose, silicate and the like. Exemplary binders 
include water, ethanol, propanol, sweet syrup, sucrose solu­
tion, starch solution, gelatin solution, carboxymethylcellu­
lose, hydroxypropyl cellulose, hydroxypropyl starch, meth­
ylcellulose, ethylcellulose, shellac, calcium phosphonate 
and polypyrrolidone. Examples of the disintegrant include 
dry starch, sodium arginate, agar powder, sodium bicarbon­
ate, calcium carbonate, sodium lauryl sulfate, stearic mono- 45 
glyceride and lactose. Further, purified talc, stearates, 
sodium borate, and polyethylene glycol may be used as a 
lubricant; and sucrose, bitter orange peel, citric acid, tartaric 
acid, may be used as a flavoring agent. In some embodi­
ments, the pharmaceutical composition can be made into 50 
aerosol formulations ( e.g., they can be nebulized) to be 
administered via inhalation. 
Cosmetic compositions containing the 15-PGDH inhibi-
35 tor can include any substance or preparation intended to be 
brought into contact with the various superficial parts of the 
human body ( epidermis, body hair and hair system, nails, 
lips and external genital organs) or with the teeth or the 
buccal mucous membranes for the purpose, exclusively or 
40 mainly, of cleansing them, of giving them a fragrance, of 
modifying their appearance and/or of correcting body odors 
and/or protecting them or of maintaining them in good 
condition. 
The 15-PGDH inhibitors described herein may be com­
bined with flavoring agents, buffers, stabilizing agents, and 
the like and incorporated into oral liquid dosage forms such 55 
as solutions, syrups or elixirs in accordance with conven­
tional methods. One example of the buffers may be sodium 
citrate. Examples of the stabilizing agents include traga­
canth, acacia and gelatin. 
In some embodiments, the 15-PGDH inhibitors described 60 
herein may be incorporated into an injection dosage form, 
for example, for a subcutaneous, intramuscular or intrave­
nous route by adding thereto pH adjusters, buffers, stabiliz­
ing agents, relaxants, topical anesthetics. Examples of the 
pH adjusters and the buffers include sodium citrate, sodium 65 
acetate and sodium phosphate. Examples of the stabilizing 
agents include sodium pyrosulfite, EDTA, thioglycolic acid 
The cosmetic composition can comprise a cosmetically 
acceptable medium that may be water or a mixture of water 
and at least one solvent selected from among hydrophilic 
organic solvents, lipophilic organic solvents, amphiphilic 
organic solvents, and mixtures thereof. 
For topical application, the cosmetic composition can be 
administered in the form of aqueous, alcoholic, aqueous­
alcoholic or oily solutions or suspensions, or of a dispersion 
of the lotion or serum type, of emulsions that have a liquid 
or semi-liquid consistency or are pasty, obtained by disper­
sion of a fatty phase in an aqueous phase (0/W) or vice versa 
(W /0) or multiple emulsions, of a free or compacted powder 
to be used as it is or to be incorporated into a physiologically 
acceptable medium, or else of microcapsules or micropar­
ticles, or of vesicular dispersions of ionic and/or nonionic 
type. It may thus be in the form of a salve, a tincture, milks, 
a cream, an ointment, a powder, a patch, an impregnated 
pad, a solution, an emulsion or a vesicular dispersion, a 
lotion, aqueous or anhydrous gels, a spray, a suspension, a 
shampoo, an aerosol or a foam. It may be anhydrous or 
aqueous. It may also comprise solid preparations constitut­
ing soaps or cleansing cakes. 
The cosmetic compositions may in particular comprise a 
hair care composition, and in particular a shampoo, a setting 
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lotion, a treating lotion, a styling cream or gel, restructuring 
lotions for the hair, a mask, etc. The cosmetic compositions 
can be a cream, a hair lotion, a shampoo or a conditioner. 
These can be used in particular in treatments using an 
application that may or may not be followed by rinsing, or 
else in the form of a shampoo. A composition in the form of 
a foam, or else in the form of spray or an aerosol, then 
comprising propellant under pressure, is also intended. It can 
thus be in the form of a lotion, serum, milk, cream, gel, 
salve, ointment, powder, balm, patch, impregnated pad, cake 10 
or foam. 
In particular, the compositions for application to the scalp 
or the hair can be in the form of a hair care lotion, for 
example for daily or twice-weekly application, of a shampoo 
or of a hair conditioner, in particular for twice-weekly or 15 
weekly application, of a liquid or solid soap for cleansing the 
scalp, for daily application, of a hairstyle shaping product 
(lacquer, hair setting product or styling gel), of a treatment 
mask, or of a foaming gel or cream for cleansing the hair. 
These may also be in the form of a hair dye or mascara to 20 
be applied with a brush or a comb. 
Moreover, for topical application to the eyelashes or body 
hair, the compositions may be in the form of a pigmented or 
unpigmented mascara, to be applied with a brush to the 
eyelashes or alternatively to beard or moustache hair. For a 25 
composition administration by injection, the composition 
may be in the form of an aqueous lotion or an oily suspen­
sion. For oral use, the composition may be in the form of 
capsules, granules, oral syrups or tablets. According to a 
particular embodiment, the composition is in the form of a 30 
hair cream or hair lotion, a shampoo, a hair conditioner or a 
mascara for the hair or for the eyelashes. 
In a known manner, the cosmetic compositions may also 
contain adjuvants that are normal in the cosmetics field, such 
as hydrophilic or lipophilic gelling agents, hydrophilic or 35 
lipophilic additives, preservatives, antioxidants, solvents, 
fragrances, fillers, UV-screening agents, odor absorbers and 
dyestuffs. The amounts of these various adjuvants are those 
conventionally used in the cosmetics field, and are for 
example from 0.1 % to 20%, in particular less than or equal 40 
to 10%, of the total weight of the composition. According to 
their nature, these adjuvants can be introduced into the fatty 
phase, into the aqueous phase and/or into the lipid spherules. 
In some embodiments, the 15-PGDH inhibitor can be 
administered in a combinatorial therapy or combination 45 
therapy that includes administration of a 15-PGDH inhibitor 
with one or more additional active agents. The phrase 
"combinatorial therapy" or "combination therapy" embraces 
the administration of the 15-PGDH inhibitor, and one or 
more therapeutic agents as part of a specific treatment 50 
regimen intended to provide beneficial effect from the 
co-action of these therapeutic agents. Administration of 
these therapeutic agents in combination typically is carried 
out over a defined period (usually minutes, hours, days or 
weeks depending upon the combination selected). "Cambi- 55 
natorial therapy" or "combination therapy" is intended to 
embrace administration of these therapeutic agents in a 
sequential manner, that is, wherein each therapeutic agent is 
administered at a different time, as well as administration of 
these therapeutic agents, or at least two of the therapeutic 60 
agents, in a substantially simultaneous marmer. Substantially 
simultaneous administration can be accomplished, for 
example by administering to the subject an individual dose 
having a fixed ratio of each therapeutic agent or in multiple, 
individual doses for each of the therapeutic agents. Sequen- 65 
tial or substantially simultaneous administration of each 
therapeutic agent can be effected by any appropriate route 
38 
including, but not limited to, oral routes, intravenous routes, 
intramuscular routes, and direct absorption through mucous 
membrane tissue. The therapeutic agents can be adminis­
tered by the same route or by different routes. The sequence 
in which the therapeutic agents are administered is not 
narrowly critical. 
In some embodiments, the additional active agent can be 
chosen in particular from lipoxygenase inhibitors as 
described in EP 648488, the bradykinin inhibitors described 
in particular in EP 845700, prostaglandins and their deriva­
tives, in particular those described in WO 98/33497, WO 
95/11003, JP 97-100091, JP 96-134242, the agonists or 
antagonists of the receptors for prostaglandins, and the 
nonprostanoic analogues of prostaglandins as described in 
EP 1175891 and EP 1175890, WO 01/74307, WO 01/74313, 
WO 01/74314, WO 01/74315 or WO 01/72268. 
In other embodiments, the 15-PGDH inhibitors can be 
administered in combination with active agents, such as 
vasodilators, prostanoid agonists, antiandrogens, 
cyclosporins and their analogues, antimicrobials, triter­
penes, alone or as a mixture. The vasodilators can include 
potassium charmel agonists including minoxidil and its 
derivatives, aminexil and the compounds described in U.S. 
Pat. Nos. 3,382,247, 5,756,092, 5,772,990, 5,760,043, 
5,466,694, 5,438,058, 4,973,474, chromakalin and diazox­
ide. The antiandrogens can include 5.alpha.-reductase 
inhibitors such as finasteride and the compounds described 
in U.S. Pat. No. 5,516,779, cyprosterone acetate, azelaic 
acid, its salts and its derivatives, and the compounds 
described in U.S. Pat. No. 5,480,913, flutamide and the 
compounds described in U.S. Pat. Nos. 5,411,981, 5,565,467 
and 4,910,226. The antimicrobial compounds can include 
selenium derivatives, ketoconazole, triclocarban, triclosan, 
zinc pyrithione, itraconazole, asiatic acid, hinokitiol, mipi­
rocine, and the compounds described in EP 680745, cliny­
cine hydrochloride, benzoyl or benzyl peroxide and mino­
cycline. The anti-inflanimatory agents can include inhibitors 
specific for Cox-2 such as for example NS-398 and DuP-697 
(B. Batistini et al., DN&P 1994; 7(8):501-511) and/or inhibi­
tors of lipoxygenases, in particular 5-lipoxygenase, such as 
for example zileuton (F. J. Alvarez & R. T. Slade, Pharma­
ceutical Res. 1992; 9(11):1465-1473). 
Other active compounds, which can be present in phar­
maceutical and/or cosmetic compositions can include 
aminexil and its derivatives, 60-[(9Z,12Z)octadec-9,12-di­
enoyl]hexapyranose, benzalkonium chloride, benzethonium 
chloride, phenol, oestradiol, chlorpheniramine maleate, 
chlorophyllin derivatives, cholesterol, cysteine, methionine, 
benzyl nicotinate, menthol, peppermint oil, calcium pantho­
tenate, panthenol, resorcinol, protein kinase C inhibitors, 
prostaglandin H synthase 1 or COX-1 activators, or COX-2 
activators, glycosidase inhibitors, glycosaminoglycanase 
inhibitors, pyroglutamic acid esters, hexosaccharidic or 
acylhexosaccharidic acids, substituted ethylenearyls, N-acy­
lated amino acids, flavonoids, derivatives and analogues of 
ascomycin, histamine antagonists, triterpenes, such as urso­
lic acid and the compounds described in U.S. Pat. Nos. 
5,529,769, 5,468,888, 5,631,282, saponins, proteoglycanase 
inhibitors, agonists and antagonists of oestrogens, pseudop­
terins, cytokines and growth factor promoters, IL-1 or IL-6 
inhibitors, IL-10 promoters, TNF inhibitors, vitamins, such 
as vitamin D, analogues of vitamin 812 and panthotenol, 
hydroxy acids, benzophenones, esterified fatty acids, and 
hydantoin. 
Pharmaceutical and/or cosmetic compositions including 
the 15-PGDH inhibitor described herein can additionally 
contain, for example, at least one compound chosen from 
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prostaglandins, in particular prostaglandin PGEi, PGE2, 
their salts, their esters, their analogues and their derivatives, 
in particular those described in WO 98/33497, WO 
95/11003, JP 97-100091, JP 96-134242, in particular ago­
nists of the prostaglandin receptors. It may in particular 5 
contain at least one compound such as the agonists (in acid 
form or in the form of a precursor, in particular in ester form) 
of the prostaglandin F 2a receptor, such as for example 
latanoprost, fluprostenol, cloprostenol, bimatoprost, unopro­
stone, the agonists (and their precursors, in particular the 10 
esters such as travoprost) of the prostaglandin E2 receptors 
such as 17-phenyl PGE2, viprostol, butaprost, misoprostol, 
sulprostone, 16,16-dimethyl PGE2, 11-deoxy PGEi, 1-de­
oxy PGEi, the agonists and their precursors, in particular 15 
esters, of the prostacycline (IP) receptor such as cicaprost, 
iloprost, isocarbacycline, beraprost, eprostenol, treprostinil, 
the agonists and their precursors, in particular the esters, of 
the prostaglandin D2 receptor such as BW245C ((4S)-(3-
[ (3R,S)-3-cyclohexyl-3-isopropyl]-2,5-dioxo )-4-imidazoli- 20 
dinehept-anoic acid), BW246C (( 4R)-(3-[(3R,S)-3-cyclo­
hexy 1-3-isopropy l]-2,5-dioxo )-4-imidazolidinehept-anoic 
acid), the agonists and their precursors, in particular the 
esters, of the receptor for the thromboxanes A2 (TP) such as 
I-BOP ([1S-[la,2a(Z), 3b(1E,3S),4a]]-7-[3-[3-hydroxy-4- 25 
[ 4-(iodophenoxy )-1-buteny l]-7 -oxabicyclo-[2 .2 .1 ]hept-2-
y l]-5-heptenoic acid).
Advantageously, the composition can include at least one 
15-PGDH inhibitor as defined above and at least one pros­
taglandin or one prostaglandin derivative such as for 30 
example the prostaglandins of series 2 including in particu-
lar PGF 2a and PGE2 in saline form or in the form of
precursors, in particular of the esters (example isopropyl 
esters), their derivatives such as 16,16-dimethyl PGE2, 
17-phenyl PGE2 and 16,16-dimethyl PGF2a 17-phenyl 35 
PGF2w prostaglandins of series 1 such as 11-deoxyprosta­
glandin El, 1-deoxyprostaglandin El in saline or ester form, 
is their analogues, in particular latanoprost, travoprost, flu­
prostenol, unoprostone, bimatoprost, cloprostenol, viprostol, 
butaprost, misoprostol, their salts or their esters. 40 
In accordance with another aspect of the application, the 
modulator of 15-PGDH can be a 15-PGDH activator that 
can promote or stimulate the activity of 15-PGDH. In certain 
embodiments, the 15-PDGH activator can include a com-
pound having the formula (IV): 45 
(IV) 
R11 
40 
Rs, R9, R10, Ru, and R12 are each selected from the group 
consisting ofH, F, Cl, Br, I, an alkyl group, (CH2)nPR' 
(wherein nl=l, 2, or 3), CF3, CH2----CH2X, O----CH2-
CH2X, CH2----CH2----CH2X, O-CH2----CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
N02, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is H or a lower alkyl group), a substituted 
or unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, a substituted or unsubstituted heterocyclyl, 
and Rs and R9 may be linked to form a cyclic or 
polycyclic ring; and pharmaceutically acceptable salts 
thereof. 
In other embodiments, the 15-PDGH activator can 
include a compound having the formula (V): 
(V) 
wherein U is OR" (wherein R" is H, a substituted or 
unsubstituted alkyl group, or substituted or unsubsti­
tuted aryl group) or 
Rs, R9, R10, Ru, and R12 are each selected from the group 
consisting ofH, F, Cl, Br, I, an alkyl group, (CH2)nPR' 
(wherein nl=l, 2, or 3), CF3, CH2----CH2X, O----CH2-
CH2X, CH2----CH2----CH2X, O-CH2----CH2X 
(wherein X=F, Cl, Br, or I), CN, (C=O)-R', N(R')2, 
N02, (C=O)N(R')2, O(CO)R', OR', SR', COOR' 
(wherein R' is H or a lower alkyl group), a substituted 
or unsubstituted aryl, a substituted or unsubstituted 
cycloalkyl, a substituted or unsubstituted heterocyclyl, 
and Rs and R9 may be linked to form a cyclic or 
polycyclic ring; and pharmaceutically acceptable salts 
thereof. 
In certain embodiments, a 15-PGDH activator having 
formula (IV) or (V) can be selected that can: ia) at 7.5 µM I 
O Y2=0 
II I 
U R10 
,.....x3YN' 
R12 
50 concentration, stimulate a Vaco503 reporter cell line 
expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 50 (using a scale on 
which a value of 100 indicates a doubling ofreporter output 
over baseline); iia) at 7 .5 µM concentration stimulate a V9m 
wherein X3 and Y 2 are independently C or SO; 
U is OR" (wherein R" is H, a substituted or unsubstituted 
alkyl group, or substituted or unsubstituted aryl group) 
or 
55 reporter cell line expressing a 15-PGDH luciferase fusion 
construct to a luciferase output level of greater than 50; iiia) 
at 7.5 µM concentration stimulate a LS174T reporter cell 
line expressing a 15-PGDH luciferase fusion construct to a 
luciferase output level of greater than 50; iva) at 7.5 µM 
60 concentration, does not activate the negative control V9m 
cell line expressing TK-renilla luciferase reporter to a level 
any greater than 25; and va) against recombinant 15-PGDH 
protein the compound shows an IC50 concentration for 
inhibiting 15-PGDH enzyme activity of greater than 2.5 µM. 
65 In certain embodiments, a 15-PGDH activator having 
formula (IV) or (V) can be selected that can: ib) at 7 .5 µM 
concentration, stimulate a Vaco503 reporter cell line 
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expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; iib) at 7 .5 µM concentration 
stimulate a V9m reporter cell line expressing a 15-PGDH 
luciferase fusion construct to increase luciferase output; iiib) 
at 7.5 µM concentration stimulate a LS174T reporter cell 5 
line expressing a 15-PGDH luciferase fusion construct to 
increase luciferase output; ivb) at 7 .5 µM concentration, 
does not activate the negative control V9m cell line express­
ing TK-renilla luciferase reporter to a luciferase level any 
greater than 25% above; and vb) against recombinant 10 
15-PGDH protein the compound shows an IC50 concentra­
tion for inhibiting 15-PGDH enzyme activity of greater than
or equal to 2.5 µM.
In other embodiments, a 15-PGDH activator having for- 15 
mula (IV) or (V) that meets the above noted criteria (ia-va) 
and/or that meet the above noted criteria (ib-vb) includes a 
compound having the formula (VI): 
(VI) 
and pharmaceutically acceptable salts thereof. 
In other embodiments, the 15-PGDH activator can be an 
analogue of a compound having the formula (VI). Such 
analogues can have the following formula (VII): 
0 H3C}---c�-Ph O �LH,-L 
OC H3 
(VII) 
wherein U is OR" (wherein R" is H, a substituted or 
unsubstituted alkyl group, or substituted or unsubsti­
tuted aryl group) or 
Rs and R9 are each selected from the group consisting of 
20 
25 
30 
35 
40 
45 
50 
55 
H, F, Cl, Br, I, an alkyl group, (CH2)niOR' (wherein 
nl=l, 2, or 3), CF3, CH2----CH2X, O----CH2----CH2X, 
CH2-CH2-CH2X, O-CH2-CH2X (wherein X=F, 60 
Cl, Br, or I), CN, (C=O)-R', N(R')2, N02, (C=O)N 
(R')2, O(CO)R', OR', SR', COOR' (wherein R' is H or 
a lower alkyl group), a substituted or unsubstituted aryl, 
a substituted or unsubstituted cycloalkyl, a substituted 
or unsubstituted heterocyclyl, and Rs and R9 may be 65 
linked to form a cyclic or polycyclic ring; and phar­
maceutically acceptable salts thereof. 
42 
Examples of 15-PGDH activators having the formula 
(VII) include: 
0 O=S-Ph O I � II -Vo Me; MeO I II �N-C H2- C -NH # �OMe OMe ¢=0 II =S-Ph O � I h-C H2-M-NH 0 
�Ac; OMe 
0 O=�-Ph O -v� Me; MeOUI II N-C H2-C -NH #OMe 
0 O=�-Ph O F3CD� MeOUI II ; N-C H2-C -NH # OMe 
0 O=S-Ph O I � II -VF; MeO I II �N-C H2- C -NH # �OMe 
Cl 
TI 
-&
c1; MeOU
O ,-Ph 
TI I � N-C H2-C -NH # OMe 
0 MeOU
O r-Ph TI (YCl; N-C H2-C -NH--v OMe OMe O =,-Ph I �;¢=TI H2N-=DII N-C H2-M-NH ,# OMe OMe O =,-Ph I �;¢=TI MeO-=DII N-C H2-M-NH ,# OMe 
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-continued
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0Me O -0 II O -S-Ph 
II h-CH2-C-NH # 
OMe 
IT 
Cl
)) 
O=S-Ph IT I ; I -NH # MeO
Y"(-
N-CH2-C 
�OMe 
IT 
Cl
)) 
O=S-Ph IT I ; I -NH # MeO
Y"(-
N-CH2-C 
�OMe OMe O 
OMe 
II � -S-Ph IT I h-m,-C-NH-Qc,, 
10 
15 
20 
25 
30 
table salts thereof. d pharmaceutically accep 
d h ving formula (VII) 
an 
f compoun s a 
35 
Other examples o 
include: 
Cl 
40 
NH 
0-�-Nr-{O 11-0-- O f \ OMe; MeO 
45 
50 
OEt 
0-�-Nr-{O 11-0-- O f \ OMe; MeO 55 
OH 
0-�-Nr-{O 11-0-- O f \ OMe; MeO 
60 
65 
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0-�-Nr-{O 11-0-- O f \ OMe; MeO 
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10 
15 
20 
25 
30 
35 
and pharmaceutically acceptable salts thereof. 
In other embodiments, the 15-PGDH activator can be an 
40 analogue of compound (VI) having the following formula 
(VIII): 
45 
50 
55 
60 
65 
(VIII) 
wherein R10 is selected from the group consisting of a 
substituted or unsubstituted aryl, a substituted or 
unsubstituted cycloalkyl, and a substituted or unsub­
stituted heterocyclyl; and pharmaceutically acceptable 
salts thereof. 
Examples of 15-PGDH activators having the formula 
(VIII) include: 
0- II 
O Ph-S=O 
II I o 
N NH-C-CH,-N-
--CX
O
) 
US 9,790,233 B2 
53 
-continued0 
II O=S-Ph O 
(t-Lm,-LNH-0 
MeO� OMe 0 
II O=S-Ph O M,�LH,-LNH-o:N; 
�OMe 0 
II O=S-Ph O 
()-LH,-LNH-o:N; 
EtO� 
0 
II O=S-Ph O MeOvh-m,-LNH-0 
O Ph O 
II I II 
g I �N; 
Ph-S-N-CH2-C-NHD 
# 0 
II O=S-Ph O 
c,�LH,-LNH-o:N; 
�OMe 0 
II O=S-Ph O 
c,�LH,-LNH-o:N; 
�OMe 0 
II O=S-Ph O �h-CH2-M-NH-o�N; MeO�OMe # 
10 
15 
20 
54 
-continued0 
II O=S-Ph O 
Cl
Y'rr---
1 II -0 �:-CH,-C-NH I :N 
25 and pharmaceutically acceptable salts thereof. 
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Still other examples of compounds having the formula 
(VIII) include: 
65 
and pharmaceutically acceptable salts thereof.
In still other embodiments, the 15-PGDH activator can be 
an analogue of compound (VI) having the formula (IX): 
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(IX) 
10 
wherein R11 is H, F, Cl, Br, I, a lower alkyl group, 
(CH2)niOR' (wherein nl=l, 2, or 3), CF 3, CH2-
CH2X, O----CH2----CH2X, CH2----CH2----CH2X, 
O----CH2----CH2X (wherein X=F, Cl, Br, or I), CN, 15 
(C=O)-R', N(R')2, N02, (C=O)N(R')2, O(CO)R', 
OR', SR', COOR' (wherein R' is H or a lower alkyl 
group), a substituted or unsubstituted aryl, a substituted 
or unsubstituted cycloalkyl, and a substituted or unsub­
stituted heterocyclyl; and pharmaceutically acceptable 20 
salts thereof. 
Examples of 15-PGDH activators having the formula (IX) 
include: 
and pharmaceutically acceptable salts thereof. 
Still other examples of compounds having formula (IX) 
include: 
('Y
Cl 
J:(�:�/OMe• HN 
� 6 MeO # 
N 
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and pharmaceutically acceptable salts thereof. 
In other embodiments, the 15-PGDH activator can be an 
analogue of compound (IV) having the following formulas: 
US 9,790,233 B2 
59 60 
-continued
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
US 9,790,233 B2 
61 62 
-continued
35 
40 
45 
50 
55 
60 
65 
63 
US 9,790,233 B2 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
64 
-continued
0 °�s,V
�I
� 
N
:Q1 Br � O O· 
I 1' 
OY') 
}J N�0-,,()'�1 I
, 
0 
0#s'Q 
66 
-continued
67 
-continued
HN O 
y \I!° I l_ / S
'CC
O 
N I 
/
O
u # O · 
� 
I 1' 
I 
US 9,790,233 B2 
68 
10 
15
20 
25 
30 
35
40 
45
50
and pharmaceutically acceptable salts thereof. 
The 15-PGDH activators described herein can be used for 
the prevention or the treatment of diseases that are associ­
ated with decreased 15-PGDH levels and/or increased pros-
55 taglandin levels. Increasing tissue levels of 15-PGDH 
should decrease tissue levels of prostaglandins. Activities 
associated with compounds that decrease tissue prostaglan­
dins include decreasing development of human tumors. For 
60 example, administration of 15-PGDH activators can be used 
to treat patients with colon neoplasia, e.g., colon cancer or 
colon adenoma, or to treat and prevent new disease in 
patients with a history of colon neoplasia, or to reverse 
resistance to NSAID therapy for neoplasia therapy or neo-
65 plasia preventive therapy. Further, administration of
15-PGDH activators described herein can be used to treat
subjects having an NSAID-responsive condition. In certain
US 9,790,233 B2 
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embodiments, 15-PGDH activators enhance NSAID-re­
sponsiveness in subjects who are relatively unresponsive to 
NSAID treatment. 
The 15-PGDH activators described herein can be also be 
used in a method of treating any NSAID-responsive condi­
tion. The NSAID-responsive condition applies to a subject 
who is NSAID-resistant or a subject who was determined to 
be resistant to NSAID therapy. In the method, a therapeu­
tically effective amount of 15-PGDH activators can be 
administered alone or in combination with an effective an 10 
effective amount of 15-PGDH protein, cDNA, or an active 
fragment thereof. The patient may be a subject at risk of 
developing colon neoplasia (e.g., based on family history), 
or a subject at risk of colon adenoma relapse, but is 
suspected of being resistant to NSAID therapy. Further, the 15 
patient may be any subject who is undergoing or about to 
undergo NSAID therapy for any NSAID-responsive condi­
tion, but who experiences NSAID resistance. 
The 15-PGDH activators described herein can be pro­
vided in a pharmaceutical composition that includes phar- 20 
maceutically acceptable carrier. In some embodiments, the 
15-PGDH activator can be provided alone or in combination
with other components (e.g., an NSAID), can be made into
aerosol formulations (i.e., they can be "nebulized") to be
administered via inhalation. The 15-PGDH activator can 25 
also be provided alone or in combination with other com­
ponents in aqueous and non-aqueous solutions, isotonic
sterile solutions, which can contain antioxidants, buffers,
bacteriostats, and solutes that render the formulation iso­
tonic, and aqueous and non-aqueous sterile suspensions that 30 
can include suspending agents, solubilizers, thickening
agents, stabilizers, and preservatives. Compositions includ­
ing the 15-PGDH activator can be administered, for
example, orally, nasally, topically, intravenously, intraperi­
toneally, or intrathecally. The formulations can be presented 35 
in unit-dose or multi-dose sealed containers, such as
ampoules and vials. Solutions and suspensions can be pre­
pared from sterile powders, granules, and tablets of the kind
previously described. The modulators can also be adminis-
tered as part of a prepared food or drug. 40 
The dose administered to a patient should be sufficient to 
induce a beneficial response in the subject over time. The 
optimal dose level for any patient will depend on a variety 
of factors including the efficacy of the specific modulator 
employed, the age, body weight, physical activity, and diet 45 
of the patient, on a possible combination with other drugs, 
and on the severity of the case of diabetes. It is recom­
mended that the daily dosage of the 15-PGDH activator can 
be determined for each individual patient by those skilled in 
the art. The size of the dose also will be determined by the 50 
existence, nature, and extent of any adverse side-effects that 
accompany the administration of a particular compound in a 
particular subject. 
In some embodiments, the 15-PGDH activator can be 
administered in a combination therapy includes administra- 55 
tion of a single pharmaceutical dosage formulation that 
contains a 15-PGDH activator and one or more additional 
active agents, as well as administration of a 15-PGDH 
activator and each active agent in its own separate pharma­
ceutical dosage formulation. For example, a 15-PGDH acti- 60 
vator and celecoxib can be administered to the human 
subject together in a single oral dosage composition, such as 
a tablet or capsule, or each agent can be administered in 
separate oral dosage formulations. In other embodiments, an 
NSAID, e.g., celecoxib or aspirin, may be administered with 65 
an effective amount of the 15-PGDH activator. Where 
separate dosage formulations are used, a 15-PGDH activator 
70 
and one or more additional active agents can be adminis­
tered at essentially the same time (i.e., concurrently), or at 
separately staggered times (i.e., sequentially). Combination 
therapy is understood to include all these regimens. 
The invention is further illustrated by the following 
example, which is not intended to limit the scope of the 
claims. 
EXAMPLE 1 
This Example describes the activities of four compounds 
with respect to the enzyme 15-Prostaglandin Dehydrogenase 
(15-PGDH) (encoded by the gene HPGD). The compounds 
are SW033291, SW054384, SW124531, SW145753 and 
have the following formulas: 
SW033291 
0 
0 
s� 
H3CO II 
�c:J_ij--0 
0 
OCH3 
SW054384 
(YN 
O�N
= 
0 
SW145753 
F 
SW124531 
F 
F 
FIG. 1 shows that SW033291, SW054384, and 
SW145753 all increase luciferase activity of cells the 
express a 15-PGDH luciferase fusion construct created by 
targeted gene knock-in of renilla luciferase into the last 
coding exon of 15-PGDH. The activity is demonstrated in 
three different colon cancer cell lines all engineered to 
US 9,790,233 B2 
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contain the 15-PGDH-luciferase fusion. These cell lines are 
Vaco-9m (V9m), LSI 74T, Vaco503 (V503). SW054384 is in 
general the best inducer, and shows maximum activity at 
6.25 µM. Value of 1.0 on the Y-axis is the basal level of 
reporter activity in cells treated with drug free DMSO 
vehicle. 
FIG. 2 shows western blots demonstrating that 
SW033291, SW054384, and SW145753 all increase levels 
of 15-PGDH protein in cell lines V503, LSI 74T, and V503 
treated with 7.5 µM compound for 48 hours. Untreated FET 
cells provide a positive control for 15-PGDH expression. 
FIG. 3 shows western blot demonstrating SW124531 also 
increases 15-PGDH protein levels in colon cell lines (FET 
cells treated with TGF-� (10 ng/ml) for 48 hours are used as 
a positive control for 15-PGDH expression in certain pan­
els). 
72 
inhibitor of 15-PGDH activity, with an IC50 of <1.25 nM. 
This contrasts with the IC50 of between 25 nM-62.5 nM 
measured for the commercial 15-PGDH inhibitor available 
from Cayman Chemical (Cayman catalogue item 10638, 
Cayman Chemical number 13695). 
FIG. 11 also shows that at very high concentration 
SW054384 can inhibit recombinant 15-PGDH activity, with 
an IC50 of between 5 µM-50 µM. We conclude that 
SW054384 increases total 15-PGDH level and activity in 
10 cells treated with 7.5 µM compound, but can inhibit in vitro 
recombinant 15-PGDH protein in vitro assays using 5 
µM-50 µM compound. 
FIG. 11 also shows that SW145753 can inhibit activity of 
recombinant 15-PGDH enzyme in an in vitro assay at an 
15 IC50 between 12-6.25 nM. This suggests the activity of 
SW145753 in increasing versus in inhibiting 15-PGDH 
activity may be discordant in cells versus in the in vitro 
assay (perhaps due to washout of drugs when washing the 
FIG. 4 shows western blot demonstrating 5 µM 
SW124531 increases levels of 15-PGDH protein (wt­
PGDH) expressed from a cDNA expression vector in V 400-
S3-2-32 cells, and also increases protein levels of a cata- 20 
lytically dead mutant 15-PGDH (mu-PGDH) also expressed 
from a cDNA expression vector in V400-M3-2-72 cells. As 
these proteins are expressed from a heterologous CMV 
promoter, the findings suggest that the compounds work 
directly on stabilizing the 15-PGDH protein. The com­
pounds show no effects on levels of a related enzyme, 
17-beta-estradiol-dehydrogenase.
cells), or may be concentration dependent. 
FIG. 12 shows repeat testing of the effects of SW033291 
and SW054384 on activity of recombinant 15-PGDH pro­
tein tested in vitro. Assays were done by measuring the 
transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 
1 µM PGE2 substrate) shown at left (panels A, C), or by 
25 direct fluorescence monitoring of NADH generation by 
15-PGDH (done at 20 µM PGE2 substrate) shown at right
(panels B, D). SW033291 is again confirmed as a highly
potent 15-PGDH inhibitor with an IC50 of 0.7 nM as
measured in the tritium assay and an IC50 of 1.6 nM as
FIG. 5 shows increase in 15-PGDH protein levels in V503
cells treated with SW124531 as assayed by immuno-fluo­
rescence (upper two rows) and by western blot (lower 
panel). 
FIGS. 6-9 show that SW033291, SW054384, SW145753, 
and SW124531 do not in general alter 15-PGDH mRNA 
levels in treated colon cancer cell lines as assessed by 
real-time PCR. The only exception is the slight increase in 
15-PGDH mRNA in SW033291 treated V503 cells, which is
less than the induction of 15-PGDH protein as well as
15-PGDH-luciferase reporter levels seen in SW033291
treated V503 cells. In these studies parental cell lines (not
containing the 15-PGDH-luciferase reporter) are employed.
FIG. 10 shows the effects of three compounds on total 
15-PGDH activity in cell lines treated with the compounds.
Cell lines were treated with compounds at 7 .5 µM for 48
hours, and then pelleted. Pellets were lysed and total
15-PGDH activity measured and normalized to 1,000,000
input cells per pellet. 15-PGDH activity was assayed by
measuring the transfer of tritium from 15(S)-[15-3H] PGE2 
to glutamate by coupling 15-PGDH with glutamate dehy­
drogenase as described in (Chi X, Freeman B M, Tong M,
Zhao Y, Tai H H. 15-Hydroxyprostaglandin dehydrogenase
(15-PGDH) is up-regulated by flurbiprofen and other non­
steroidal anti-inflammatory drugs in human colon cancer
HT29 cells. Arch Biochem Biophys. 2009; 487(2):139-45.).
Activity is measured as pmol PGE/min/million cells. As
shown, SW033291 markedly inhibits 15-PGDH activity in
all three of the cell lines tested. We conclude that although
SW033291 increases total 15-PGDH protein levels in cells,
it also inactivates 15-PGDH enzyme activity.
In contrast, 15-PGDH enzyme activity is increased in 
cells treated with SW054384 and in cells treated with 
SW145753. 
FIG. 11 shows the effect on activity of recombinant 
15-PGDH protein (a 15-PGDH-GST fusion protein) incu­
bated with varying concentrations of the test compounds,
with 15-PGDH activity across a range of compound con­
centrations recorded on the table and displayed on the
corresponding graphs. As shown, SW033291 is a potent
30 measured in the fluorescence assay. The relative insensitivity 
of the IC50 to substrate concentration suggests that 
SW033291 is a non-competitive inhibitor of 15-PGDH. 
SW054384 shows very weak inhibitory activity, with 
IC50s that are 10,000 fold higher than that of SW033291 
35 (8.4 µM and 11 µM in the tritium and fluorescent based 
assays respectively). This is consistent with the activity of 
SW054384 being on balance to increase 15-PGDH protein 
level and enzyme activity in cells. 
FIG. 13 shows results of assays of 15-PGDH activity 
40 using the tritium method in cells treated with SW124531 
(upper panel) and in recombinant 15-PGDH protein treated 
with SW124531 (lower panel). SW124531 shows activity in 
increasing 15-PGDH activity in most cell lines, though this 
activity is best in cell lines in which basal 15-PGDH activity 
45 is >10 units. SW124531 also inhibits activity of 15-PGDH 
recombinant protein at an IC50 of 50 nM. 
FIG. 14 shows assay of different compounds for ability to 
directly bind to recombinant 15-PGDH protein as measured 
by shifting the melting temperature of the protein. The 
50 melting of the protein is followed by measurement of the 
fluorescence of SYPRO Orange dye (Sigma #S5692) that 
increases as the dye binds to hydrophobic residues exposed 
as the protein melt. The graph at upper left shows the melt 
curves of 15-PGDH with all of the assays done in the 
55 presence of the different compounds superimposed on each 
other. The graph at upper right plots the negative derivative 
of fluorescence versus temperature for each of the curves 
shown at left, with the melting point measured as the 
temperature of the negative peak (i.e., the point of most 
60 rapid change in the fluorescence versus temperature plot). 
The results are shown in tabular form on the table below. 
Lapatinib is used as a negative control. There is no binding 
of any drug in the absence of enzyme co-factor ( either NAD 
or NADH). In the presence of either NAD or NADH, 
65 SW033291 creates two peaks in the melting curve, with one 
of these peaks displaced by 15 degrees Celsius, consistent 
with SW033291 binding directly to 15-PGDH. SW124531 
US 9,790,233 B2 
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and SW145753 also show evidence of direct binding to 
15-PGDH. In this assay, SW054384 cannot be demonstrated
to bind 15-PGDH. It is possible that SW054384 does bind 
74 
following addition of PGE2 into the medium of Vaco-503 
cells. In this study cells are treated with compound for 24 
hours after which PGE2 is added into the medium. After an 
to 15-PGDH, but that the binding is weak and is melted off 5 
added 24 hours PGE2 levels remaining in the medium are 
assayed by Elisa. Data labeled "medium" is a control lane 
with PGE2 added to medium alone, in the absence of cells. 
Data labeled DMSO is a control in which cells are treated 
with DMSO only (the diluent for the compounds). The 
at a temperature below the melting temperature of the 
15-PGDH protein. Assays were done at both 10 µM and 100
µM cofactor (testing both NAD and NADH), which com­
pares well with the published Km of NAD of 15.8 µM. 
FIG. 15 shows that none of the four compounds tested 
10 difference between the "medium" and the "DMSO" lanes 
represents the cell dependent degradation of PGE2 by 
induce a shift in the melting temperature of catalytically 15-PGDH. Again demonstrated, is the near complete block-
inactive mutant 15-PGDH protein. We interpret the induc- ade of 15-PGDH activity by addition of 2.5 uM SW033291,
tion of 15-PGDH mutant protein by SW124531 as suggest- 15 as reflected by the blockade in PGE2 degradation. Addition­
ing that SW124531 likely has weak binding to mutant 
15-PGDH that is able to stabilize protein at 37° C., but with
the drug melted off at a temperature below 50° C., that is the
melting temperature of the protein.
20 
FIG. 16 shows the in vivo modulation by compounds of 
15-PGDH activity as reflected in PGE2 levels that are
assayed in the medium of A549 cells that have been stimu­
lated by ILi-beta for 23 hours, with compound added for the
last 5 hours (blue bars). The increment in PGE2 level shows
25 
the clear inhibition of 15-PGDH activity in the cells by
addition of SW033291 (as well as SW145753, SW124531,
and a commercial 15-PGDH inhibitor from Cayman Chemi­
cal. In an additional iteration (red bars)(2), SW054384 was 30 
added commencing 24 hours before addition of ILi-beta, 
and then maintained for the next 26 hours in the presence of 
ILi-beta. The lower level of PGE2 produced supports that in 
these cells SW054384 increased the 15-PGDH activity. 35
Panel at left shows raw data; whereas, panel at right shows 
ally demonstrated is the stimulation of 15-PGDH activity by 
SW054384, as reflected by the increased degradation of 
PGE2. 
FIG. 19 shows the activity of 2.5 µM SW033291 in 
speeding the healing of a model wound consisting of a 
scratch in a monolayer of HaCaT cells observed over 48 
hours of treatment. TGF-beta serves as the positive control 
in the assay. 
FIG. 20 shows the quantitation of the width of the scratch 
at O and 48 hours in the control, 2.5 µM SW033291 treated 
cells, and the TGF-beta (1 ng/ml) treated cells. 
EXAMPLE 2 
Analysis of Analogues of Lead Compounds SW033291, a 
15-PGDH Inhibitor
This Example provides data on a group of structural
analogues of SW033291. Data provided includes level of 
data normalized for cell numbers present at end of the induction of a 15-PGDH-luciferase fusion gene reporter, 
experiment. PGE2 levels are assayed by ELISA. recorded as % increased luciferase activity over basal level, 
FIG. 17 shows the dose response of effect on SW033291 40 in three colon cancer cell lines, V9m, V503, and LSI 74T, 
on PGE2 production from ILi-beta treated A549 cells, as 
reflected in PGE2 levels that are assayed in the medium of 
A549 cells that have been stimulated by ILi-beta for 24 
hours, with SW033291 added for the last 8 hours. 
FIG. 18 shows the in vivo modulations by 2.5 µM 
compounds of 15-PGDH activity as reflected in PGE2 levels 
engineered to contain the reporter, and treated with either 2.5 
uM or 7.5 uM compound (i.e., Values are recorded on a scale 
where 100 indicates of doubling of luciferase activity over 
45 baseline level). Also recorded is the IC50 of each compound 
for inhibiting enzymatic activity of recombinant 15-PGDH 
in an in vitro assay. 
TABLE 2 
Structures 
f s 
� 
s 
NH2 � 
ID 
SW033291 
Enzyme 
inhibition 
(IC so, 
nM) 
1.23 nM 
V9M V9M 
reporter reporter 
activity activity 
(2.5 (7.5 
uM) uM) 
98.24 93.16 
LS174T LS174T V503 V503 
reporter reporter reporter reporter 
activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 
uM) uM) uM) uM) 
123.46 106.73 126.32 99.34 
75 
Structures 
F 
F 
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TABLE 2-continued 
ID 
SW033291 
isomer B 
SW033291 
isomer A 
SW033292 
413423 
980653 
Enzyme 
inhibition 
(ICso, 
nM) 
0.76 nM 
56.56 nM 
76 
V9M V9M LS174T LS174T V503 V503 
reporter reporter reporter reporter reporter reporter 
activity activity activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 (2.5 (7.5 
uM) uM) uM) uM) uM) uM) 
Note: Structures shown are for illustrative purposes. 
We don't know which structure corresponds to 
Isomer A or B. Residual activity of isomer A 
may be due to small amounts of Isomer B 
present in the preparation. 
Note: Structures shown are for illustrative purposes. 
We don't know which structure corresponds to 
Isomer A or B. Residual activity of isomer A 
may be due to small amounts of Isomer B 
present in the preparation. 
1.51 
-5.65 -8.76 3.41 3.91 7.89 3.13 
8.83 11.96 5.76 10.99 -10.47 -15.21 
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TABLE 2-continued 
ID 
405320 
SW208078 
SW208079 
SW033290 
V9M 
Enzyme reporter 
inhibition activity 
(!Cso, (2.5 
nM) uM) 
8.77 
25 nM 36.16 
125 nM 36.01 
525 nM -34.33
SW208080 2.64 nM 102.08 
V9M 
reporter 
activity 
(7.5 
uM) 
-15.45
34.90 
32.75 
-25.45 
98.65 
78 
LS174T LS174T 
reporter reporter 
activity activity 
(2.5 (7.5 
uM) uM) 
9.95 -2.57 
72.71 40.01 
53.42 43.83 
-0.24 -6.58 
V503 V503 
reporter reporter 
activity activity 
(2.5 (7.5 
uM) uM) 
-7.73 -33.68
87.73 83.77 
85.29 61.82 
30.93 17.71 
117.81 116.64 103.70 127.19 
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TABLE 2-continued 
Enzyme 
inhibition 
(!Cso, 
ID nM) 
SW208081 18 nM 
SW206976 >7.5 uM 
SW206977 >7.5 uM 
SW206978 >7.5 uM 
V9M 
reporter 
activity 
(2.5 
uM) 
37.79 
11.80 
3.5028 
7.5141 
SW206979 >7.5 uM -12.59 
V9M 
reporter 
activity 
(7.5 
uM) 
63.56 
17.51 
0.45 
8.02 
-20.62 
80 
LS174T LS174T V503 V503 
reporter reporter reporter reporter 
activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 
uM) uM) uM) uM) 
64.53 95.14 90.46 105.37 
42.38 20.56 16.79 49.53 
34.88 29.35 33.00 37.62 
31.44 26.19 38.84 35.75 
34.26 32.79 21.66 42.92 
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TABLE 2-continued 
V9M 
Enzyme reporter 
inhibition activity 
(!Cso, (2.5 
ID nM) uM) 
SW206980 0.97 nM 99.37 
SW206992 1.411 nM 86.44 
SW208064 151.4 nM 82.58 
SW208065 4.865 nM 120.19 
SW208066 1.368 nM 122.72 
SW208067 2.395 nM 121.69 
82 
V9M LS174T LS174T V503 V503 
reporter reporter reporter reporter reporter 
activity activity activity activity activity 
(7.5 (2.5 (7.5 (2.5 (7.5 
uM) uM) uM) uM) uM) 
92.71 117.24 92.15 129.57 108.51 
121.75 85.81 72.03 161.20 145.39 
50.11 126.18 96.23 126.18 96.23 
118.92 73.50 87.74 73.50 87.74 
111.63 123.89 93.74 123.89 93.74 
108.47 94.30 79.63 94.30 79.63 
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TABLE 2-continued 
V9M 
Enzyme reporter 
inhibition activity 
(ICso, (2.5 
ID nM) uM) 
SW208068 >7.5 uM 12.90 
SW208069 >7.5 uM -14.48
SW208070 >7.5 uM 22.56 
V9M 
reporter 
activity 
(7.5 
uM) 
12.35 
0.23 
12.11 
84 
LS174T LS174T V503 V503 
reporter reporter reporter reporter 
activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 
uM) uM) uM) uM) 
14.90 15.00 14.90 15.00 
19.47 15.13 19.47 15.13 
19.69 15.43 19.69 15.43 
We first note that the 15-PGDH inhibitory activity of 
SW033291 is at least 98% due to the activity of one of the 40
two optical isomers of this compound, designated isomer A 
and B. The structural assignment of isomer A versus isomer 
sponding: ketone (SW206976), amide (SW206977), ester 
(SW206978), and carboxylic acid (SW206979). However, 
inhibitory activity is observed for the sulfone analogs. 
B is not yet established. 
There is an important effect on the length of the carbon 
side chain of SW033291 on the IC50 for inhibiting recom- 45 
binant 15-PGDH in vitro. Compared to SW033291 (4 car­
bons): SW208080 (5 carbons) has IC50 1.5 times higher, 
SW208081 (6 carbons) has IC50 10 times higher, and 
SW208079 (1 carbon) has IC50 over 60-fold higher, with 
marked loss of activity in inducing the cell line reporters. 50 
The sulfoxide group appears to be a critical substituent, as 
inactive substitutions of the sulfoxide include the corre-
Deletion of the phenyl group on SW033291 (SW206980) 
lowers the IC50 by half. SW206980 continues to be a highly 
active compound in reporter induction when applied to 
reporter cell lines at 2.5 uM concentration. 
EXAMPLE 3 
The following Example describes the synthesis of 
SW033291 and analogues thereof as well as provides mass 
spectrometry NMR confirmation of the structures. 
Scheme 1 
RY�"( 
'Y"CN 
R' 
Cl S Me 
� � 1.0 equiv. 
Et3N 1.5 equiv. 
CH3CN reflux, 45 min 
R � thiophene, R' � Ph, n � 3, 92% 
R � thiophene, R' � Ph, n � 0 
R � thiophene, R' � Ph, n � 4 
R � thiophene, R' � Ph, n � 5 
R � thiazole, R' � Ph, n � 3, 90% 
R � thiophene, R' � H, n � 3, 58% 
R � thiazole, R' � H, n � 3, 70% 
R� H, R' � H, n �3, 57% 
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-continued
0 
I � 
i"1n 
R
yC
N s '-.../ s , .,.. Me 
# CN ACOH/CH3Cl 32° C. R � thiophene, R' � Ph, n � 3, 98% R � thiophene, R' � Ph, n � 0 R � thiophene, R' � Ph, n � 4 
I � 
Mn I R
yC
N s'-.../ s , .,.. Me 
# CN R' 
0 
Ry:ti- M, 
R' NH2 SW2085078: R � thiophene, R' � Ph, n � 3, SW033290: R � thiophene, R' � Ph, n � 0 
0 
s Bu 
R � thiophene, R' � Ph, n � 5 R � thiazole, R' � Ph, n � 3, 98% R � thiophene, R' � H, n � 3, 92% R � thiazole, R' � H, n � 3, 97% R � H, R' � H, n � 3, 56% 
0 R N s I wS� Me 
R' NH2 SW033291: R � thiophene, R' � Ph, n � 3, 96% SW208079: R � thiophene, R' � Ph, n � 0 SW208080: R � thiophene, R' � Ph, n � 4 SW208081: R � thiophene, R' � Ph, n � 5 SW208066: R � thiazole, R' � Ph, n � 3, 95% SW206980: R � thiophene, R' � H, n � 3, 92% SW206992: R � thiazole, R' � H, n � 3, 87% SW208064: R� H, R' � H, n� 3, 11% 
35 
40 
45 
R' 
KOH, DMF, 37' C. 0.6 equiv. 
0 
I 
s'-.../ s ......._ Bu 
CN 
SW033291 2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl) 
thieno[2,3-b ]pyridin-3-amine was prepared using procedure 
describe by Kalugin. To the solution of 4-(((butylthio) 
methyl)sulfinyl)-2,6-diphenylpyrimidine-5-carbonitrile 
2-(((butylthio )methyl)sulfinyl)-4-phenyl-6-(thiophen-2-50 yl)nicotinonitrile. Acetic Acid (900 µL) and hydrogen per-
oxide (0.57 mmol, 1.5 equiv., 30% solution in water) were 
added to the solution of 2-(((butylthio )methyl)sulfinyl)-4-
phenyl-6-(thiophen-2-yl)nicotinonitrile (0.38 mmol, 150 55 mg) in chloroform (900 µL). The reaction mixture was 
(0.53 mmol, 220 mg) in DMF (0.25 M)/EtOH (0.5 M) was 
added KOH (0.32 mmol, 18 mg, 0.6 equiv., 0.1 M in water). 
The reaction mixture was stirred at 35° C. for 40 min Once
complete, the reaction was diluted with EtOAc and washed 
with 10% aq. solution of acidic acid, the organic phase was 
separated and aqueous layer was extracted twice with 
EtOAc, dried over magnesium sulfate, filtered and concen­
trated under reduced pressure to give 211 mg of SW033291 60 
2-(butylsulfiny 1)-4-phenyl-6-( thiophen-2-yl )thieno [2,3-b] 
pyridin-3-amine (96%). 1H NMR (400 MHz, CDC13) Ii
7.67-7.60 (m, lH), 7.57-7.35 (m, 7H), 7.10 (dd, J=5.0, 3.7 
Hz, lH), 4.54 (s, 2H), 3.26 (ddd, J=12.8, 9.1, 6.0 Hz, lH), 
3.09 (ddd, J=12.8, 9.1, 6.6 Hz, lH), 1.83-1.61 (m, 2H), 65 
1.53-1.38 (m, 2H), 0.93 (t, J=7.3 Hz, 3H). ESI-MS (m/z): 
413 [M+Ht. 
stirring at 32° C. for 45 min. The reaction was then diluted
with EtOAc and washed with saturated NaHC03 solution, 
dried over magnesium sulfate, filtered and concentrated 
under reduced pressure to give 153 mg of designed product 
(98%). 1H NMR (400 MHz, CDC13) Ii 7.75 (dd, J=3.8, 1.1
Hz, lH), 7.66-7.57 (m, 2H), 7.58-7.51 (m, 4H), 7.47 (s, lH), 
7.16 (dd, J=5.0, 3.8 Hz, lH), 4.74 (d, J=13.0 Hz, lH), 4.41 
(d, J=13.0 Hz, lH), 2.97 (dt, J=13.0, 8.2 Hz, lH), 2.81 (dt, 
J=12.9, 7.3 Hz, lH), 1.94-1.76 (m, 2H), 1.53-1.38 (m, 2H), 
0.94 (t, J=7.4 Hz, 3H). ESI-MS (m/z): 413 [M+Ht 
US 9,790,233 B2 
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S
'-../
SBu 
CN 
10 
2-(( (butylthio )methyl)thio )-4-phenyl-6-(thiophen-2-yl) 
nicotinonitrile. A mixture of 4-phenyl-6-(thiophen-2-yl)-2- 15 
thioxo-1,2-dihydropyridine-3-carbonitrile (0.34 mmol, 101 
mg), butyl(chloromethyl)sulfane (0.34 mmol, 48 mg, 1.0 
equiv.) and Et3N (0.51 mmol, 72 µL, 1.5 equiv.) was 
refluxed in dry CH3CN (350 µL) for 20 min. The reaction 
mixture was then diluted with EtOAc and water. The organic 20 
phase was separated and aqueous layer was extracted twice 
with EtOAc. The combined extractions were washed with 
saturated NaCl solution, dried over magnesium sulfate, 
filtered and concentrated under reduced pressure. The resi­
due was purified by flash chromatography to give 124 mg of 25 
designed product (92% ). 1 H NMR ( 400 MHz, CDCl3) Ii 7. 70
(dd, J=3.8, 1.1 Hz, lH), 7.64-7.56 (m, lH), 7.55-7.47 (m, 
SH), 7.40 (d, J=l.1 Hz, lH), 7.14 (dd, J=5.0, 3.8 Hz, lH), 
88 
4.53 (s, 2H), 2.74 (t, J=8.0 Hz, 2H), 1.72-1.57 (m, 2H), 
1.49-1.34 (m, 2H), 0.90 (t, J=7.4 Hz, 3H). ESI-MS (m/z): 
397 [M+Ht. 
s 
CN 
4-pheny 1-6-( thiophen-2-y 1)-2-thioxo-l ,2-dihydropyri­
dine-3-carbonitrile. To a solution of 3-phenyl-1-(thiophen-
2-yl)prop-2-en-1-one (2.34 mmol, 500 mg) and cyanothio­
acetamide (7.0 mmol, 717 mg, 3.0 equiv.) in ethanol (7 mL),
a few drops of piperidine were added. The reaction was
refluxed for 3 h. The solid that formed was collected and
recrystallized from acetic acid to give designed product in
46% isolated yield. 1 H NMR (400 MHz, DMSO-d6) Ii 8.17
(d,J=3.8 Hz, lH), 7.96 (d,J=5.0 Hz, lH), 7.74-7.62 (m, 2H),
7.54 (dd, J=5.1, 2.0 Hz, 3H), 7.31-7.19 (m, lH), 7.01 (s, lH).
ESI-MS (m/z): 295 [M+Ht.
Scheme 2 
)----0 
1.0 equiv. 
0 
X = C, conditions A 
X = N, conditions B 
)----0 KOHmmH 
0 
EtO�
Br 
(
S 
L) 
Dondoni, A.; Marra, A.; Merino, P. J. Am. Chem. Soc., 1994, 116, 3324 
s 
CN 
A: X = C, cyanothioacetamide 3 equiv.; piperidine 0.5 equiv.; 
EtOH reflux, 3 h 46% 
B: X � N, cyanothioacetamide 1.1 equiv.; DABCO 0.5 equiv.; 
EtOH, reflux, 12 h, 40% 
Parveen, H.; Iqbal, P. F.; Azam, A. Synth. Comm, 2008, 38, 3973 
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synthetic procedures described for the preparation of analog 
SW033291 and showed in Scheme 1 and 2. 1H NMR (500
MHz, CD2Cl2) ll 7.98-7.36 (m, SH), 7.33-6.85 (m, lH), 4.47 
(s, 2H), 3.28-3.15 (m, lH), 3.09-2.99 (m, lH), 1.81-1.59 (m, 
5 2H), 1.50-1.25 (m, 4H), 0.88 (t, J=7.2 Hz, 3H). ESI-MS 
(m/z): 427 [M+Ht. 
3-pheny 1-1-( thiophen-2-y l)prop-2-en-1-one was prepared
from benzaldehyde and l-(thiophen-2-yl)ethanone via aldol 10 
condensation using procedure described by Azam showed in 
Scheme 2. 1 H NMR ( 400 MHz, CDCl3) ll 7 .88-7 .80 (m, 2H),
7.67 (dd, J=4.9, 1.1 Hz, lH), 7.66-7.59 (m, 2H), 7.47-7.34 
(m, 4H), 7.18 (dd, J=5.0, 3.8 Hz, lH). ESI-MS (m/z): 215 
[M+Ht. 15 
0 
I 
s 
\ 
Hex 
0 
3-pheny 1-1-( thiazol-2-y l)prop-2-en-1-one was prepared
from via Wittig reaction using procedure described by 
Merino showed in Scheme 2. 1 H NMR ( 400 MHz, Chloro­
form-d) Ii 8.06 (d, J=3.0 Hz, lH), 7.99 (s, lH), 7.96 (s, lH), 
7.75-7.67 (m, 3H), 7.44-7.38 (m, 3H). ESI-MS (m/z): 216 
[M+Ht. 
0 
I 
s 
\ 
Me 
SW208079-l-A 2-(methylsulfinyl)-4-phenyl-6-(thio-
phen-2-yl)thieno[2,3-b ]pyridin-3-amine was prepared by 
using synthetic procedures described for the preparation of 
analog SW033291 and showed in Scheme 1 and 2. 1H NMR
(500 MHz, CDCl3) ll 7.67-7.50 (m, SH), 7.50-7.36 (m, 3H), 
7.16-7.09 (m, lH), 4.58 (s, 2H), 2.99 (s, 3H). ESI-MS (m/z): 
371 [M+Ht. 
0 
I 
s 
\ 
Pent 
SW208080-l-A 2-(pentylsulfinyl)-4-phenyl-6-(thiophen-
2-yl)thieno[2,3-b ]pyridin-3-amine was prepared by using
20 
S W20808 l -1-A 2-(hexy lsulfinyl )-4-phenyl-6-( thiophen-
2-y l)thieno[2,3-b ]pyridin-3-amine was prepared by using
synthetic procedures described for the preparation of analog
SW033291 and showed in Scheme 1 and 2. 1H NMR (500
25 MHz, CD2Cl2) Ii 7.78-7.66 (m, lH), 7.63-7.46 (m, 7H),
7.27-7.02 (m, lH), 4.11 (s, 2H), 3.43-3.20 (m, lH), 3.11 
(ddd, J=13.8, 9.4, 6.4 Hz, lH), 1.89-1.63 (m, 2H), 1.58-1.39
(m, 4H), 1.40-1.21 (m, 2H), 0.91 (d, J=6.8 Hz, 3H). ESI-MS
30 (m/z): 441 [M+Ht.
�r 
0 
35 s I 
s 
\ 
Bu 
40 
SW208066, 2-(butylsulfinyl)-4-phenyl-6-(thiazol-2-yl) 
45 
thieno[2,3-b ]pyridin-3-amine was prepared by using syn­
thetic procedures described for the preparation of analog 
SW033291 and showed in Scheme 1 and 2. 1H NMR (400
MHz, CDCl3) Ii 8.06 (s, lH), 7.92 (d, J=3.2 Hz, lH), 
7.65-7.39 (m, 6H), 4.63 (s, 2H), 3.28 (ddd, J=12.8, 9.0, 6.2 
50 
Hz, lH), 3.11 (ddd, J=12.8, 9.0, 6.8 Hz, lH), 1.85-1.63 (m, 
2H), 1.56-1.42 (m, 2H), 0.94 (t, J=7.3 Hz, 3H). ESI-MS 
(m/z): 414 [M+Ht. 
55 
0 
I 
s 
\ 
60 Bu 
NH2 
SW206980, 2-(butylsulfinyl)-6-(thiophen-2-yl)thieno[2, 
65 3-b ]pyridin-3-amine was prepared by using synthetic pro­
cedures described for the preparation of analog SW033291 
and showed in Scheme 1 and 2. 1 H NMR ( 400 MHz, CDCl3) 
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ll 7.79 (d, 1=8.5, lH), 7.65-7.49 (m, 2H), 7.39 (dt, 1=5.1, 0.7 
Hz, lH), 7.06 (dd, 1=5.0, 3.7, Hz, lH), 5.20 (s, 2H), 3.26 
(ddd, 1=12.8, 9.0, 6.2 Hz, lH), 3.10 (ddd, 1=12.8, 9.1, 6.6 
Hz, lH), 1.78-1.60 (m, 2H), 1.55-1.39 (m, 2H), 0.92 (t, 
1=7.3 Hz, 3H). ESI-MS (m/z): 337 [M+Ht 
er s 0 I 
s 
Bu 
SW206992, 2-(butylsulfinyl)-6-(thiazol-2-yl)thieno[2,3-
92 
reaction mixture was stirring at 32° C. for 4 h. The reaction 
was diluted with EtOAc and washed with saturated NaHC03 
solution, dried over magnesium sulfate, filtered and concen-
5 trated under reduced pressure to give crude 2-(butylsulfo­
nyl )-4-phenyl-6-( thiophen-2-y l)thieno[2,3-b ]pyridin-3-
amine, which was purified by flash chromatography in 8% 
isolated yield. 1H NMR (400 MHz, CDC13) ll 7.71 (d, 1=3.8
10 Hz, lH), 7.64-7.54 (m, 3H), 7.53-7.42 (m, 4H), 7.15 (dd,
1=5.0, 3.7 Hz, lH), 5.09 (s, 2H), 3.38-3.02 (m, 2H), 1.92-
1.67 (m, 2H), 1.52-1.28 (m, 2H), 0.92 (t, 1=7.4 Hz, 3H). 
ESI-MS (m/z): 429 [M+Ht. 
15 
0 
b ]pyridin-3-amine was prepared by using synthetic proce­
dures described for the preparation of analog SW033291 and 20 
showed in Scheme 1 and 2. 1 H NMR ( 400 MHz, CDC13) Ii
8.15 (d, 1=8.5 Hz, lH), 7.95 (d, 1=8.5 Hz, lH), 7.90 (d, 1=3.2 
Hz, lH), 7.44 (d, 1=3.2 Hz, lH), 3.29 (ddd, 1=12.7, 9.0, 6.2 
Hz, lH), 3.13 (ddd, 1=12.8, 9.0, 6.7 Hz, lH), 1.83-1.61 (m, 25 
2H), 1.59-1.38 (m, 2H), 0.92 (t, 1=7.3 Hz, 3H). ESI-MS 
(m/z): 338 [M+Ht. 
II 
S-Me 
II 
0 
SW208064, 2-(butylsulfinyl)thieno[2,3-b ]pyridin-3-
SW033290-2-A 2-(methylsulfonyl)-4-phenyl-6-(thio-
30 phen-2-yl)thieno[2,3-b ]pyridin-3-amine was prepared by 
using synthetic procedures described for the preparation of 
analog SW208078-l-A and showed in Scheme 1 and 2. 1H
NMR (500 MHz, CDC13) ll 7.78-7.68 (m, lH), 7.64-7.54 (m, 
35 3H), 7.53-7.45 (m, 4H), 7.18-7.10 (m, lH), 5.08 (s, 2H), 
3.14 (s, 3H). ESI-MS (m/z): 387 [M+Ht. 
amine was prepared by using synthetic procedures described 
for the preparation of analog SW033291 and showed in 40 
Scheme 1. 1H NMR (400 MHz, CDC13) Ii 8.61 (dd, 1=4.7, (') N 
�I 
0 
1.6 Hz, lH), 7.89 (dd, 1=8.1, 1.6 Hz, lH), 7.33 (dd, 1=8.1, 
4.6 Hz, lH), 3.39-3.18 (m, lH), 3.20-3.03 (m, lH), 1.74 (p, 
1=7.6 Hz, 2H), 1.63-1.38 (m, 2H), 0.94 (t, 1=7.3 Hz, 3H). 45 
ESI-MS (m/z): 255 [M+Ht. 
N� 
I 
s 
Bu 
0 
II 
S-Bu 
II
0 
SW208078-l-A 2-(butylsulfonyl)-4-phenyl-6-(thiophen-
2-yl)thieno[2,3-b ]pyridin-3-amine. Acetic Acid (50 µL) and
hydrogen peroxide (0.036 mmol, 1.5 equiv., 30% solution in
water) were added to the solution of SW033291 2-(butyl­
sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b ]pyridin-3-
amine (0.024 mmol, 10 mg) in chloroform (50 µL). The
50 
SW208065, 6-(butylsulfinyl)-2,4-diphenylthieno[2,3-d] 
pyrimidin-5-amine. To the solution of 4-(((butylthio )methyl) 
sulfinyl)-2,6-diphenylpyrimidine-5-carbonitrile (0.07 mmol, 
55 30 mg) in DMF (0.25 M) was added KOH (0.035 mmol, 2 
mg, 0.5 equiv., 0.1 M in water). The reaction mixture was 
stirred at room temperature for 20 min Once complete, the 
reaction was diluted with EtOAc and washed with 5% aq. 
60 solution of acidic acid. The organic phase was separated and 
aqueous layer was extracted twice with EtOAc, dried over 
magnesium sulfate, filtered and concentrated under reduced 
pressure to give crude product, which was purified by flash 
65 
chromatography in 70% isolated yield. 1 H NMR ( 400 MHz,
CDC13) ll 8.73-8.37 (m, 2H), 7.78-7.68 (m, 2H), 7.66-7.55 
(m, 3H), 7.53-7.40 (m, 3H), 4.83 (s, 2H), 3.30 (ddd, 1=12.7, 
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8.9, 6.3 Hz, lH), 3.21-3.01 (m, lH), 1.87-1.66 (m, 2H), 
1.57-1.41 (m, 2H), 0.95 (t, J=7.3 Hz, 3H). ESI-MS (m/z): 
408 [M+Ht 
94 
pressure. The residue obtained was then purified by flash 
chromatography to give 59 mg of designed product (75%). 
1H NMR (400 MHz, CDC13) ll 8.75-8.36 (m, 2H), 8.35-7.91
5 (m, 2H), 7.71-7.41 (m, 6H), 4.59 (s, 2H), 2.74 (t, J=7.5 Hz, 
2H), 1.75-1.58 (m, 2H), 1.49-1.34 (m, 2H), 0.91 (t, J=7.3 
Hz, 3H). ESI-MS (m/z): 392 [M+Ht. 
0 
s
'-..../
s......._ 
Bu 
CN 
4-( ( (buty lthio )methyl )sulfiny 1)-2,6-dipheny lpyrimidine-
5-carbonitrile. Acetic Acid (600 µL) and hydrogen peroxide
(0.37 mmol, 1.5 equiv., 30% solution in water) were added
10 
15 
20 
to the solution of 4-(((butylthio )methyl)thio )-2,6-diphe- 25 
nylpyrimidine-5-carbonitrile (0.25 mmol, 98 mg) in chloro­
form (900 µL). The reaction mixture was stiffing at 32° C.
s 
CN 
4,6-dipheny 1-2-thioxo-l ,2-dihydropyridine-3-carbonitrile 
was prepared according procedure described by Soto. A 
mixture of NaOiPr (1.5 mmol, 1.0 equiv., prepared in situ 
from sodium and dry iPrOH), benzothioamide (1.5 mmol, 
205 mg, 1.0 equiv.) and 2-(ethoxy(phenyl)methylene)ma-
for 45 min. Once complete, the reaction was diluted with lononitrile (1.5 mmol, 297 mg, 1.5 equiv.) in iPrOH (75 mL) 
EtOAc and washed with saturated NaHC03 solution, dried 30 
over magnesium sulfate, filtered and concentrated under
reduced pressure to give 88 mg of designed product (98%).
1H NMR (400 MHz, CDC13) Ii 8.57 (dt, J=7.7, 1.2 Hz, 2H),
8.28-8.05 (m, 2H), 7.80-7.40 (m, 6H), 4.82 (d, J=13.2 Hz, 35 
lH), 4.49 (d, J=13.3, lH), 2.95 (dt, J=13.0, 8.1 Hz, lH), 2.84
(dt, J=13.0, 7.3 Hz, lH), 1.91-1.74 (m, 2H), 1.56-1.40 (m,
2H), 0.95 (t, J=7.4 Hz, 3H). ESI-MS (m/z): 408 [M+Ht
40 
OyN 
� 
S
'-..../
SBu 45 
N # 
CN 
50 
55 
4-(( (butylthio )methyl)thio )-2,6-diphenylpyrimidine-5-
carbonitrile. A mixture of 4,6-diphenyl-2-thioxo-1,2-dihy­
dropyridine-3-carbonitrile (0.35 mmol, 101 mg), butyl(chlo­
romethyl)sulfane (0.35 mmol, 48 mg, 1.0 equiv.) and Et3N 60 
(0.87 mmol, 2.5 equiv.) was refluxed in dry CH3CN (200 
µL) for 20 min. The reaction was diluted with EtOAc and 
water. The organic phase was separated and aqueous layer 
was extracted twice with EtOAc. The combined extractions 65
were washed with saturated NaCl solution, dried over mag­
nesium sulfate, filtered and concentrated under reduced 
was stirred for 5 h at room temperature. The reaction was 
then acidified with con. HCl and stirred overnight, evapo­
rated and obtained solid was recrystallized from acetic acid 
to give 265 mg of 4,6-diphenyl-2-thioxo-1,2-dihydropyri­
dine-3-carbonitrile (61 %). 1H NMR (400 MHz, DMSO-d6) 
Ii 8.23-8.12 (m, 2H), 8.07-7.91 (m, 2H), 7.74-7.49 (m, 6H). 
ESI-MS (m/z): 290 [M+Ht 
OyN 0 
,:::," I 
s 
N� Bu 
SW208067, 6-(butylsulfinyl)-4-phenyl-2-(thiophen-2-yl) 
thieno[2,3-d]pyrimidin-5-amine was prepared by using syn­
thetic procedures described for the preparation of analog 
SW208065 and showed in Scheme 3. 1H NMR (400 MHz,
CDC13) Ii 8.10 (dd, J=3.7, 1.3 Hz, lH), 7.74-7.65 (m, 2H), 
7.62-7.53 (m, 3H), 7.50 (dd, J=5.0, 1.2 Hz, lH), 7.14 (dd, 
1=5.0, 3.7 Hz, lH), 4.79 (s, 2H), 3.28 (ddd, J=12.8, 9.0, 6.2 
Hz, lH), 3.11 (ddd, J=12.8, 9.0, 6.7 Hz, lH), 1.84-1.63 (m, 
2H), 1.54-1.41 (m, 2H), 0.94 (t, J=7.3 Hz, 3H). ESI-MS 
(m/z): 414 [M+Ht. 
US 9,790,233 B2 
Ph WS206977-1 0 Cl0NHPr EtONa/EtOH 1.6 equiv. 61% 
s 
CN 
95 
0 Br II �OEt 1.6 equiv. Et3N 1.6 equiv. 
Scheme 3 
DMP 74% after 2 steps 
96 
's
\xt<
: Ph NH2 WS206976-1 
lKOH/MeOH 1.0 equiv. 98% 
0 <\x O Br0 s00Et NaOH, OEt DMF EtONa/EtOH 63% after 1.6 equiv. CN 2 steps Ph 79% 
Ph WS206978-1 
Ph WS206979-1 
1H NMR (400 MHz, CDCl3) Ii 7.65 (dd, J=3.8, 1.1 Hz,45 lH), 7.62-7.56 (m, 2H), 7.55-7.48 (m, 4H), 7.40 (s, lH),
7.13 (dd, J=5.0, 3.8 Hz, lH), 4.13 (s, 2H), 2.72 (t, J=7.4 Hz, 
2H), 1.72-1.56 (m, 2H), 1.42-1.25 (m, 2H), 0.88 (t, J=7.3 
Hz, 3H). ESI-MS (m/z): 393 [M+Hi+. 
SW20697 6-1, 1-(3-amino-4-phenyl-6-(thiophen-2-yl) 
50 
55 
thieno[2,3-b ]pyridin-2-yl)pentan-1-one. To the solution of 
2-( (2-oxohexyl )thio )-4-pheny 1-6-( thiophen-2-y l)nicotinoni­
trile (0.13 mmol, 50 mg) in ethanol (500 µL) was added 60 
KOH (0.13 mmol, 2 mg, 1.0 equiv.). The reaction mixture 
was stirred at 50° C. for 30 min Once complete, the reaction 
was diluted with EtOAc and washed with 10% aq. HCI. The 
organic phase was separated and aqueous layer was 
extracted twice with EtOAc, dried over magnesium sulfate, 65 
filtered and concentrated under reduced pressure to afford 
designed product in 98% yield. 
2-( (2-oxohexyl )thio )-4-pheny 1-6-( thiophen-2-y l)nicoti­
nonitrile. A mixture of 4-phenyl-6-(thiophen-2-yl)-2-thioxo-
1,2-dihydropyridine-3-carbonitrile (0.068 mmol, 20 mg), 
Et3N (0.11 mmol, 15 µL, 1.6 equiv.) and 2-butyloxirane 
(0.11 mmol, 11 mg, 1.6 equiv.) in MeOH (500 µL) was 
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stirred at room temperature. When the reaction was com­
plete as judged by TLC, the reaction mixture was evapo­
rated; the crud product dissolved in DCM and DMP (0.10 
mmol, 1.5 equiv.) was added at 0° C. The reaction mixture
was stirred at room temperature for 2 h and then was 5 
quenched by addition of 1: 1 mixture of 20% Na2S20/ 
NaHC03 solution. The organic layer was separated, dried 
over magnesium sulfate and the solvent was removed under 
reduced pressure. The crude product was purified by flash 
chromatography to afford designed product in 72% yield. 
1 H 10 
NMR (400 MHz, CDCl3) Ii 8.02 (s, lH), 7.97 (d, J=3.1 Hz, 
lH), 7.71-7.59 (m, 2H), 7.55 (d, J=3.2 Hz, lH), 7.55-7.46 
(m, 4H), 4.52 (s, 2H), 2.75 (t, J=7.8 Hz, 2H), 1.73-1.54 (m, 
2H), 1.51-1.26 (m, 2H), 0.91 (t, J=7.3 Hz, 3H). ESI-MS 
(m/z): 393 [M+Ht. 15 
20 
98 
was separated and aqueous layer was extracted twice with 
EtOAc, dried over magnesium sulfate, filtered and concen­
trated under reduced pressure to afford designed product in 
79% yield. 1H NMR (400 MHz, DMSO-d6) ll 8.01 (d, J=3.7
Hz, lH), 7.87-7.67 (m, 2H), 7.56 (d, J=6.5 Hz, SH), 7.36-
6.90 (m, lH), 5.73 (s, 2H), 4.23 (q, J=7.1 Hz, 2H), 1.25 (t, 
1=7.0 Hz, 3H). ESI-MS (m/z): 381 [M+Ht. 
SW206979, 3-Amino-4-phenyl-6-(thiophen-2-yl)thieno 
[2,3-b]pyridine-2-carboxylic acid. To a solution of -phenyl-
6-( thiophen-2-y 1)-2-thioxo-l ,2-dihydropyridine-3-carboni-
25 trile (0.34 mmol, 100 mg) and ethyl 2-chloroacetate (0.54
mmol, 1.6 equiv.) in ethanol (1 mL), Et3N (0.54 mmol, 1.6 
equiv.) was added. The reaction was refluxed for 20 min. 
The reaction was then diluted with EtOAc and water. The 
30 organic phase was separated and aqueous layer wasSW206977, 3-amino-4-phenyl-N-propyl-6-(thiophen-2-
yl)thieno[2,3-b ]pyridine-2-carboxamide. A mixture of 
4-pheny 1-6-( thiophen-2-yl )-2-thioxo-1,2-dihydropyridine-
3-carbonitrile (0.12 mmol, 35 mg), 2-chloro-N-propylacet­
amide (0.12 mmol, 16 mg, 1.0 equiv.) and EtONa (0.19 
mmol, 1.6 equiv.) in ethanol (1 mL) was stirred at 50° C.
When the reaction was complete as judged by TLC, the 
reaction was diluted with EtOAc and washed with 10% aq. 
HCI. The organic phase was separated and aqueous layer 
was extracted twice with EtOAc, dried over magnesium 
sulfate, filtered and concentrated under reduced pressure to 40 
afford designed product in 61 % yield. 1 H NMR ( 400 MHz,
CDCl3) ll 7.65 (d, J=3.7, lH), 7.58-7.49 (m, 3H), 7.49-7.38 
(m, 4H), 7.10 (dd J=4.9, 3.7 Hz, lH), 5.75 (s, 2H), 5.59-5.38 
(m, lH), 3.35 (td J=7.0, 5.9 Hz, lH), 1.64-1.58 (m, 2H), 0.96 
extracted twice with EtOAc. The combined extractions were 
washed with saturated NaCl solution, dried over magnesium
sulfate, filtered and concentrated under reduced pressure to 
35 afford designed product. Ethyl 2-((3-cyano-4-phenyl-6-
(t, J=7.4 Hz, 3H). ESI-MS (m/z): 394 [M+Ht. 45 
(thiophen-2-yl)pyridin-2-yl)thio )acetate was then dissolved 
in DMF and treated with IM aq. NaOH at 50° C. to give
SW206979, 3-amino-4-phenyl-6-(thiophen-2-yl)thieno[2,3-
b ]pyridine-2-carboxylic acid in 63% yield. 1H NMR (400
MHz, DMSO-d6) ll 8.00 (dd, J=3.7, 1.1 Hz, lH), 7.79-7.64 
(m, 2H), 7.55 (dt, J=7.6, 3.2 Hz, SH), 7.16 (dd, J=5.0, 3.7
Hz, lH), 5.72 (s, 2H). ESI-MS (m/z): 353 [M+Ht. 
Scheme 4 
OCN Cl NaS� 50 
55 
SW206978, Ethyl 3-amino-4-phenyl-6-(thiophen-2-yl) 60 
thieno[2,3-b ]pyridine-2-carboxylate. A mixture of 4-phenyl-
6-(thiophen-2-yl)-2-thioxo-1,2-dihydropyridine-3-carboni-
trile (0.34 mmol, 100 mg), ethyl 2-chloroacetate (0.54 
mmol, 1.6 equiv.) and EtONa (0.54 mmol, 1.6 equiv.) in 
ethanol (1 mL) was stirred at reflux. When the reaction was 65 
complete as judged by TLC, the reaction was diluted with 
EtOAc and washed with 10% aq. HCI. The organic phase 
N02 
OCNI s�
N02 
AcOH/HCl/Zn 
0 
I 
OCNI s�
N02 
SW208069 
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-continued 
100 
mixture, and the resulting mixture was extracted with ethyl 
acetate. The organic layer was washed with a saturated 
aqueous solution of sodium chloride, and dried over mag­
nesium sulfate, filtered and concentrated under reduced 
OCN I s� -A
-
cO
_
H/
_
H
-
20
_
2
_ 1.5 equiv. 
NH2 
SW208068 
0 
I OCNI s�
5 pressure to afford crude product. Because of difficulties with 
purification, impure 2-(butylthio)-3-nitropyridine was used 
directly for the next step. Nitropyridine (0.47 mmol, 100 
mg) was dissolved in a mixed solvent of acetic acid (1.2 ml) 
and chloroform (1.2 mL), and hydrogen peroxide (0.7 mmol, 
NH2 
SW208070 
10 1.5 equiv., 30% solution in water) was added. After the 
mixture was stirred for 45 minutes, at 32° C., the reaction 
was diluted with EtOAc and washed with saturated NaHC03 
solution, dried over magnesium sulfate, filtered and concen­
trated under reduced pressure to 2-(butylsulfinyl)-3-nitrop-
CXN s......_ 
Bu 
15 yridine. 1H NMR (400 MHz, CDC13) Ii 9.14 (dd, J=4.6, 1.5 
Hz, lH), 8.54 (dd, J=8.2, 1.5 Hz, lH), 7.67 (dd, J=8.2, 4.6 
Hz, lH), 3.18 (ddd, J=12.7, 9.3, 7.2 Hz, lH), 3.00 (ddd, 
J=12.7, 9.1, 4.9 Hz, lH), 2.17-1.92 (m, lH), 1.91-1.70 (m, 
lH), 1.68-1.35 (m, 2H), 0.96 (t, J=7.3 Hz, 3H). ESI-MS 
20 (m/z): 229 [M+Ht. 
NH2 
SW208068, 2-(butylthio )pyridin-3-amine. To the solution 
ofbutane-1-thiol (7.0 mmol, 628 mg, 1.1 equiv.) in THF (30 25 
mL) was added NaH (6.6 mmol, 158 mg, 1.05 equiv.) at 0° 
0 
I CXN s......_ 
Bu 
NH2 
SW208070, 2-(butylsulfinyl)pyridin-3-amine was pre­
pared by using synthetic procedure described for the prepa­
ration of analog SW208069 and showed in Scheme 4. 1H 
NMR (400 MHz, CDC13) Ii 7.90 (dd, J=4.4, 1.4 Hz, lH), 
7 .09 ( dd, J=8.3, 4.4 Hz, lH), 6.93 ( dd, J=8.3, 1.4 Hz, lH), 
5.30 (s, 2H), 3.24 (ddd, J=13.0, 9.5, 5.4 Hz, lH), 3.03 (ddd, 
J=13.0, 9.8, 6.3 Hz, lH), 1.95-1.61 (m, 2H), 1.55-1.35 (m, 
2H), 0.93 (t, J=7.3 Hz, 3H). ESI-MS (m/z): 199 [M+Ht. 
EXAMPLE 4 
Analysis of the Mechanism of 15-PGDH Inhibition 
by SW033291 and Related Compounds 
C. After the reaction mixture was stirred at room tempera­
ture for 30 min 2-chloro-3-nitropyridine (6.33 mmol, 1.0 g)
was portion wise added and left with stirring at room
temperature, for 2 h. Water was then added to the reaction 30 
mixture, and the resulting mixture was extracted with ethyl 
acetate. The organic layer was washed with a saturated 
aqueous solution of sodium chloride, and dried over sodium 
sulfate, filtered and concentrated under reduced pressure to 
afford crude product. Because of difficulties with purifica- 35 
tion, impure 2-(butylthio )-3-nitropyridine was directly used 
for the next step. Nitropyridine (0.47 mmol, 100 mg) was 
dissolved in a mixed solvent of acetic acid. (3.3 ml) and 
cone. hydrochloric acid (130 µL), and zinc (5.7 mmol, 370 
mg) was added in small portions while being cooled with 40 
ice. After the mixture was stirred for 30 minutes, the reaction 
mixture was filtered, and the filtrate was neutralized with an 
aqueous solution ofNaHC03 , and extracted with DCM. The 
organic layer was washed with water and then with a 
saturated aqueous solution of sodium chloride, and dried 
over sodium sulfate. Subsequently, the solvent was evapo­
rated to obtain 2-(butylthio )pyridin-3-amine as a pale yellow 
oil. 1H NMR (400 MHz, CDC13) ll 7.94 (dd, J=4.1, 2.0 Hz, 
lH), 7.05-6.51 (m, 2H), 3.84 (s, 2H), 3.51-2.95 (m, 2H), 
1.72-1.60 (m, 2H), 1.56-1.36 (m, 2H), 0.91 (t, J=7.4 Hz, 50 
3H). ESI-MS (m/z): 183 [M+Ht. 
The following Example provides data relating to the 
45 mechanism of action by which SW033291 inhibits 
15-PGDH.
0 
I CXN s......_ 
Bu 
N02 
SW208069, 2-(butylsulfinyl)-3-nitropyridine. To the solu­
tion ofbutane-1-thiol (7.0 mmol, 628 mg, 1.1 equiv.) in THF 
(30 mL) was added NaH (6.6 mmol, 158 mg, 1.05 equiv.) at 
Duplicate titrations of 15-PGDH Inhibitor (SW033291)
were run at 4 different concentrations of 15-PGDH (24 nM, 
12 nM, 6 nM, 3 nM). Reactions contained the indicated 
concentration of enzyme, 250 µM NAD( + ), 25 µM PGE-2, 
and were assembled and incubated at room temperature for 
3 minutes. 
FIGS. 21 (A-B) show the shift in IC50 value with chang­
ing enzyme concentration. The result is indicative of a 
55 tight-binding mode of inhibition with dependency on 
enzyme: inhibitor stoichiometry, rather than on the absolute 
concentration of the inhibitor. In all cases, the IC50 values 
are less than the enzyme concentration, indicating that nM 
60 
drug is almost fully bound by the enzyme. 
FIGS. 22 (A-B) indicate that SW033291 behaves very 
much like an irreversible inhibitor of 15-PGDH, and cannot 
be efficiently dialyzed off the 15-PGDH protein. 
0° C. After the reaction mixture was stirred at room tem­
perature for 30 min 2-chloro-3-nitropyridine (6.33 mmol, 65 
1.0 g) was portion wise added and left with stirring at room 
temperature, for 2 h. Water was then added to the reaction 
The testing of whether SW033291 is a reversible inhibitor 
proceeded by: 
(i) an 8 ul aliquot taken of 15-PGDH stock (8 mg/mL 
15-PGDH in 500 µL of15-PGDH assay buffer) (4 nmol
15-PGDH, 4 µM 15-PGDH), was incubated on ice
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with: (a) addition of 5 µL of 100 mM NAD( + )+addition 
of 3.2 µL of 2.5 mM SW033291 stock, then dialyzed 
versus 1 L buffer for 12 hours, followed by a fresh 1 L 
of buffer for 12 more hours; or (b) addition of 5 µL, 100 
mM NAD( + )+addition of 3.2 µL DMSO then dialyzed 5 
versus 1 L buffer for 12 hours, followed by a fresh 1 L 
of buffer for 12 more hours. 
(ii) Pre-dialysis, remove 1 µL and dilute in 200 µL assay
Buffer (20 nM), then measure 15-PGDH activity.
(iii) Post-Dialysis, at 24 hrs, remove 1 µL and dilute in 10 
200 µL assay Buffer (20 nM), then measure 15-PGDH
activity.
Dialysis buffer is 50 mM Tris pH7.4, 40 mM NaCl, 0.1 
mM DTT, 0.01 % Tween-20. 
Under the conditions of the assay SW033291 inhibited 15 
91 % of 15-PGDH pre-dialysis, and 85% of 15-PGDH activ-
ity post-dialysis-that is dialysis did not reverse the inhibi­
tion of 15-PGDH. Control 15-PGDH protein that was dia­
lyzed in the absence of SW033291 remained fully active. 
FIGS. 23(A-B) show (A) at upper right the reaction rates 20 
for 15-PGDH in the presence of a graded set of increasing 
concentrations of SW033291. In the graph at upper right P 
is the NADH concentration as a proxy for 15-keto-PGE2. 
(P+S) is the starting PGE2 concentration of 20 µM. The 
assay was carried out in the presence of 10 nM recombinant 25 
15-PGDH. In the graph at lower left (B), Vo is the initial
velocity of the reaction in the absence of SW033291 and Vi
is the initial velocity of the reaction in the presenc� of the
corresponding concentration of SW033291. The line shows
the curve generated by fitting the data to the Morrison 30 
equation. The curve fitting yields a calculated a KiApp value
of 0.1015 nM. The dashed line intersects the X axis at 8.5
nM. This represents the point at which [inhibitor]=[active
enzyme] showing that the enzyme preparation contains 85%
active enzyme. In the Morrison equation, Ki is the binding 35 
affinity of the inhibitor; [SJ is substrate concentration; and
Km is the concentration of substrate at which enzyme
activity is at half maximal. Note that IC50 is the functional
strength of the inhibitor. Whereas the IC50 value for a
compound may vary between experiments depending on 40 
experimental conditions, the Ki is an absolute value. Ki is
the inhibition constant for a drug; the concentration of
competing ligand in a competition assay which would
occupy 50% of the receptors if no ligand were present.
FIGS. 24(A-B) show duplicate titrations of 15-PGDH 45 
Inhibitor (SW033291) that were run at 6 different concen­
trations of PGE2 (1.25 uM-40 uM). In the graph at top, 
Y-axis is % inhibition of the reaction by SW033291. The
X-axis is the concentration of SW033291 in nM. Reactions
contain 5.0 nM added 15-PGDH, 250 µM NAD(+), and 50 
indicated concentrations of PGE-2, were assembled and
incubated at room temperature for 60 minutes. The Km for
PGE2 is approximately 5 uM, and reactions run with PGE2
concentrations below 5 uM go very slowly making it diffi­
cult to quantitate inhibition by SW033291. However, in 55 
reactions with PGE2 at concentrations of 5 uM-40 uM the
IC50 for SW033291 is unaffected by the increasing PGE2
concentration, showing that the inhibition is noncompeti­
tive.
102 
isomer is the faster eluting isomer. The 'B' isomer is the 
slower eluting isomer. 
The analogue family shows that SW033291 with a 4 
carbon side chain, is 2-fold more potent than SW208080 (5 
carbon side chain), 15-fold more potent than SW208081 (6 
carbon side chain), and 100-fold more potent than 
SW208079 (1 carbon side chain). SW033291 is also 20-fold 
more potent than SW208078, the analogue that converts the 
sulfoxide group to a sulfone. 
FIG. 26 shows structures of additional SW033291 ana­
logs that convert the sulfoxide group to a ketone, an amide, 
an ester, or a carboxylic acid. Also shown is structure 
SW206980 that deletes the phenyl ring from SW033291. 
FIGS. 27(A-C) show graphs that show the level of com­
pound's activity in inducing the 15-PGDH-luciferase fusion 
reporter in three different test cell line backgrounds V9m 
LS174T, and V503. Each compound was tested �t tw� 
concentrations, 2.5 uM, and 7.5 uM. Y-axis is luciferase 
activity. 
At 2.5 µM-7.5 µM, SW206980, that deletes the phenyl 
group of SW033291, shows activity comparable to 
SW033291 in all three reporter lines. 
Structures that have converted the sulfoxide group to a 
ketone, amide, ester, or carboxylic acid show major loss of 
activity in inducing the reporter. 
FIG. 28 shows graphs that show the percent of 15-PGDH 
enzyme activity that is inhibited at 2.5 uM and at 7.5 uM by 
each of the 5 test compounds. SW206980 that deletes the 
phenyl group of SW033291, shows at these concentrations 
similar potency to SW03291 in inhibiting 15-PGDH activ­
ity. 
Structures that have converted the sulfoxide group to a 
ketone, amide, ester, or carboxylic acid show major loss of 
activity as 15-PGDH inhibitors. 
FIGS. 29(A-B) show a titration curve that plots percent 
inhibition of 15-PGDH enzyme activity at different concen­
trations of SW033291 and SW0206980. Under identical 
assay conditions, SW206980 shows a slightly lower IC50. 
FIGS. 30(A-B) show that SW206980 binds directly to 
15-PGDH and markedly shifts its melting curve. Shown at
left is the melt curve of 15-PGDH as reflected by fluores­
cence of the hydrophobic dye SYPRO Orange. Shown at
right is the negative first derivative of the melt curve.
Three conditions are plotted, that of 10 uM 15-PGDH, 
that of 10 uM 15-PGDH plus 10 uM SW206980, and that of 
10 uM 15-PGDH plus 125 uM NADH plus 10 µM 
SW206980. The melting temperature, as reflected by the 
inflection point of the curve at right is shifted by 20° C., 
from 48-degrees up to 68-degrees, in the presence of 
SW206980 and NADH, reflecting that SW206980 directly 
binds to and markedly stabilizes the tertiary structure of 
15-PGDH, in a marmer requiring the presence of the NADH
cofactor.
FIGS. 31(A-C) show further analogues of SW033291 that 
build on the previous finding that removal of the SW033291 
phenyl ring (SW206980) retained activity. The new analog 
(SW206992) adds a nitrogen to the left-hand ring. 
Table 3 provides a comparison of the properties of 
SW033291, SW206980, and SW206992. 
ICso 
TABLE 3 
Summary of three SW033291 analogs 
SW033291 SW206980 SW206992 
FIG. 25 shows the structure activity relationships of 60 
analogues of SW033291 versus their IC50 against recom­
binant 15-PGDH. Assignments of structures to the two 
isomers, A and B, of SW033291 are arbitrary, as the struc­
ture of the active isomer (isomer B) has not been deter­
mined. The optical isomers of SW033291 were separated by 
preparative HPLC using a 10 mmx250 mm Chiralcel ODH 
colunm, 5% isopropanol in hexanes, 1 mL/min. The 'A' 
65 Time to inhibition 
(10 nM) 
1.59 nM 
-5 mins 
0.97 nM 
-2 mins 
1.411 nM 
-2 mins
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TABLE 3-continued 
Summary of three SW033291 analogs 
SW033291 SW206980 
LI. Tm (NADH) 19° C. 15.5° C. 
Concentration for Full -100 nM >300 nM 
Cell Line Reporter 
Induction 
Hepatocyte stability Stable > couple T1/2 - 80 mins 
hrs 
Toxicity >10 µM >7.5 µM 
SW206992 
19° C. 
>1 uM 
>7.5 µM 
104 
ing temperature of the protein, with the order of the tem­
perature shifts being SW03329l>SW206980>SW206992. 
FIGS. 36(A-B) show the shift in the melt curve of 
recombinant 15-PGDH protein (10 uM) by 20 uM 
5 SW033291, SW206980, and SW206992 in the presence of 
the cofactor NADH (100 uM). Control melting temperature 
is 55 degrees centigrade. SW033291 shifts the melting 
temperature to 74 degrees. SW206980 shifts the melting 
temperature to 70.5 degrees. SW206992 shifts the melting 
10 temperature to 68.5 degrees. Thus all three compounds 
directly bind to 15-PGDH and markedly increase the melt­
ing temperature of the protein, with the order of the tem­
perature shifts being SW03329l>SW206980>SW206992. Time to inhibition refers to the time needed to inhibit the 
generation of NADH by 15-PGDH from the moment with 
drug is added into the reaction mix. Delta Tm refers to the 15 
shift in melting temperature of recombinant 15-PGDH in the 
presence of drug (with cofactor NADH also present). Con­
centration of Full Cell Line Reporter Induction refers to the 
concentration of drug that needs to be added to reporter cell 
line to achieve maximal induction of the 15-PGDH-lu­
ciferase gene fusion reporter cassette, as measured by 
luciferase assays. Hepatocyte stability refers to the half-life 
FIGS. 37(A-C) show a titration curve of 15-PGDH inhibi-
tor compounds in an assay measuring effect on PGE2 levels 
in the medium of A549 cells that have been stimulated with 
ILl-beta. Highest PGE2 levels, 3000 pg/ml, are achieved 
with SW033291, with maximal effect attained at 2.5 uM 
20 compound. Next highest PGE2 level, 2500 pg/ml are 
achieved with SW206980, with maximal effect attained at 
7.5 uM compound. Lowest induction, to 2100 pg/ml PGE2 
is achieved with SW206992, with maximal effect attained at 
2.5 uM. In these reactions, A549 cells were maintained in 
of compound in the presence of hepatocytes in culture. 
Toxicity refers to the concentration of compound needed to 
decrease cell numbers in a cell culture assay. 
FIGS. 32(A-C) show titration of induction by SW033291 
of the 15-PGDH-luciferase gene fusion reporter in three 
different cell line backgrounds. In general between 80-160 
nM SW033291 exposure for 24 hours is needed to induce 
maximal reporter induction. 
FIGS. 33(A-C) show titration of induction by SW206980 
of the 15-PGDH-luciferase gene fusion reporter in three 
different cell line backgrounds. In general >300 nM 
SW206980 exposure for 24 hours is needed to induce 
maximal reporter induction. 
FIGS. 34(A-C) show titration of induction by SW206992 
of the 15-PGDH-luciferase gene fusion reporter in three 
different cell line backgrounds. In general > 1000 nM 
25 F12K medium supplemented with 10% fetal calf serum 
(FBS) and 50 µg/mL gentamicin in a humidified atmosphere 
containing 5% C02 at 37
° C. Cells were plated in 24-well 
plates (0.5 mL per well) at about 100,000 cells per well in 
duplicate and grown for 24 h before stimulation with IL-1 � 
30 (1 ng/mL) overnight (16 h) to generate PGE2. SW033291 
and its analogs were added at the indicated concentrations, 
and the incubation continued for 8 h. Medium was collected, 
and the level of PGE2 was analyzed by enzyme immuno­
assay. Data were analyzed from results of three independent 
35 experiments. 
FIGS. 38(A-C) show assays of cellular toxicity on A549 
cells at 24 hours of 15-PGDH inhibitors as assayed by 
CellTiter-Glo measurement. No effect on CellTitre-Glo lev-
SW206992 exposure for 24 hours is needed to induce els is seen by concentrations of up to 10 uM of SW033291, 
maximal reporter induction. 40 SW206980, and SW2206992. 
FIGS. 35(A-C) show the shift in the melt curve of FIG. 39 shows structures of 7 SW033291 analogues, 
recombinant 15-PGDH protein (10 uM) by 20 uM SW208064, SW208065, SW208066, SW208067, 
SW033291, SW206980, and SW206992 in the presence of SW208068, SW208069, SW208070. 
the cofactor NAD ( +) (100 uM). Control melting tempera- Table 4 provides tabular summary of the properties of 4 
ture is 49 degrees centigrade. SW033291 shifts the melting 45 analogues, SW208064, SW208065, SW208066, 
temperature to 63 degrees. SW206980 shifts the melting SW208067, and in particular lists the IC50 for each of these 
temperature to 61 degrees. SW206992 shifts the melting 4 compounds against 2.5 nM recombinant 15-PGDH. 
TABLE 4 
Summary of four SW033291 analogs from UTSW set 8 
SW033291 SW2068064 SW208065 SW208066 SW208067 
IC50 1.23 nM 151.4 nM 4.865 nM 1.368 nM 2.395 nM 
Time to -5 mins 
inhibition 
(10 nM) 
LI. Tm (NADH) 19° C. 5° C. 13° C. 16.5° C. 16.5° C. 
Concentration -100 nM -600 nM -100 nM -100 nM -500 nM 
for Full Cell 
Line Reporter 
Induction 
Hepatocyte 
stability 
Toxicity 
temperature to 59 degrees. Thus all three compounds 
directly bind to 15-PGDH and markedly increase the melt-
65 
Stable> 
couple hrs 
>10 µM 
Time to inhibition refers to the time needed to inhibit the 
generation of NADH by 15-PGDH from the moment with 
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drug is added into the reaction mix. Delta Tm refers to the 
shift in melting temperature ofrecombinant 15-PGDH in the 
presence of drug (with cofactor NADH also present). Con­
centration of Full Cell Line Reporter Induction refers to the 
concentration of drug that needs to be added to reporter cell 5 
line to achieve maximal induction of the 15-PGDH-lu­
ciferase gene fusion reporter cassette, as measured by 
luciferase assays. Hepatocyte stability refers to the half-life 
of compound in the presence of hepatocytes in culture. 
Toxicity refers to the concentration of compound needed to 10 
decrease cell numbers in a cell culture assay. 
FIG. 40 provides graphical summary showing the activity 
of each of the compounds in inducing a 15-PGDH-luciferase 
fusion gene reporter introduced into three different colon 
15 
cancer cell lines, V9m, LSI 74T, and V503. Results are 
measured by assay of luciferase activity after exposure of 
cells to compound at either 2.5 uM or 7.5 uM compounds 
concentration. 
FIG. 41 provides graphical summary showing the activity 
20 
of each of the compounds in inhibiting the enzymatic 
activity ofrecombinant 15-PGDH enzyme when compound 
is added at 2.5 uM and at 7.5 uM. 100% inhibition corre­
sponds to complete inhibition of the enzyme. 
106 
D5W at a concentration of 125 ug/200 ul. As shown, both 
vehicle and drug treated mice show equal weight gain during 
the 21 day period, with no evidence for SW033291 reducing 
mouse weight. N=6 mice in both the SW033291 treated and 
the vehicle treated arms. 
EXAMPLE 6 
Analysis of Effect ofSW033291 on Bone Marrow Function 
This Example shows effects of SW033291 on bone mar­
row function. 
FIGS. 46(A-C) show analysis of bone marrow of wild­
type mice versus mice that are homozygous genetic knock­
outs for 15-PGDH (PGDH -/- mice). Total bone marrow 
cellularity and percent of Scal+/c-Kit+ cells in lineage 
negative (SKL) cells are the same in both sets of mice. 
However, bone marrow from 15-PGDH -/- mice shows an 
approximately 50% increase in numbers of hematopoietic 
colonies generated when marrow is plated into methylcel­
luose. Experimental conditions are noted on the figure. 
15-PGDH knockout mice are denoted by label PGDH -/­
and by label 15-PGDH.
FIG. 47 shows assay in which bone marrow is harvested 
FIG. 42 shows measurement of IC for inhibiting 2.5 nM 
ofrecombinant 15-PGDH when incubated across a range of 
concentrations of SW208064, SW208065, SW208066, and 
SW208067. Y-axis of each graph records percent inhibition 
of the 15-PGDH enzymatic activity. 100% Inhibition corre­
sponds to complete inhibition of the enzyme. X-axis of each 
graph records the log of the inhibitor concentration 
expressed in nM. 
25 from a wild-type mouse, and incubated ex vivo on ice for 2 
hours with either SW033291 (0.5 uM), or 1 uM PGE2 or 1 
uM 16,16-dimethyl PGE2 (dmPGE2). Treated marrow is 
again then plated into methylcellulose for counting of 
hematopoietic colonies. SW033291 treated marrow again 
EXAMPLE 5 
30 shows an approximately 50% increase in the number of bone 
marrow derived colonies generated. Under these conditions, 
a lesser increase is seen in marrow treated with PGE2, and 
a slightly greater increase is seen in marrow treated with 
dmPGE2. 
Analysis of Toxicity of SW033291 35 FIGS. 48(A-C) show a study of C57BL/6J mice treated 
with IP SW033291 administered in a vehicle of 10% Etha­
nol, 5% Cremophor EL, 85% D5W at a dose of 5 mg/kg or 
20 mg/kg. Panel A shows mouse bone marrow cellularity, 
white blood count (wbc ), red blood count (rbc) and platelets 
Table 5 shows a summary of a group of 8-12 week old 
male FVB mice in control or SW033291 treatment arms 
assessed for toxicity ofSW033291, with 6 mice in each arm 
of the study. 
TABLE 5 
Baseline Characteristics FVB male mice-8-12 weeks old 
40 counts. Panel B shows percent of Scal+/c-Kit+ cells in 
lineage negative (SKL) cells are unchanged in SW033291 
treated mice. Panel C shows that marrow from SW033291 
treated mice gives rise to approximately 30% increase in 
Toxicity Study WT-Control W T -Treatment p-value 
Number 
Sex M M 
Age (Days) 73.7.1 ± 4.7 73.2 ± 5.0 0.465 
Weight (gm) 27.5 ± 2.4 26.8 ± 3.1 0.412 
FIG. 43 shows the dose response curve for induction of a 
15-PGDH-luciferase fusion gene reporter in the V9m cell
line background of SW033291, SW208064, SW208065,
SW208066, and SW208067.
45 
50 
FIG. 44 Shows titration curves of 15-PGDH inhibitor 55 
compounds in an assay measuring effects on PGE2 levels in 
the medium of A549 cells that have been stimulated with 
ILi-beta in the same experimental design described for FIG. 
37. At 100 nM concentration of drug, the highest levels of
PGE2 in the medium are achieved by treating cells with 60 
SW208066 or with SW208067, after which the next highest
level of PGE2 in the medium is achieved by treating cells
with SW033291.
FIG. 45 shows the daily weights of a group of 8-12 week 
old FVB mice treated with vehicle or with SW033291 IP at 65 
5 mg/kg twice daily for 21 days. SW033291 was adminis­
tered in a vehicle of 10% Ethanol, 5% Cremophor EL, 85% 
numbers of hematopoietic colonies generated when marrow 
is plated into methylcelluose. Experimental conditions are 
noted on the figure. 
FIGS. 49(A-B) show analysis of marrow from CD45.2 
antigen marked C57BL/6J mice that were treated with 
SW033291 5 mg/kg IP daily for 3 doses in a vehicle of 10% 
Ethanol, 5% Cremophor EL, 85% D5W or that were treated 
with vehicle alone. On day 3 mice were sacrificed, marrow 
flushed and mixed at a 1: 1 ratio with vehicle treated CD45 .1 
marrow. 2 million whole BM cells were injected into the tail 
vein of lethally irradiated CD45.1 mice and percent chime­
rism measured via flow cytometry at weeks 8, 12, 16. As 
shown, at weeks 12 and 16 the percent blood chimerism of 
CD45.2 marked cells was significantly increased in recipient 
mice whose CD45.2 marked marrow was harvested from 
SW033291 treated donor mice, as opposed to vehicle con­
trol treated donor mice. In other words, marrow from 
SW033291 treated mice demonstrated long term increased 
fitness in competition with control marrow. In particular, at 
week 16 CD45.2 harvested from SW033291 treated mice 
show a significant increase in contribution to B and T cell 
populations, suggesting marrow from SW033291 treated 
mice promotes earlier reconstitution of lymphoid popula-
tions and earlier return to immune competence. 
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In an additional study, C57BL/6J mice are irradiated with 
11 Gy on day 0, followed by treatment with SW033291 5 
mg/kg IP twice daily (bid) in a vehicle of 10% Ethanol, 5% 
Cremophor EL, 85% D5W, or with vehicle only for 21 days. 
Mice treated with vehicle or with SW033291 all receive an 
allograft of marrow from a donor C57BL/6J mouse at a dose 
of either 100,000 cells, 200,000 cells, 500,000 cells. 3 
13- 14- 15- 16- 17-
Mar Mar Mar Mar Mar 
Cell Day Day Day Day Day 
Treatment number 0 1 2 3 4 
Control 1 x 10-5 2 0 
Control 2 x 10-5 
Control 5 x 10-5 
SW033291 1 x 10-5 2 
SW033291 2 x 10-5 
SW033291 5 x 10-5 
control and 3 SW033291 mice are assessed under each 
condition. The experimental design is depicted in FIG. 50. 
Table 6 shows the number of surviving mice in each 25
cohort over the first 19 days of study. Under the conditions 
of the mouse colony during this study, control mice receiv­
ing 100,000-500,000 cells are all dead between days 4-13 of 
study. In contrast, two SW033291 treated mice receiving 
500,000 cells remain alive on day 19 of the study and are 30
presumed to have full hematopoietic reconstitution. Thus 
treatment with the 15-PGDH inhibitor SW033291 promoted 
survival of mice receiving a bone marrow transplant, an 
observation consistent with SW033291 enabling more rapid 
and complete hematopoietic reconstitution in the trans- 35 
planted mice. Other 15-PGDH inhibitors with activity simi-
lar to SW033291 would be predicted to have similar activity 
in supporting hematopoietic reconstitution. Treatment with 
10/2 10/3 10/4 10/5 
Radiation Treatment Day Day Day Day 
Dose Arm 0 5 6 7 
7 Gy Saline 
SW033291 
9 Gy Saline 
SW033291 
11 Gy Saline 2 
SW033291 
108 
blood stem cell transplants. Improved survival of trans­
planted mice treated with SW033291 is consistent with 
SW033291, and by extension other similar 15-PGDH inhibi­
tors, having activity in reducing infections in the trans­
planted mice, and/or in promoting recovery of mice intes­
tines from damage by radiation, and/or in reducing 
pulmonary toxicity from radiation. 
TABLE 6 
Mouse survival 
18- 19- 20- 21-
Mar Mar Mar Mar
Day Day Day Day 
5 6 7 8 
2 0 
2 
0 
2 2 2 
2 
22- 23- 24-
Mar Mar Mar 
Day Day Day 
9 10 11 
2 2 2 
2 2 2 
EXAMPLE 7 
25-
Mar 
Day 
12 
2 
26-
Mar 
Day 
13 
0 
0 
2 
1-
Apr 
Day 
19 
2 
Analysis of Effect of SW033291 on Radiation Survival 
This Example shows studies of the effect ofSW033291 in 
mice receiving whole body irradiation. 
Table 7 shows the results of a study of 15 week old 
C57BL/6J female mice irradiated with 7 Gy, 9 Gy, or 11 Gy, 
and receiving daily SW033291 5 mg/kg IP in a vehicle of 
10% Ethanol, 5% Cremophor EL, 85% D5W for 7 doses, or 
receiving vehicle alone. The table shows the number of mice 
surviving on sequential days of the study. Under the condi­
tions of the mouse colony during this experiment, mice 
receiving a lethal dose of 11 Gy lived 48 hours longer if 
treated with SW033291 than if receiving vehicle control, 
with control mice all dead on day 8; whereas SW033219 
treated mice were all dead on day 10. 
TABLE 7 
10/6 10/7 10/8 10/9 10/10 10/11 10/12 10/13 10/23 
Day Day Day Day Day Day Day Day Day Day 
8 9 10 11 12 13 14 15 16 25 
Looks 
Healthy 
Looks 
Healthy 
2 0 
2 2 0 
0 
2 0 
Table 8 shows the number of mice surviving on sequential 
55 days of a study of mice treated at 11 Gy treated with either
vehicle control or with SW033291 IP, in a vehicle of 10% 
Ethanol, 5% Cremophor EL, 85% D5W, with SW033291 
administered either at 5 mg/kg daily for 7 days, 5 mg/kg 
daily throughout the study, or at 5 mg/kg twice daily for 7 
SW033291 also enabled mice to be successfully trans­
planted with a smaller inoculum of donor bone marrow than 
the 1,000,000 cells that are standardly needed. These obser­
vations suggest SW033291, as well as other similar 
15-PGDH inhibitors, is able to support successful transplan­
tation with smaller numbers of donor stem cells. Such 
activity would be of particular utility in settings, such as 
transplantation with umbilical cord stem cells, in which 
donor cell numbers are limited. Improved survival of trans­
planted mice treated with SW033291 suggests efficacy of 
SW033291, and of similar 15-PGDH inhibitors, as replace­
ments for, or in enabling decreased use of, other treatments 65 
or growth factors commonly employed in support of patients 
receiving bone marrow, hematopoietic stem cell, and cord 
60 days. Again mice treated with SW033291 on any of these 
dosing schedules live on average 1-2 days longer than mice 
receiving vehicle control. The activity of SW033291 in 
promoting resistance to toxic effects of radiation may extend 
to SW033291 and other similar 15-PGDH inhibitors in 
promoting resistance to other similar toxic insults including 
but not limited to Cytoxan, fludarabine, chemotherapy and 
immunosuppressive therapy. 
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TABLE 8 
Friday Wed. Thurs. Friday Saturday Sunday Monday 
Treatment 
Cond itions 
11 Saline (7 
Gy days, 1 does 
daily) 
11 SW033291 
Gy (1 does/daily) 
for 7 days 
11 SW033291 
Gy (1 does/daily, 
continuous 
every day) 
11 Saline (7 
Gy days, 
2 does/daily 
11 SW033291 
Gy (7 days, 2 
dos e daily) 
12-0ct 17-0ct 18-0ct 
Day O Day 5 Day 6 
2 2 2 
EXAMPLE 8 
19-0ct 20-0ct 21-0ct 
Day 7 Day 8 Day 9 
2 0 
2 
2 
2 0 
2 
20 
Analysis of Effect ofSW033291 on Liver Regeneration Post 
Partial Hepatectomy 
This Example shows studies assessing the effect of 25 
SW033291 on liver regeneration in mice following partial 
hepatectomy. 
22-0ct 
Day 10
0 
0 
0 
0 
SW033291 treated mouse versus the control mouse, with 
mitotic figures marked by yellow arrows in the SW033291 
treated mouse liver at left and by green arrows in the control 
mouse liver at right. 
FIG. 55 shows a graph of the number of mitosis per high 
powered field in livers of SW033291 treated versus control 
mice on post-operative days two through five (2D-5D). 
Mitotic figures were counted in 10 high powered fields ( 40x) FIG. 51 shows a drawing of the anatomy of the mouse 
liver and of the partial hepatectomy procedure described in 
Mitchell et al., Nature Protocols, 3, 1167-1170 (2008), in 
which the median and left lateral lobes are resected, and then 
liver regeneration is observed via hypertrophy of the remain­
ing right and caudate lobes. The total resection is of approxi­
mately 70% of the mouse liver mass. In these studies mice 
were euthanized using carbon dioxide inhalation. The mouse 
body was weighed in its entirety. The liver was removed 
from the mouse; the necrotic renmant from the surgical 
resection was trimmed; and the regenerated liver was 
weighed. 
30 from each of 5 livers per SW033291 or control mice per day. 
SW033291 treated mice demonstrated significantly 
increased hepatic mitosis versus controls on days 3 and 4. 
Table 9 shows the numbers of mitosis per random high 
powered field counted in livers of control versus SW033291 
35 
treated mice on post operative days 2 through 5 (2D-5D). 
FIG. 52(A-D) show an anatomical view of the mouse 
liver. Pictures at left are pre-operative views, and those at 
right are post-resection views. The upper two pictures show 
anterior view of liver and at left display the median lobe and 
40 
a part of the Lateral lobe. The lower two pictures show 45 
Inferior view of liver and at left display the Lateral lobe. In 
the partial hepatectomy procedure, the median and lateral 
lobes are resected as shown at right. 
SW033291 treated mice show significantly increased num­
bers of mitotic liver cells on post-operative days 3 and 4. 
TABLE 9 
M itotic index 
(40x) mean+ SD Control SW033291 p-value 
2D 0.7000 ± 0.1933 1.240 ± 0.2330 0.0915 
3D 2.000 ± 0.4364 6.160 ± 0.3250 <0.0001 
4D 2.560 ± 0.2242 4.560 ± 0.7190 0.0107 
SD 0.2000 ± 0.1069 0.2400 ± 0.08718 ns 
FIG. 56 shows the liver to body weight ratios attained 
following partial hepatectomy in control versus SW033291 
treated C57Bl/6j mice injected at 5 mg/kg SW033291 IP 
daily ( qd) starting on post operative day O and continuing 
FIG. 53(A-D) at left reiterates photographs of the imme­
diate post-hepatectomy views of the mouse liver, with so 
anterior view at top and inferior view at bottom. Figure at 
top right shows the in situ view of the regenerated liver on 
post operative day (POD) 10, showing hypertrophy of the 
renmant right and caudate lobes. Photograph at lower right 
shows the anterior view of the regenerated liver after 
removal from the mouse body. Whitish region at the upper 
right liver edge is the necrotic stump from the resection, and 
throughout. Graph displays values from post-operative days 
55 2-7 (POD 2-7). The SW033291 qd injection group of mice 
is trimmed prior to weighing. 
attain a higher liver to body weight ratio from post-operative 
days 4-7, with the increase being statistically significant on 
postoperative day 4 and day 7. 
An additional group of mice received SW033291 5 mg/kg 
twice daily (bid) and were analyzed on post-operative day 3, 
with the data graphed as POD3b. This group of mice also 
showed a statistically significant increase in liver to body 
The first study was performed in 10 week old male 
C57BL/6J mice, receiving daily SW033291 5 mg/kg IP in a 60
vehicle of 10% Ethanol, 5% Cremophor EL, 85% D5W, 
versus vehicle alone, and assessed daily for liver regenera­
tion with 5 control and 5 SW033291 recipient mice sacri­
ficed on each time point. In this study, ketamine anesthesia 
was employed. 65 weight ratio compared to control mice. 
FIG. 54(A-B) show micrograph of the hematoxylin and 
eosin stained liver on post-operative day 3 (POD 3) in the 
Another study was performed testing the effects of 
SW033291 given 5 mg/kg IP twice daily (bid) on liver 
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regeneration in C57BL/6J mice. 10 mice were used in the 
control and 10 mice in the drug treated arm for analysis of 
each time point of the study. The study again employed 10 
week old male mice receiving daily SW033291 5 mg/kg IP 
5 
in a vehicle of 10% Ethanol, 5% Cremophor EL, 85% D5W, 
versus vehicle alone, with 10 drug treated and 10 control 
with 10 treated mice and 10 control mice used for analysis 
at each time point from post operative day (POD) 1-7. In this 
study isoflurane anesthesia was employed. Vehicle treated 
15-PGDH knockout (KO) mice were also used as an addi­
tional comparator. 
FIG. 62 shows a graph depicting the pre-operative body 
mice sacrificed daily for comparison. In this study ketamine weights of the FVB mice used for analysis of liver regen-
anesthesia was employed. eration on post-operative days 2, 3, 4 and 7. SW033291 and 
10 
FIG. 57 shows graph of the liver to body weight ratio 
attained following partial hepatectomy in control versus 
SW033291 treated C57BL/6J mice injected at 5 mg/kg 
SW033291 IP twice daily (bid) starting at 1 hour post-
control treated mice used on each day are well matched. 
FIG. 63 shows a graph depicting the weight of the 
resected liver segment (resected LWt) from mice treated 
with either SW033291 or vehicle control and assayed for 
surgery and continued throughout. Graph displays values 15 liver regeneration on post-operative days (POD) 2, 3, 4, and 
from post-operative days 2-7 (POD 2-7). The SW033291 bid 7. Weight of the resected livers is well matched between
injected group of mice show a statistically significant higher control and drug treated mice on each day, except on day 7, 
liver to body weight ratio versus control mice on post- when the weight of the resected liver was greater in the 
operative days 3, 4, and 7. 20 SW033291 treated than in the control mice. 
FIG. 58 reprises the graph of the liver to body weight ratio FIG. 64 shows a graph depicting the liver weights attained 
attained following partial hepatectomy in control mice ver- (Regenerated_LWt) post partial hepatectomy in SW033291 
sus in mice treated with sw033291 5 mg/kg IP twice daily. and control mice on post-operative days 2, 3, 4 and 7 (POD 
In data enclosed within the blue box, drug was started 1 hour 25 2, 3, 4, 7). SW033291 treated mice show significantly 
following surgery, and significant increases in liver to body 
weight ratio are seen in drug treated mice from post­
operative day (POD) 3 onward. In data enclosed within the 
greater liver weights versus control mice at all time points, 
with SW033291 treated mice having approximately 25% 
greater liver weight on post-operative day 7 than control 
red box, the first dose of sw033291 is delivered commencing 30 mice. 
1 hour before surgery, and significant increase in liver to 
body weight ratio is seen as early as post-operative day 1, the 
day following the surgery. 
FIGS. 59(A-B) show graphs of the serum ALT levels 
following partial hepatectomy in one control mouse versus 
one mouse treated with sw033291 at 5 mg/kg IP twice daily 
(bid). Post-operative day 1 values are compared at left, and 
FIG. 65 shows a graph depicting the liver to body weight 
ratios attained (LBWR) post partial hepatectomy in 
SW033291 and control mice on post-operative days 2, 3, 4 
35 and 7 (POD 2, 3, 4, 7). SW033291 treated mice show 
significantly greater liver to body weight ratios versus 
control mice at all time points, with SW033291 treated mice 
having approximately 20% greater liver to body weight ratio 
post-operative day 2-7 values are compared at right. ALT on post-operative day 7 than control mice. 
40 
values are lower in the drug treated mouse. 
FIG. 60 shows graph of serum bilirubin levels following 
partial hepatectomy in one control mouse versus one mouse 
treated with SW033291 at 5 mg/kg IP twice daily (bid) from 
post-operative days (POD) 1-7. 
In another study, SW033291 was tested in the partial 
hepatectomy model using the FVB strain of mice adminis­
tered SW033291 5 mg/kg IP twice daily (bid), administered 
FIG. 66 shows "box and whisker" plot comparing liver to 
body weight ratio's on post-operative day 4 following partial 
hepatectomy of FVB mice treated twice daily with 
SW033291 5 mg/kg or with vehicle control, with 10 mice in 
45 each arm. Thick bars denote population median. Upper box 
margin denotes lower boundary of the highest quartile. 
Lower box margin denotes upper boundary of the lowest 
quartile. SW033291 treated mice show a significantly 
in a vehicle of 10% Ethanol, 5% Cremophor EL, 85% D5W, 50 increased liver to body weight ratio at P=0.004. 
using 5 treated mice versus 5 control mice treated with FIG. 67 shows "box and whisker" plot comparing liver to 
vehicle alone for analysis at each time point from post body weight ratio's on post-operative day 7 following partial 
operative day (POD) 1-7. In this study ketamine anesthesia hepatectomy of FVB mice treated twice daily with 
was employed. 55 SW033291 5 mg/kg or with vehicle control, with 10 mice in 
FIG. 61 shows a graph of the liver to body weight ratio of each arm. Thick bars denote population median. Upper box 
attained following partial hepatectomy in FVB mice treated margin denotes lower boundary of the highest quartile. 
with 5 mg/kg IP SW033291 versus control mice treated with Lower box margin denotes upper boundary of the lowest 
vehicle alone. SW033291 treated mice show increased liver 60 quartile. SW033291 treated mice show a significantly 
to body weight ratio from post-operative days 2-7, with the increased liver to body weight ratio at P=0.001. 
increase being statistically significant on POD, 2, 3, 4 and 7. 
In another study, SW033291 was tested in a partial 
FIG. 68 shows "box and whisker" plot comparing liver to 
body weight ratio's on post-operative day 4 following partial 
hepatectomy model using the FVB strain of mice adminis-
65 
hepatectomy of FVB mice treated twice daily with 
tered SW033291 5 mg/kg IP twice daily (bid), starting 1 SW033291 5 mg/kg or with vehicle control, with 10 mice in 
hour before surgery. 10 week old male mice were employed, each arm. Also shown is the liver to body weight ratio on 
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EXAMPLE 9 
Analysis of Effect of SW033291 on Survival Following 
post-operative day 4 of 15-PGDH knockout mice (PGDH­
KO) treated with vehicle only. Thick bars denote population 
median. Upper box margin denotes lower boundary of the 
highest quartile. Lower box margin denotes upper boundary 
5 Acetaminophen (Tylenol) Overdose 
of the lowest quartile. SW033291 treated mice show a 
significantly increased liver to body weight ratio at P=0.001. 
15-PGDH knockout mice also show greater a greater liver to
body weight ratio than do vehicle treated 15-PGDH wild­
type mice, supporting that the liver regeneration activity of 10
SW033291 is mediated through inhibition of 15-PGDH. The
larger effect of 15-PGDH gene knockout suggests further
increase in effect of SW033291 may be attainable with
additional modification of dosing schedule and delivery. 
This Example provides data showing effects of 
SW033291 in mediating resistance to lethal doses of the 
liver toxin acetaminophen (Tylenol). 
In the study, 11 week old female C57BL/6J mice are 
injected IP with a suspension of acetaminophen in phosphate 
buffered saline administered at the LD50 dose of 600 mg/kg. 
FIG. 69 shows visualization of S-phase cells following 
partial hepatectomy on post-operative day 2 in livers of 
Table 10 provides a tabular summary of the number of 
15 mice surviving out of an initial cohort of 6 mice that are all 
treated with acetaminophen (Tylenol) in phosphate buffered 
saline administered IP at the LD50 dose of 600 mg/kg. 
TABLE 10 
Treatment O hrs 16 hr 24 hrs 40 hrs 48 hrs 64 hrs 72 hrs 88 hr 96 hr 112 hr 120 hr 
1 does/daily, First dose immediately after Tylenol injection 
Saline 
5 mg/kg 
SW033291 
4 
4 4 4 4 4 4 4 4 
2 dose/daily, First dose immediately after Tylenol injection 
Saline 
5 mg/kg 
SW033291 
SW033291 treated and vehicle treated control mice. Mice 
were injected with BrdU at 50 mg/kg IP 2 hours before 
sacrifice, and then S-phase cells were visualized by staining 35 
the livers with an antibody that detects BrdU that has been 
4 
4 
Test mice are additionally treated with SW033291 5 
mg/kg IP in a vehicle of 10% Ethanol, 5% Cremophor EL, 
85% D5W beginning immediately following acetaminophen 
and continued once daily, or twice daily. Control mice are 
additionally treated with vehicle alone once daily or twice 
daily. Survival is recorded from the O time point of admin­
istration of acetaminophen through 120 hours following. No 
incorporated into DNA. Representative fields at lOx mag­
nification show the clear increase in numbers of BrdU 
positive cells in the SW033291 treated liver. 40 difference is noted between survival of SW033291 treated 
and control mice. 
FIG. 70 shows high powered ( 40x) views of representa­
tive fields from the study of FIG. 69. 
FIG. 71 shows "box and whiskers" plot comparing per­
cent of BrdU positive cells in livers of SW033291 treated 45 
versus vehicle control treated mice on post-operative day 2 
Table 11 shows a summary of the number of mice 
surviving out of an initial cohort of 12 eleven week old 
C57BL/6J female mice that are all treated with acetamino­
phen (Tylenol) in phosphate buffered saline administered IP 
at the LD50 dose of 600 mg/kg, Mice are additionally 
treated with either SW033291 or vehicle control. 
TABLE 11 
Survival O hrs 16 hr 24 hrs 40 hrs 48 hrs 64 hrs 72 hrs 88 hr 96 hr 112 hr 120 hr 
5 mg/kg 
SW033291 
Saline 
12 
12 
12 
12 
following partial hepatectomy. Plotted in each group are the 
percent BrdU positive cells from 100 random high powered 
fields (40x magnification) counted as 10 fields from each of 
12 
12 
55 
10 drug treated and each of 10 control vehicle treated mice. 60
Heavy black bars show median values of each distribution. 
Upper box margin denotes lower boundary of the highest 
quartile. Lower box margin denotes upper boundary of the 
lowest quartile. SW033291 show a greater than 2-fold 
65 
increase in median S-phase cells on post-operative day 2 
(P<0.05). 
11 10 10 10 10 10 10 10 
SW033291 5 mg/kg was administered IP in a vehicle of 
10% Ethanol, 5% Cremophor EL, 85% D5W twice daily 
(bid) beginning 48 hours prior to acetaminophen injection 
and continuing for 48 hours following acetaminophen injec­
tion for 9 doses total. At 120 hours post acetaminophen 
injection, 10 of 12 mice have survived in the SW033291 
treated cohort versus 5 of 12 mice in the vehicle control 
treated cohort, P=0.045 in a one-tailed Fisher's exact test. 
Thus pre-administration of SW033291 protects from the 
lethal hepatotoxicity of acetaminophen. 
Table 12 shows a summary of the number of mice 
surviving out of an initial cohort of 6 eleven week old 
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C57BL/6J female mice that are treated with acetaminophen 
(Tylenol) in phosphate buffered saline administered IP at the 
LD50 dose of 600 mg/kg. 
TABLE 12 
116 
control group mice used in the study. Also provided is 
baseline characteristics of 4 FVB male 15-PGDH knockout 
(KO) mice that are used as a comparator group. 
Survival O hrs 16 hr 24 hrs 40 hrs 48 hrs 64 hrs 72 hrs 88 hr 96 hr 112 hr 120 hr 
5 mg/kg 
SW033291 
Saline 
4 
2 2 2 
Mice are additionally treated with either SW033291 or 
vehicle control. SW033291 5 mg/kg was administered IP in 
a vehicle of 10% Ethanol, 5% Cremophor EL, 85% D5W 
twice daily (bid) beginning 3 hours prior to acetaminophen 
injection and continuing at time O through 48 hours follow­
ing acetaminophen injection for 6 total doses. At 120 hours 
post acetaminophen injection 3 of 6 mice have survived in 
the SW033291 treated cohort versus 2 of 6 mice in the 
vehicle control treated cohort. 
15 
20 
Table 13 shows a summary of the number of mice 
surviving out of an initial cohort of 7 C57BL/6J 25 week old 
female 15-PGDH wild-type (WT) or 7 C57BL/6J 25 week 
old female 15-PGDH knockout (KO) mice treated with 25
acetaminophen (Tylenol) in phosphate buffered saline 
administered IP at the LD50 dose of 600 mg/kg. 
TABLE 13 
2 2 2 2 
TABLE 14 
FVB PGDH WT/KO male mice 
8-12 weeks old 
DSS Study WT -Control WT -Treatment KO p-value 
Number 24 24 4 
Sex M M M 
Age (Days) 74.1 ± 3.7 74.2 ± 4.0 73.9 ± 3.4 0.655 
Weight (gm) 26.3 ± 1.19 26.8 ± 1.78 27.4 ± 1.4 0.391 
FIG. 72 shows a graph of the average changes from 
baseline weight of the cohort of control versus SW033291 
treated mice across the 22 days of the study. SW033291 
treated mice show greater weight at all time points, and in 
Survival O hrs 16 hr 24 hrs 40 hrs 48 hrs 64 hrs 72 hrs 88 hr 96 hr 112 hr 120 hr 
WT 
KO 
7 
7 
7 
7 
7 
7 
4 
At 120 hours post acetaminophen injection, 6 of 7 knock-
out mice survive versus 3 of 7 wild-type mice. Increased 
survival of 15-PGDH knockout mice is consistent with the 
survival benefit of SW033291 being mediated through inhi­
bition of 15-PGDH. 
EXAMPLE 10 
35 
particular, show faster weight gain after washout of DSS 
then do the control mice, P=0.001. 
FIG. 73 shows a graph of the daily Disease Activity Index 
(DAI) of the cohort of control versus SW033291 treated 
40 mice across the 22 days of the study. The Disease Activity 
Index is calculated as an equally weighted average of the 
change from baseline weight, the consistency of stool, and 
the presence of rectal bleeding, with each component nor-
Analysis of Effect of SW033291 on Dextan Sodium Sulfate 45 
(DSS) Induced Colitis 
malized to span an identical numerical range. SW033291 
treated mice show a lower Disease Activity Index than do 
control on each day of the study, P<0.001. 
This Example provides data from studies of the effect of 
SW033291 on prevention of induction of colitis in the 
dextran sodium sulfate (DSS) treated mouse. In the study, 50 
8-12 week old FVB male mice are fed with 2% DSS in
drinking water for days 1-7, and then switched to normal 
drinking water beginning on day 8, and continued through 
day 22. Mice are treated with twice daily SW033291 5 55 
mg/kg IP in a vehicle of 10% Ethanol, 5% Cremophor EL, 
85% D5W, at 125 ug/200 ul, versus with vehicle alone. 
Clinical scoring (body weight, rectal bleeding, stool consis-
tency) is recorded daily, endoscopic scoring (ulcer number, 60 
FIG. 74 shows the design of the study in which colono-
scopic examination of the left colon, up to the splenic 
flexure, was performed on live mice on days 8, 11 and 15, 
under isoflurane anesthesia. In addition, post-mortem 
colonoscopy of the full colon was performed on two 
SW033291 treated and two control treated mice on day 15, 
with findings confirming that DSS induced ulcerations are 
largely confined to the descending colon distal to the splenic 
flexure. 
FIGS. 75(A-B) show at bottom left the colon as visualized 
during colonoscopy of a DSS treated control mouse that 
shows loss of the mucosa! vascular pattern and a gross 
ulceration. At bottom right is shown the colonoscopic find­
ings of a DSS treated mouse receiving SW033291, with only 
a small ulcer and with maintenance of the normal mucosa! 
vascular pattern otherwise. Graph at top shows numbers of 
ulcers present on days 8, 11, and 15 in the control versus 
SW033291 treated mice. SW033291 treatment prevents 
mucosa! thickening, and vascular pattern) is assessed on 
days 8, 11, 15. Mice are sacrificed on days 1, 8, 15 and 22 
for assessment of colon length, colon weight, ulcer number, 
ulcer area, and crypt damage. 
Table 14 shows summary of the baseline properties of age 
and weight of the 24 SW033291 treated mice and the 24 
65 two-thirds of ulcer formation. Additional studies of 
15-PGDH knockout mice show that 15-PGDH gene knock­
out prevents 95% of colon ulcer formation. These findings
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support that the colitis prevention activity of SW033291 is 
mediated through its activity as a 15-PGDH inhibitor, and 
suggest further modifications of drug dosing and delivery 
may provide added colitis prevention. 
FIG. 76 shows quantitation of ulcer burden on day 15 of 5 
DSS treated mice as determined by embedding the full 
length of the formalin fixed colons of mice in paraffin 
blocks, and then microscopic inspection of a random 5 µm 
section along the full colon length for visualization and 
measurement of ulcerated mucosa. The graph shows that the 10 
average length of ulcerated mucosa is 4.48 mm per colon 
section in control mice (N=9 mice) and is reduced by 61 % 
to a length of 1.74 mm per colon section in SW033291 
(drug) treated mice (N=6 mice), P=0.045. Again, 15-PGDH 
gene knockout (KO) is highly effective in preventing colon 
1 
15 
u ceration, supporting that the therapeutic effect of 
SW033291 is mediated through inhibition of 15-PGDH. 
FIGS. 77(A-B) shows examples of scoring murine 
colonic mucosa according to the Murine Endoscopic Index 
of Colitis Severity (MEICS) (Becker C. et al. Gut 2005; 54: 
950-954). At top (A) is shown the colonoscopic findings and 20
MEICS scoring for a DSS treated mouse receiving 
SW033291. At bottom (B) is shown the colonoscopic find­
ings and MEICS scoring of a DSS treated mouse receiving 
vehicle only. 
FIG. 78 shows graphs of the MEICS scores for DSS 25 
treated mice receiving SW033291 (treatment) versus vehicle 
( control). MEI CS scores show significantly less colitis activ-
ity in SW033291 treated mice on days 8, 11 and 15 of the 
study. 
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also not counted. On the photomicrograph shown crypts are 
displayed as vertically oriented in control and SW033291 
treated mice, and crypts are displayed as horizontally ori­
ented in the 15-PGDH knockout mice. In the photographs 
the numbers of S-phase cells are fewest in the control mice 
and are increased in the SW033291 treated mice, and 
increased further in the knockout mice. In the particular 
photographs shown, the crypts from control mice both lack 
S-phase cells and are also visually decreased in height;
whereas, crypt height is increased in the crypts shown from
SW033291 treated mice, and crypt heights is increased
further in the crypts shown from 15-PGDH knockout mice.
The graph depicts the sum of the average number of BrdU
positive cells per crypt in the distal colon plus the average
number of BrdU positive cells per crypt middle colons of
control (Cn), SW033219 treated (Tx), and 15-PGDH knock­
out mice (KO) on day 1, day 8, and day 15 of the DSS
treatment protocol. On day 8, SW033291 treated mice
demonstrate 5.7-fold greater numbers ofBrdU positive cells
than do control mice, which have lost 85% of the day 1 value
of BrdU positive cells per crypt. 15-PGDH knockout mice
show no loss of BrdU positive cells in the crypt on day 8,
consistent with the protective effect of SW033291 being
mediated by inhibition of 15-PGDH.
Table 15 shows a summary of colon length (in cm) in DSS 
treated mice sacrificed on days 8, 15 and 22, in SW033291 
treated mice, versus vehicle treated control mice, versus 
15-PGDH knockout (KO) mice, where shortening of the
colon is a measure of disease activity.
In addition to the gross visual inspection and scoring of TABLE 15 
colitis activity by the MEICS index, full length colons of 30 ---------------------­
mice were formalin fixed and paraffin embedded, and micro­
scopic scoring of crypt damage was performed using the 0-4 
severity scale of Cooper H S. Et al., Lab Invest. 1993; 
69:238-249. For this analysis, the colons were divided into 
3 segments of proximal, middle, and distal colon, each 35 
approximately 1.6 cm in length, with each segment was 
further subdivided into 4 sections each approximately 4 mm 
in length. For each section the crypt damage severity score 
was multiplied by the length in mm of the damaged area, 
creating a 0-16 cryptitis severity index. An average cryptitis 40 
se:'erity index was calculated for each segment (proximal,
middle, and distal colon), and the summed whole colon 
cryptitis severity index was determined on a scale of 0-48 for 
each mouse colon. In parallel with the visual MEICS score, 
the microscopic cryptitis severity index on day 8 of the DSS 
protocol was significantly greater in control mice (value of 45 
9.49) than in the SW033291 treated mice (value of 3.16), 
P<0.05 (data described but not shown in the figure). 
FIG. 79 shows assessment of the effect of SW033291 on 
maintaining DNA synthesis in the colonic mucosa of DSS 
treated mice. Mice were injected with BrdU at 100 mg/kg IP 50 
3 hours before sacrifice and then full length colons were 
formalin fixed and embedded in paraffin. S-phase cells, that 
have incorporated BrdU into DNA, were visualized by 
immuno-fluorescent staining of 5 um thick sections with an 
antibody that detects the BrdU. Colonic crypts were visu- 55 
alized by immuno-fluorescent staining with an antibody to 
the epithelial marker E-Cadherin. Photographic insets show 
photomicrographs of high powered fields taken from the 
mid-colon on day 8 of the DSS protocol from control mice, 
SW033291 treated mice (treatment) and 15-PGDH knock- 60 
out mice (KO). Red immune-fluorescence identifies BrdU 
positive nuclei, and green immune-fluorescence identifies 
E-Cadherin positive colonocytes. The number of BrdU
positive cell per crypt is determined by counting the number
of dual labeled red and green cells per average crypt. Green 65 
only cells that are not in S-phase are not counted, and red 
only cells, that are likely stromal cells outside of crypts, are 
Colon length shortening may be correlated to severity of the colon 
ulceration 
Time Point Control SW033291 KO P-value 
Baseline 8.3 + 0.2 8.4 + 0.2 0.71 
Day 8 6.6 + 0.4 6.6 + 0.1 1.0 
Day 15 7.1 + 0.1 7.5 + 0.1 8.5 + 0.1 0.001 
Day 22 7.4 + 0.2 8.6 + 0.3 0.012 
Vehicle treated control mice show significantly greater 
colon shortening at day 22 versus SW033291 treated mice, 
P=0.012. This comparison is also shown graphically in FIG. 
80. 
Table 16 shows a summary on day of sacrifice of mouse 
weights (gms) and colon lengths (cm) for DSS treated mice 
receiving SW033291 or vehicle control. 
TABLE 16 
Vehicle SW033291 KO 
Wt@ sacrifice-gm 
Time Point 
Baseline 26.3 + 0.7 25.9 + 0.7 
Day 8 25.4 + 0.7 26.4 + 0.5 
Day 15 24.4 + 0.5 25.2 + 0.9 29.2 + 1.3 
Day 22 * 26.3 + 0.7 28.2 + 0.5 
Colon length-cm 
Time Point 
Baseline 8.3 + 0.2 8.4 + 0.2 
Day 8 6.6 + 0.4 6.6 + 0.1 
Day 15 7.1 + 0.1 7.5 + 0.1 8.5 + 0.1 
Day 22 * 7.4 + 0.2 8.6 + 0.3 
On day 22 SW033291 treated mice show greater body 
weight and greater colon lengths, indicative of therapeutic 
effect of SW033291 in protecting against DSS induced 
colitis. 
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EXAMPLE 11 
Analysis of Analogues of Lead Compound SW054384, a 
15-PGDH Activator
This Example provides data on a group of structural 5
analogues of SW054384. Data on Table 17 characterize 
Structures 
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analogues obtained by Case Western Reserve University 
from a chemical library shared with the University of 
Cincinnati. Data on Table 18 are analogues ordered from 
commercial sources. Data on Table 19 are analogues held in 
chemical libraries or synthesized by members of the inven­
tors group at University of Texas Southwestern. 
TABLE 17 
V9M V9M LS174T 1S174T V503 V503 
reporter reporter reporter reporter reporter reporter 
activity activity activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 (2.5 (7.5 
Name 
µM) 
µM) µM) 
µM) 
µM) 
µM) 
292301 12.92 23.57 12.07 -3.67 -0.91 -3.60 
396087 -8.51 10.08 4.37 10.18 17.23 30.79 
407572 -8.45 -6.12 2.22 6.94 17.22 35.88 
121 
Structures 
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TABLE 17-continued 
V9M V9M LS! 74T lSl 74T V503 V503 
reporter reporter reporter reporter reporter reporter 
activity activity activity activity activity activity 
�5 D5 �5 D5 �5 D5 
Name µM) µM) µM) µM) µM) µM) 
408961 -12.39 0.56 2.46 -4.51 11.71 17.61 
414177 10.61 7.72 9.51 -0.62 -2.80 -5.73 
414183 -9.15 -3.89 5.35 -4.77 11.49 37.17 
414195 -13.95 -16.76 -1.15 2.34 13.14 19.47 
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TABLE 17-continued 
Structures 
0 ll�o H (Y s ' NIT N
'Q 6 o � I 
I 
F 
H � I 
on cr N�N � o 
o� �o os,,jD I 
I# 
Y' Q 0/ 
s " Nl g�o 
O NH 
Cl 
F 
V9M V9M 
reporter reporter 
activity activity 
(2.5 (7.5 
Name µM) µM) 
474738 -7.27 3.48 
474759 2.58 6.40 
0 
I 
503270 -4.47 24.06 
537833 -7.54 -7.44 
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LS174T 1S174T V503 V503 
reporter reporter reporter reporter 
activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 
µM) µM) µM) µM) 
-0.36 3.50 17.03 24.59 
5.54 -0.03 -5.04 -12.72 
12.29 32.82 29.88 42.14 
4.94 9.04 42.31 73.22 
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TABLE 17-continued 
V9M V9M LS174T 1S174T V503 V503 
reporter reporter reporter reporter reporter reporter 
activity activity activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 (2.5 (7.5 
Structures Name µM) 
µM) 
µM) 
µM) 
µM) µM) 
539430 21.27 21.35 5.62 10.45 38.75 103.04 
543512 36.82 79.64 18.05 8.33 -4.56 -4.26
543716 4.20 -0.14 3.26 -2.08 -8.04 -8.60 
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TABLE 17-continued 
V9M V9M LS174T 1S174T V503 V503 
reporter reporter reporter reporter reporter reporter 
activity activity activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 (2.5 (7.5 
Structures Name µM) 
µM) 
µM) 
µM) 
µM) µM) 
742790 13.79 23.09 12.77 17.32 5.94 34.38 
771064 43.32 -19.19 -2.11 -29.63 -13.75 -24.80 
771069 -22.56 -54.66 -29.88 -82.88 -62.71 -90.88 
771074 13.50 24.69 20.67 20.60 22.96 39.52 
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TABLE 17-continued 
Structures 
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Y' 0 °�, ,,CY �I N Nn Br H � I 
0 0 
I I 
V9M V9M 
reporter reporter 
activity activity 
(2.5 (7.5 
Name µM) µM) 
771081 -14.22 7.58 
771130 8.67 5.84 
771132 -2.26 12.24 
771138 -4.36 6.75 
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LS174T 1S174T V503 V503 
reporter reporter reporter reporter 
activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 
µM) µM) µM) µM) 
5.74 15.38 31.87 51.68 
8.66 -0.48 -10.19 -3.48 
13.98 13.54 24.75 40.76 
13.64 9.23 34.44 72.58 
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TABLE 17-continued 
Structures 
IonH I N�N � 0 
11 0�1 I o �s
' o�
'Q 
V9M V9M 
reporter reporter 
activity activity 
(2.5 (7.5 
Name µM) µM) 
771146 -38.07 -78.30 
771432 -7.11 -3.13 
785160 -15.99 21.00 
LS174T 
reporter 
activity 
(2.5 
µM) 
-31.58
3.86 
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1S174T V503 V503 
reporter reporter reporter 
activity activity activity 
(7.5 (2.5 (7.5 
µM) µM) µM) 
-68.78 -49.73 -86.60 
4.24 33. 72 42.82 
5.93 48.64 33.85 44.75 
785161 0.54 3.48 10.68 -41.92 56.72 -52.51 
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TABLE 17-continued 
V9M V9M LS174T 1S174T V503 V503 
reporter reporter reporter reporter reporter reporter 
activity activity activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 (2.5 (7.5 
Structures Name µM) µM) µM) µM) µM) µM) 
785254 -16.05 -8.48 2.93 4.29 16.14 28.28 
918280 -16.26 -77.26 -21.21 -72.09 -35.68 -74.96 
919570 87.71 127.26 78.80 102.68 80.94 104.40 
919576 49.89 63.03 17.49 30.74 49.20 73.74 
� N 
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TABLE 17-continued 
Structures 
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V9M V9M 
reporter reporter 
activity activity 
(2.5 (7.5 
Name µM) µM) 
920847 9.26 17.73 
924740 -0.54 6.33 
924787 -1.45 18.08 
928861 64.65 134.49 
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LS174T 1S174T V503 V503 
reporter reporter reporter reporter 
activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 
µM) µM) µM) µM) 
6.18 2.97 -4.47 -10.57 
7.69 16.73 20.16 52.17 
4.32 13.10 21.87 47.97 
74.89 124.37 73.17 138.59 
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TABLE 17-continued 
Structures 
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V9M V9M 
reporter reporter 
activity activity 
(2.5 (7.5 
Name µM) µM) 
939417 -11.15 -9.81 
967134 -10.12 -2.64 
1002065 7.38 18.64 
1002654 -2.58 -3.96 
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LS174T 1S174T V503 V503 
reporter reporter reporter reporter 
activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 
µM) µM) µM) µM) 
6.50 -1.64 12.58 16.25 
5.11 5.73 18.43 36.12 
9.90 15.22 38.12 52.53 
5.51 -1.24 0.78 19.23 
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TABLE 17-continued 
Structures 
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V9M V9M LS174T 1S174T V503 V503 
reporter reporter reporter reporter reporter reporter 
activity activity activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 (2.5 (7.5 Name µM) µM) µM) µM) µM) µM) 
1003012 -10.45 -0.90 5.54 19.77 34.43 58.54 
1003132 -5.60 -0.21 5.16 
1003378 -4.42 -3.27 7.30 
1.73 15.40 16.05 
1.27 7.23 16.73 
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-������������TTAABLEl? -continued-�-----� V9M V9M LS174T 1S174T V503 V503 
reporter reporter reporter reporter reporter reporter 
activity activity activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 (2.5 (7.5 
Structures Name µM) 
µM) 
µM) 
µM) 
µM) µM) 
1003429 12.60 4.17 8.82 -6.88 -7.46 -19.23 
1003669 6.30 7.58 5.98 -1.93 1.22 27.08 
1004292 0.88 -0.21 20.34 0.14 23.50 21.16 
1004571 -6.09 10.99 12.35 29.28 29.09 85.80 
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TABLE 1 7 -continued 
Structures Name 
1004631 
F 
Structure 
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OMe 
V9M V9M 
reporter reporter 
activity activity 
(2.5 (7.5 
µM) µM) 
-3.66 12.03 
CAS# 
333447-10-2 
332419-63-3 
311333-86-5 
428460-22-4 
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LS174T 1S174T V503 V503 
reporter reporter reporter reporter 
activity activity activity activity 
(2.5 (7.5 (2.5 (7.5 
µM) µM) µM) µM) 
4.51 45.32 52.12 87.08 
V9M-SC3 V9M-SC3 Ls174T-SCl 
Reporter Reporter reporter 
activity activity activity, 
(2.5 µM) % % 
(%) (7.5 µM) (2.5 µM) 
-0.5 10 7.54 
2.5 2 12.44 
53 117.25 29.97 
1.5 15.25 -7.63 
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339589-55-8 -7 -5.54 
339589-53-6 -1 4.25 51.18 
530107-57-4 59.5 116.5 5.45 
333449-58-4 6.5 71.25 -5.90 
333446-93-8 16.5 44 12.90 
333450-97-8 
311315-25-0 62.59 
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TABLE 18-continued 
0 701217-00-7 -2.05 79.49 -6.89 0- II 
O Ph-S=O 
N NH-LH,-L-cx) 
0 592469-85-7 -9.74 18.46 3.77 
II 
0-S-Ph 0 
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OMe 
0 526206-05-3 23.08 113.85 68.46 
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TABLE 18-continued 
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328012-52-8 
310875-38-8 
833428-03-8 
528580-69-0 
461439-84-9 
680599-58-0 
505072-23-1 
527699-66-7 
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-15.38 0.51 127.66 
-8.72 -16.41 27.66 
-4.10 17.44 25.08 
4.71 -0.5 11.49 
-30.29 -41.75 4.83 
-5.29 -22.5 11.489 
94.71 71.5 100.91 
-31.03 -37.25 7.31 
US 9,790,233 B2 
151 152 
������������- TABLE18 ------c�
o
;
n
�
t1
;
n
;
u
�
ed
;�-;;::------
Lsl74T-SCl 
reporter 
V503-3H9-7 V503-3H9-7
-;-------
­
Structure 
0 
II 
MeO 
O=S-Ph Uh- TI -v� OMe CH2-C-NH .,,::::;
OMe 
=�-Ph 
I 
o -::?"° 
¢=OMe 
O 
N-CH-
11 
_Q
2 C-NH � 
OMe 
,\c 
0 
II 
MeO
ti 
1-,>, O 
-
V
M, 
N-CH-
11 I 2 C-NH .,,::::; 
OMe 
0 
II 
MeO
tc 
;-
,S O 
C;C
-D N-CH
-11 I 2 C-NH .,,::::; 
OMe 
0 
II 
M�
tc
l-"' 
0 
-0" 
N-CH-
11 I 2 C-NH .,,::::; 
OMe 
0 
II 
MeO
'Cr:
O 
1
-Ph O 
-
V
Cl 
N-CH-
11 I 2 C-NH .,,::::; 
OMe 
activity, 
reporter 
% 
activity, 
(7.5 µM) 
% 
(2.5 µM) 
14.44 76.87 
9.81 1.65 
53.41 102.18 
-1.99 1.39 
22.07 64.02 
8.81 63.97 
89.74 199.56 
8.27 52.62 
reporter 
activity, 
% 
(7.5 µM) 
158.91 
46.28 
131.25 
47.04 
113.49 
52.49 
105.28 
84.39 
Enzyme 
inhibition 
% 
(2.5 µM) 
27.01 
36.59 
33.99 
15.05 
39.81 
19.14 
35.46 
21.74 
Enzyme 
inhibition 
% 
(7.5 µM) 
46.46 
47.22 
34.01 
19.30 
56.40 
21.99 
37.35 
9.25 
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TABLE 18-continued 
OMe O 
OMe 
o 11 
_II MeO-C 
� -S-Ph I LH,-rNH
-D 
0 
O=S-Ph O I � II c1
-D 
MeO I II u:N-CH,-C-NH ,# 
OMe 
0 0- II O Ph-S=O 
II I o N NH-C-CH,-N---CX) 
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II 0-S-Ph O 
0--t-CH2-M-NH-
o
�N 
MeO� 
,,,:::9 
OMe 
0 
II 0-S-Ph O 
Me
Ylr----
1 II -0 
�
m,
N-CH2-C-NH 
1 
:N 
OMe 
-3.99 
13.53 
75.79 
-0.54 
13.99 
145.94 
10.58 
50.08 
53.78 
20.078 
10.16 
110.21 
19.09 
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20.72 9.72 -3.12 
44.10 -5.31 5.85 
18.69 34.70 
33.42 10.07 13.12 
5.30 6.23 17.24 
197.50 41.97 70.19 
19.81 3.76 8.67 
US 9,790,233 B2 
155 
TABLE 18-continued 
0 
II 
O=S-Ph 0 
MeO 
,O-LH,-LNH-0 
0 
II 
O=S-Ph 0 
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LH,-LNH-0 
OMe 
0 
II 
O=S-Ph 0 
MeOVI II -0 I : N-CH2-C-NH I 
:
N 
0 Ph 0 
II I II 
"·-
1
-N-CH,-C-NH
D 
0 
II 
O=S-Ph 0 
c,
'(t.
1 II -0 : I N-CH2-C-NH I 
#
N
OMe 
0 
II 
O=S-Ph 0 
M
LH,-LNH-0 
MeO OMe 
# 
0 
II 
O=S-Ph 0 
c,
l):
1 II -0 I : 
:
-m,-c-NH I :N 
0 
II 
O=S-Ph 0 
ec:
-cH,-LNH-0 
0 
II 
O=S-Ph 0 
F
<,O-Lm,-LNH-0 
5.81 
-17.98 
14.32 
9.47 
175.99 
101.94 
47.36 
-4.81 
-34.97 
11.63 
-0.87 
18.89 
8.13 
242.64 
64.11 
96.38 
66.03 
1.57 
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6.68 10.85 12.12 
-6.22 8.95 34.80 
21.95 11.00 5.37 
1.14 9.65 17.53 
-4.89 67.39 82.06 
147.62 23.51 33.40 
149.97 16.39 49.25 
110.41 -8.22 10.23 
5.41 9.28 3.35 
�OMe 
I 
MeO 
N:::::,' 
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o
-NH-
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II # 
0 
0 
II 
MeO
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1
-Me O 
N-CH 
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OMe 
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28.86 31.81 50.71 
109.26 242.42 238.88 67.44 84.57 
-29.61 38.78 70.92 -20.58 27.93 
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V9M-SC3 V9M-SC3 
UTSW ID 
Reporter 
activity 
(2.5 µM) 
(%) 
SW054384 116.34 
SW202939 75.34 
SW202942 52.69 
Reporter 
activity 
(7.5 µM), 
% 
147.89 
127.84 
104.86 
TABLE 19 
Lsl 74T- Lsl 74T-
SC1 SC! 
V503-
3H9-7 
V503-
3H9-7 
reporter reporter reporter reporter 
activity, % activity, % activity, % activity, % 
(2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
129.91 155.75 148.89 157.49 
75.46 166.46 26.60 27.30 
53.59 122.86 37.26 86.87 
Enzyme 
inhibition 
% 
(2.5 µM
)
 
20.17 
53.54 
48.39 
Enzyme 
inhibition 
% 
(7.5 µM) 
58.20 
78.32 
64.86 
Enzyme 
inhibition 
(IC50) 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%
) 
41.96 
Decrease 
of 
coloning 
formation 
% 
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SW202945 
SW202949 
SW202950 
TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter Reporter SC! SC! 3H9-7 3H9-7 
activity activity reporter reporter reporter reporter 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % 
(%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
28.49 89.98 45.67 134.54 33.99 127.43 
5.76 -5.69 -1.58 -5.87 -12.46 5.32 
12.59 23.87 -2.70 10.69 -6.56 12.95 
Decrease Decrease Decrease 
Enzyme Enzyme PGE-2 Cell of 
inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
% % inhibition A549, A549 cell formation 
(2.5 µM) (7.5 µM) (IC50) %) (%) % 
8.83 11.07 
...... 
O'I ...... 
12.52 34.37 
�'° 
�N 
vJ 
vJ 
N 
46.26 56.39 
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O'I 
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TABLE 19-continued 
V9M-SC3 V9M-SC3 
UTSW ID 
Reporter 
activity 
(2.5 µM) 
(%) 
SW202953 12.97 
SW202954 2. 70 
SW202944 -0.95 
Reporter 
activity 
(7.5 µM), 
% 
34.79 
4.80 
-3.73 
Lsl 74T - Lsl 74T -
SC1 SC! 
V503-
3H9-7 
V503-
3H9-7 
reporter reporter reporter reporter 
activity, % activity, % activity, % activity, % 
(2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
20.69 30.69 31.98 50.93 
-4.59 -6.99 -8.94 2.39 
32.47 15.76 130.94 94.57 
Enzyme 
inhibition 
% 
(2.5 µM) 
8.81 
6.02 
28.28 
Enzyme 
inhibition 
% 
(7.5 µM) 
15.06 
9.88 
57.78 
Enzyme 
inhibition 
(IC50) 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
Decrease 
of 
coloning 
formation 
% 
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TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
Q
SW202948 -21.99 -23.05 -6.73 8.36 16.44 7.54 28.27 56.73 
...... 
NH O'I 
HN�O 
Ul 
M-0-0-0Me 
Q
SW202947 21.89 2.57 52.05 21.22 142.96 97.85 28.80 59.19 
�'° 
F NH �N 
Q-L�o vJ vJ to 11-b- N 
Me� 
\
--
;) 
OMe 
Q
SW202952 -20.74 -19.53 -10.30 10.58 26.18 7.16 29.01 57.03 
...... 
O'I 
O'I 
NH 
>-N�O 
:-0-o-OMe 
TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
Q
SW202940 146.58 181.17 147.86 210.71 180.73 182.58 24.30 63.29 -5 µM 80.46 45.18 
...... 
NH O'I M.,-o-Lr--<o -....J - 11
-0-Me� \--1 OMe 
Q
SW202942 1.00 32.05 46.96 86.98 95.39 129.34 -3.72 28.87 
�'° 
MeO NH �N Q-Lho vJ vJ to 11
-0-
N 
Me� \--j OMe 
Q
SW202943 7.12 17.84 33.07 55.73 72.27 146.87 -7.42 21.84 
...... 
O'I 
0- ��-Nr--<O 11
-0-Me� \--# OMe 
TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter Reporter SC! SC! 3H9-7 3H9-7 
activity activity reporter reporter reporter reporter 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
Cl SW202946 64.59 -41.52 105.33 -23.62 136.73 34.27 
� 
NH 
o-Lr-{11-0-Me� \--j OMe 
OEt SW202951 4.56 17.661 34.26 47.64 97.53 131.49 
O-Lr-<o11-0-Me� \--j OMe 
OH SW122063 1.67 4.80 22.56 19.86 42.51 44.12 
O r--< 0-�-N Ollh 
- Me�
--\__)-
OMe 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
81.60 89.84 
-15.43 -8.59 
-12.23 -10.49 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
-1.01 
Decrease 
of 
coloning 
formation 
% 
...... 
O'I 
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TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
Q
SW202938 154.92 230.12 216.99 240.95 309.09 300.99 52.66 75.64 2.67 µM -47.55 
...... 
NH -....J 
O-Lr-\o
...... 
11-0-Me� \--# OMe 
QN SW202941 -10.89 2.57 -23.79 -43.20 75.94 83.54 10.86 35.61 �'° 
NH 
�N 
O-Lr-\o vJ vJ to 11-0- N Me� \--# OMe 
Q-°\ 
SW202965 -30.92 -25.80 -23.51 3.52 23.76 98.06 11.26 33.13
...... 
-....J 
NH 
N 
O-Lr-\o11-0-Me� \--# OMe 
TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
Q
SW202966 -0.84 67.67 1.82 78.15 115.05 248.97 44.66 61.39 
...... 
-....J 
NH 
o-Lr-{11-0-Me� \--j OMe 
c 
(/). 
Q-
SW202967 -15.98 0 -11.69 9.37 34.05 69.62 -11.56 0.94 �'° 
-....J 
\0 
0 
�N 
NH vJ 
O-Lr-{ 
vJ 
to 
N 11-0-Me� \--j OMe 
q
SW202968 -21.10 -7.36 -17.50 6.08 35.18 53.87 -7.09 0.78 
...... 
-....J 
NH 
O-Lr-{11-0-Me� \--j OMe 
TABLE 19-continued
V9M-SC3 V9M-SC3 Lsl 74T- Lsl 74T - V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
--Q 
SW202969 -20.96 -14.30 -15.87 17.90 62.42 126.16 0.91 9.43 
...... NH -....J 
O-Lr-{ 
Ul 
11-b-Me� \--
;f 
OMe 
Cl SW202970 32.74 17.81 47.94 55.89 179.12 121.93 17.46 48.04 �'° 
Q �N vJ vJ to 
NH N 
0-Lt\ 11-b-Me� \--
;f 
OMe 
...... 
-....J 
0 
0--< 
SW202971 -14.51 9.67 -7.91 34.55 85.50 169.04 -0.72 -13.18 O'I 
0-LN
r-<O11-b-Me� \--
;f 
OMe 
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NH Cl 
0-�-N�O IIM 
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-\__j-
OMe 
V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW202972 -15.42 
SW202973 -15.63 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
0.14 -17.45 16.64 39.42 100.21 
5.61 -16.38 19.29 41.53 106.91 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
-6.29 -2.94 
3.3 13.55 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
Decrease 
of 
coloning 
formation 
% 
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-....J 
-....J 
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-....J 
QO 
c 
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-....J 
\0 
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�N 
vJ 
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TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T- Lsl 74T- V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
<=� 
SW202974 -9.04 35.90 -8.77 34.79 59.88 179.28 -4.42 24.85 
...... 
-....J 
NH 
o-Lr-{11-b-Me� \--j OMe 
c 
(/). 
Cl SW202977 -8.69 26.22 -16.61 15.09 16.92 85.24 -14.95 -8.63 �'° 
<=� 
-....J 
\0 
0 
�N 
vJ 
vJ 
NH to 
o-Lr-{ 
N 
11-b-Me� \--j OMe 
o 
o
-0
SW202978 -13.81 -0.07 -10.05 20.43 46.77 116.46 4.14 3.12 
...... 
QO 
0 
0-L[--{o11-b-Me� \--j OMe 
Structure 
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Cl 
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V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW202979 -14.44 
SW202980 -27.55 
SW202985 -27.34 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
10.79 -8.92 17.83 41.64 133.05 
-13.39 -7.34 5.17 11.41 50.62 
-21.87 -4.89 26.32 79.56 149.89 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
3.92 6.24 
-4.19 1.44 
13.79 30.87 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
Decrease 
of 
coloning 
formation 
% 
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QO ...... 
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N 
c 
(/). 
�'° 
�N 
vJ 
vJ 
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Structure 
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OMe 
V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW202986 -22.86 
SW202987 -22.01 
SW202988 7.36 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
-9.60 0.21 33.80 60.17 175.41 
-21.03 -8.30 20.65 70.129 145.13 
54.41 40.50 125.44 125.39 258.27 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
-2.22 2.58 
4.61 6.13 
10.27 33.70 -10 µM 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
-16.79 
Decrease 
of 
coloning 
formation 
% 
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TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
Q
SW202989 187.65 183.80 158.81 171.45 207.62 213.94 81.32 89.86 427 nM 69.40 30.59 
...... 
NH QO 
\-0-Lr{
Ul 
- 11-0-Me� \_--# OMe 
c
,
-q 
SW202990 3.57 23.49 32.01 106.56 172.00 214.22 22.88 47.16 
�'° 
-.....) 
\0 
0 
NH �N 
O-Lr-\o vJ vJ to 11-0- N Me� \_--# OMe 
Q-
SW202975 -26.64 -8.97 -7.32 17.21 47.35 116.21 -14.82 4.53 
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QO 
O'I 
NH 
O-Lr-\o11-0-Me� \_--# OMe 
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V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW202976 -18.51 
SW202991 -25.03 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
9.60 -9.97 30.14 36.75 138.31 
-7.50 -15.58 2.09 -6.08 8.90 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
7.87 29.78 
-14.71 -6 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
Decrease 
of 
coloning 
formation 
% 
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V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW131633 77.21 
SW203682 15.31 
TABLE 19-continued 
V9M-SC3 Lsl 74T- Lsl 74T- V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
140.98 8.42 149.84 103.52 -40.56 
22.45 187.26 13.76 -32.19 79.19 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
23.13 35.21 
15.73 36.23 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
Decrease 
of 
coloning 
formation 
% 
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V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW203683 137.32 
SW131635 11.39 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
190.83 3.76 209.77 103.81 -41.03 
15.05 110.93 14.07 -37.66 14.39 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
23.41 57.09 -7 µM 
11.80 35.44 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
-3.41 
Decrease 
of 
coloning 
formation 
% 
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V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW203684 50.72 
SW203685 99.95 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
74.89 170.37 119.07 81.19 52.46 
204.48 22.34 253.97 121.53 -33.18 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
36.35 64.72 
44.34 73.30 5 µM 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
17.84 
Decrease 
of 
coloning 
formation 
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TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T- Lsl 74T- V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
O-t�o-; SW203686 15.05 30.30 116.07 28.49 -11.03 65.60 14.86 34.24 ...... l,O 
-....J O�/ 
c5
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TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter Reporter SC! SC! 3H9-7 3H9-7 
activity activity reporter reporter reporter reporter 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % 
(%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
28.25 47.51 1.75 56.00 45.74 -41.65 
12.10 6.04 12.59 14.75 -28.10 -99.52 
7.78 19.82 5.47 22.03 47.07 90.04 
Decrease Decrease Decrease 
Enzyme Enzyme PGE-2 Cell of 
inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
% % inhibition A549, A549 cell formation 
(2.5 µM) (7.5 µM) (IC50) %) (%) % 
15.07 33.55 
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l,O 
l,O 
13.13 39.96 �'° 
-.....) 
\0 
0 
�N 
vJ 
vJ 
N 
2.62 3.12 36.76 0.00 
N 
0 
0 
TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503- Decrease Decrease Decrease 
Reporter Reporter SC! SC! 3H9-7 3H9-7 Enzyme Enzyme PGE-2 Cell of 
activity activity reporter reporter reporter reporter inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % % % inhibition A549, A549 cell formation 
Structure UTSW ID (%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) (IC50) %) (%) % 
� 
SW203703 108.15 105.91 85.80 80.20 142.81 77.97 26.50 58.88 31.90 -1.97 
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V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW203736 132.36 
SW203737 93.37 
SW208001 19.59 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
145.08 126.75 155.67 244.43 203.63 
103.47 76.65 85.09 175.94 153.58 
23.31 -0.61 1.87 -4.07 6.68 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
1.70 24.86 
23.81 42.45 
21.79 27.74 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
31.86 -3.06 
47.78 -2.56 
Decrease 
of 
coloning 
formation 
% 
2.5 µM 
(3.12%), 
7.5 µM 
(5.18%) 
2.5 µM 
(10.25%), 
7.5 µM 
(82.15%) 
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V9M-SC3 
Reporter 
activity 
(2.5 µM) 
UTSW ID (%) 
SW208002 -12.39 
SW208003 13.32 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter SC! SC! 3H9-7 3H9-7 
activity reporter reporter reporter reporter 
(7.5 µM), activity, % activity, % activity, % activity, % 
% (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
-21.84 -14.51 -14.57 -15.65 -16.54 
-11.46 37.00 45.62 117.02 75.883 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
34.73 59.23 
15.19 20.91 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
Decrease 
of 
coloning 
formation 
% 
N 
0 
Ul 
N 
0 
O'I 
c 
(/). 
�'° 
-.....) 
\0 
0 
�N 
vJ 
vJ 
to 
N 
Structure 
� 
� ' \DI HN�N/\ o o,� I 
0 
I I 
'Y � 
HN \D1 �N/\ o o,� I 
0 
I 
UTSW ID 
SW208004 
SW208005 
TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter Reporter SC! SC! 3H9-7 3H9-7 
activity activity reporter reporter reporter reporter 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % 
(%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
43.68 76.14 62.19 118.21 146.61 176.82 
42.44 19.75 63.86 53.93 102.72 61.24 
Decrease Decrease Decrease 
Enzyme Enzyme PGE-2 Cell of 
inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
% % inhibition A549, A549 cell formation 
(2.5 µM) (7.5 µM) (IC50) %) (%) % 
52.33 57.00 
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TABLE 19-continued 
V9M-SC3 V9M-SC3 
UTSW ID 
SW208006 
Reporter 
activity 
(2.5 µM) 
(%) 
34.85 
SW208007 -25.48 
Reporter 
activity 
(7.5 µM), 
% 
0.15 
-26.41 
Lsl 74T - Lsl 74T -
SC1 SC! 
V503-
3H9-7 
V503-
3H9-7 
reporter reporter reporter reporter 
activity, % activity, % activity, % activity, %
(2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
38.20 42.18 89.69 43.90 
-9.01 -5.15 -3.17 -2.10 
Enzyme 
inhibition 
% 
(2.5 µM) 
15.71 
48.27 
Enzyme 
inhibition 
% 
(7.5 µM) 
24.78 
38.41 
Enzyme 
inhibition 
(IC50) 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in
A549, A549 cell 
%) (%) 
Decrease 
of 
coloning 
formation 
% 
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TABLE 19-continued 
V9M-SC3 V9M-SC3 Lsl 74T - Lsl 74T - V503- V503-
Reporter Reporter SC! SC! 3H9-7 3H9-7 
activity activity reporter reporter reporter reporter 
(2.5 µM) (7.5 µM), activity, % activity, % activity, % activity, % 
(%) % (2.5 µM) (7.5 µM) (2.5 µM) (7.5 µM) 
33.54 36.63 41.98 70.53 121.50 138.25 
-5.96 -0.92 -2.16 10.01 31.93 39.63 
59.48 71.03 87.60 94.08 148.77 156.90 
Decrease Decrease Decrease 
Enzyme Enzyme PGE-2 Cell of 
inhibition inhibition Enzyme (IL-1 beta- viability in coloning 
% % inhibition A549, A549 cell formation 
(2.5 µM) (7.5 µM) (IC50) %) (%) % 
5.82 12.47 
N 
...... ...... 
58.70 70.90 
c 
(/). 
�'° 
�N 
vJ 
vJ 
N 
-7.08 -0.86 
N ...... 
N 
V9M-SC3 
Reporter 
Structure 
activity 
I 
msw ID 
05 ""1 
0 � ('Yo'- 1 swwms ;::,NIT \N ON
/\ 
0 
o
-........._ 
-..........
0 
0 ('Y
o
-........._ 
N 
o\
A)
TIN/\
0 0 ,:::::," -.......... 
-..........a 
� I 
SW207999 128.11 
TABLE 19-continued 
V9M-SC3 Lsl 74T - Lsl 74T -
Reporter SC! SC! 
activity reporter reporter 
(7.5 µM), activity,% activity,% 
% (2.5 µM) (7.5 µM) 
58.94 65.15 76.99 
124.32 98.00 122.98 
V503-
3H9-7 
reporter 
activity,% 
(2.5 µM) 
143.67 
123.99 
V503-
3H9-7 
reporter 
activity,% 
(7.5 µM) 
147.18 
110.28 
Enzyme Enzyme 
inhibition inhibition Enzyme 
% % inhibition 
(2.5 µM) (7.5 µM) (IC50) 
8.09 14.38 
-0.86 3.34 
Decrease Decrease 
PGE-2 Cell 
(IL-1 beta- viability in 
A549, A549 cell 
%) (%) 
Decrease 
of 
coloning 
formation 
% 
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Data provided include level of induction of a 15-PGDH­
luciferase fusion gene reporter, recorded as % induction of 
luciferase activity over basal level, in three colon cancer cell 
lines, V9m, V503, and LSI 74T, engineered to contain the 
reporter, and treated with either 2.5 uM or 7.5 uM com- 5 
pound. Also recorded for some compounds is the inhibition 
of enzyme activity of recombinant 15-PGDH protein treated 
with 2.5 µM or 7.5 µM compound. Also recorded for some 
compounds is the IC50 of each compound for inhibiting 
enzymatic activity of recombinant 15-PGDH in an in vitro 
10 assay. Additionally, for selected compounds is recorded the 
decrease in PGE2 levels in the media of compound treated 
A549 cells that have been stimulated with IL-1 beta. Addi­
tionally recorded for selected compounds is the effect on 
A549 cell viability as measured by a CellTiter-Glo assay, 
and the effect of compounds onA549 cell colony formation. 15 
We first note that the amino group participating in the 
peptide bond in SW054384 can be modified as shown in 
compound MCD-03-025, and that the derived compound 
retains the ability to activate expression of the 15-PGDH­
luciferease reporter in reporter cell lines, and indeed shows 20 
lesser inhibition of recombinant 15-PGDH at 2.µM in the 
test tube than does parent compound SW054384. 
We also note that addition to the phenyl ring of 
SW054384 of fluorine (SW203736) or bromine 
(SW203737), is well tolerated, and yields a compound that 25 
is active in inducing 15-PGDH-luciferase reporter activity in 
cell lines, is similar or improved compared to parental 
SW054383 in minimally inhibiting recombinant 15-PGDH 
at 2.5 uM, and is similar or improved versus parental 
SW054384 in decreasing PGE2 levels in the media of 
30 compound treatedA549 cells that have been stimulated with 
IL-1 beta. The phenyl ring of SW054384 also tolerates 
addition of a methoxy group (SW202940), which yields a 
compound that is that is active in inducing 15-PGDH­
luciferase reporter activity in cell lines, and is similar to 
parental SW054384 in not inhibiting recombinant 15-PGDH 35 
at 2.5 uM. 
216 
General Procedure 1 : 
NH2 
I 
(Het)Ar 
0 
Br, Jl 
I 'Br 
R1 
Procedure 
O'C.-R.T. 
Dioxane/DMF 
120° C. -
(Hetero )aryl amine was dissolved in 1: 1 mixture ofDMF/ 
dioxane (1.215 M based on amine) and cooled to 0° C. 
Bromoacetyl bromide (1.26 equiv) added drop-wise and 
We also note the favorable properties of compound 
SW125591, also denoted SW125991, which converts the 
nitrogen in the SW054384 peptide bond from an (Aryl)­
NH- group into a cyclic amine. This compound retains 
activity in induction of the 15-PGDH-luciferase reporter 
assay. It shows less inhibition of 15-PGDH at high com­
pound concentration than does the lead enzyme activator 
SW054384. SW125991 shows similar activity to SW054384 
40 
allowed to warm to room temperature overnight. Dioxane
and excess acid bromide were removed under reduced 
pressure, and 2,5-dimethoxy aniline (3.5 equiv) was added. 
The crude material was heated to 120° C. for three hours. 
The reaction was cooled to room temperature, diluted with 
EtOAc, and filtered through celite. The filtrate was washed 
with water (3x), sodium bicarbonate, and brine. The organic 
phase was dried with MgS04 and concentrated to give crude 
amide (1 ). The product was further purified by flash chro­
matography to afford pure N-aryl glycinamide 1. 
in reducing PGE2 levels in ILi-beta stimulated A549 cells. 45 
SW125991 shows no toxicity as assessed by effect on 
CellTiter-Glo assays done at 24 hours. Moreover, 
SW125991 shows marked improvement in metabolic sta­
bility. 
We also note the favorable properties of compounds 
SW207997, SW207998, and SW207998. These three com­
pounds, like SW125991, have all converted the nitrogen in 
the SW054384 peptide bond from an (Aryl)-NH- group 
into a cyclic amine. In addition, SW207997, SW207998, and 
SW207998, have all added a methoxy group to the phenyl 
ring in SW054384. SW207997, SW207998, and SW207998 
50 
N-Aryl glycinamide (1) was dissolved in CH2Cl2 (IM).
Pyridine (4.9 equiv) and sulfonyl chloride (2) were added 
(1.3 equiv) and the reaction was stirred overnight. The 
solution was diluted with EtOAc, washed with water (3x) 
and brine, dried over MgS04 and concentrated under 
55 
reduced pressure to give crude sulfonamide 3. The product
was purified by flash chromatography. 
all show activity equal to, or in some assays greater than, 
SW054384 in inducing the 15-PGDH-luciferase gene fusion 
reporter construct, and all show much less inhibition of 
enzymatic activity of 15-PGDH at 2.5 µM and 7.5 µM than 60 
does SW054384. 
EXAMPLE 12 
The following Example describes the synthesis of 65 
SW054384 and analogues thereof as well as provides mass 
spectrometry NMR confirmation of the structures. 
General Procedure 2: 
Pyridine 
4 
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-continued
A: T 3P, R3�NH or 
B: EDCl, R3NH2 or 
C: EDCl, DMAP, R30H 
SA:X�N� 
SB:X�NH 
SC:X�O 
Aniline 4 (1 equiv) was dissolved in CH2Cl2 (1 M based 
on 4). DMAP (0.3 equiv) and pyridine (4.9 equiv) were 
218 
extracts were washed again with water followed by brine, 
dried with MgS04, and concentrated under reduced pressure 
to provide an oil. Addition of hexanes resulted in precipi-
5 tation of the crude product, which was isolated by filtration
and used without purification. 
Ester 6 was dissolved in 3:3: 1 ratio of MeOH:THF:Water. 
Lithium hydroxide was added and the reaction was stirred 
10 
until complete (1-3 hrs). The reaction was concentrated 
under reduced pressure and then diluted with CH2Cl2. The 
acid (7) was extracted into saturated sodium bicarbonate. 
The aqueous layer was neutralized with IM HCl (pH -5) 
and extracted with CH2Cl2 to afford 7, which was used 
15 
without purification. 
General Procedure 2A 
Acid 7 (1 equiv) was dissolved in EtOAc (2 vol). Pyridine 
(1 vol) and secondary amine (1.1 equiv) were added fol-
20 lowed by T3P (2 equiv, 50% in EtOAc) and reaction was
stirred overnight. The reaction was quenched with HCl (0.5 
M, 3 vol), and the mixture was diluted with EtOAc, washed 
with water, bicarbonate, and brine, dried with sodium sulfate 
and concentrated. Compound SA was purified by flash 
chromatography. 
General Procedure 28 
Primary amine (1 equiv), DMAP (0.3 equiv) and EDCI 
30 (1.3 equiv) were added to a solution of acid 7 (1 equiv) in 
CH2Cl2 (0.5 M). The reaction vial was purged with nitrogen 
stirred for 12-24 h. The reaction mixture was diluted with 
CH2Cl2 and washed with brine, water, HCl (1 M), sodium 
35 bicarbonate and brine again. The organic layer was dried
with sodium sulfate and concentrated to afford 88. If 
added followed by sulfonyl chloride 2 (1 equiv). The reac- needed, the compound was purified by flash chromatogra-
tion was stirred for 36 hours, diluted with CH2Cl2 and phy. 
washed with water, HCl (1 M), sodium bicarbonate, and 
40 
General Procedure 2C: 
brine. The organic layer was dried over MgS04 and solvent 
was removed under reduced pressure to afford 5. 
Without purification, secondary sulfonamide 5 (1 equiv) 
was dissolved in a solution of DMF (0.1 M) and ethyl bromo 
45 
acetate ( 4 equiv). This solution was added drop-wise to 
sodium hydride at 0° C. After bubbling ceased, the reaction
was warmed to room temperature and left stirring overnight. 
After 12-18 hours, water was added and the aqueous phase 
was extracted 3 times with CH2Cl2. The combined organic 
Alcohol (4 equiv), DMAP (0.3 equiv) and EDCI (1.1 
equiv) were added to a solution of acid 7 (1 equiv) in CH2Cl2 
(0.5 M) at 0° C. After five minutes the reaction was allowed
to warm to room temperature and was stirred until complete. 
The reaction mixture was diluted with CH2Cl2 and washed 
with brine, HCl (1 M), and water. The organic phase was 
dried with MgS04 and concentrated to afford the pure ester 
SC. 
General Procedure 3 
Br 
�Br Pyridine 
THF 
10 
12 
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0 
R3 
� "-N 
I 
220 
_I_RI 
R4 HN
'O 
� I 
DCM,DMAP t 
R2S02Cl 
11 
Procedure: Pyridine (1.1 equiv) was added to a solution of 
secondary amine 9 in TI-IF (0.5M), and reaction mixture 
was cooled to 0° C. 8romoacetyl bromide (1 equiv) was then 
added drop-wise and reaction was warmed to room tem­
perature. The reaction was stirred for two hours at this 
temperature and then diluted with EtOAc and washed with 
water. The organic layer was dried with sodium sulfate and 
concentrated to afford bromo acetamide 10, which was 
purified by flash chromatography on silica gel. 
General Procedure 3A: A solution of amide 10 in DMF 
(0.075 M) was added to a solution of sulfonamide 12 (1.5 
equiv; synthesis identical to sulfonamide 5 in Procedure 2), 
potassium carbonate (2 equiv), and DMF (0.075 M). The
reaction was stirred overnight and then diluted with EtOAc
and washed with water and brine. EtOAc was removed
under reduced pressure to afford crude 12, which was
purified by flash chromatography on silica gel. 
General Procedure 38: A solution of amide 10 in DMF
(0.075 M) was added to a solution of aniline, potassium 
carbonate (2 equiv), and DMF (0.075 M). The reaction was
stirred overnight and was then diluted with EtOAc and
washed with water and brine to afford amide 11 crude, which
was used without purification. 
DMAP (0.3 equiv), pyridine (4.9 equiv) and then sulfonyl
chloride (1 equiv) were added to a solution of amide 11 in
CH2Cl2 (1 M). The reaction was stirred for 12-24 hours, 
diluted with CH2Cl2 and washed with water, HCl (1 M), 
sodium bicarbonate, and brine. The organic layer was dried
over MgS04 and compound concentrated under reduced
pressure to afford sulfonamide 12, which was purified by
flash chromatography. 
EXAMPLE 13 
Properties of Selected Analogues of Lead 
Compound SW054384, a 15-PGDH Activator
This Example provides data on properties of selected
analogues of SW054384. 
FIG. 81 shows structures of selected analogues of
SW054384. 
FIGS. 82(A-C) show graphs that show the level of activity 
SW203737 at these concentrations shows inhibitory activity 
15 
against recombinant 15-PGDH that is similar to SW054384. 
FIGS. 84(A-C) show at left (84A) activity in lowering 
PGE2 levels in media of A549 cells that are stimulated to 
produce PGE2 by treatment with ILl-beta. All of the com­
pounds tested, including SW054384, SW203703, 
20 SW125991, SW203736, and SW203737, show activity in 
lowering PGE2, consistent with their acting in vivo as 
inducers of 15-PGDH activity. FIG. 848 shows at right that 
none of the tested compounds demonstrate any toxicity 
against A549 cells as assessed by CellTitre-Glo assay levels 
25 at 24 hours of treatment. FIG. 84C shows at bottom photo­
graphs of A549 cells tested in the CellTitre-Glo assay
ordered left to right in the same order as in the graphical 
display of CellTitre-Glo data at upper right. 
FIG. 85 shows measurement of metabolic stability of 
30 SW054384 by incubation with murine liver S9 microsomes. 
Measured half-life is 21.72 minutes. SW054384 (2 mM in
DMSO) was incubated with Murine S9 (Lot KW8) fraction
and Phase I (NADPH Regenerating System) cofactors for
0-240 minutes. Reactions were quenched with a 1 mL (1:1)
35 ofMeOH/( + )IS/0.2% Formic Acid, vortexed for 15 seconds,
incubated at RT for 10 minutes and spun for 5 minutes at
2400 rpms. Supernatant (1 mL) was then transferred to an
eppendorftube and spun in a table top, chilled centrifuge for 
5 minutes at 13.2K rpms. Supernatant (800 µL) was trans-
40 ferred to an HPLC vial (w/out insert) and analyzed by 
HPLC/MS. A: dH20+0.1% FA 8: MeOH+0.1% FA 
FIG. 86 shows measurement of metabolic stability of
SW125991 by incubation with murine liver S9 microsomes. 
Measured half-life is 204 minutes. SW125991 (2 mM in
45 DMSO) was incubated with Murine S9 (Lot KW8) fraction
and Phase I (NADPH Regenerating System) cofactors for 
0-240 minutes. Reactions were quenched with 1 mL (1: 1) of
methanol containing 0.2% formic acid and 100 ng/ml IS (IS 
final conc.=50 ng/ml). Samples were vortexed for 15 sec-
50 ands, incubated at RT for 10 minutes and spun for 5 minutes 
at 2400 rpm. Supernatant (1 mL) was then transferred to an 
eppendorftube and spun in a table top, chilled centrifuge for 
5 minutes at 13.2K rpm. Supernatant (800 µL) was trans­
ferred to an HPLC vial (w/out insert). Analyzed by Qtrap 
55 3200 mass spectrometer. 
in inducing the 15-PGDH-luciferase fusion reporter in three 
different test cell line backgrounds, V9m, LSI 74T, and 
V503. Each compound was tested at two concentrations, 2.5 
uM, and 7 .5 uM. Y-axis is luciferase activity. Compounds 
active in inducing the 15-PGDH-luciferase reporter include 60 
FIG. 87 shows the structures of additional analogues of
SW054384. 
FIGS. 88-90 show graphs that show the level of activity 
in inducing the 15-PGDH-luciferase fusion reporter in three
different test cell line backgrounds, V9m, LSI 74T, and
V503. Each compound was tested at two concentrations, 2.5SW20370, SW203704, SW125991, SW203736, 
SW203737. 
FIG. 83 shows activity of tested compounds in inhibiting
enzymatic activity ofrecombinant 15-PGDH when tested at
high concentrations of 2.5 uM and 7.5 uM. SW125991 and
SW203736 show lesser inhibitory activity at high concen­
tration than the lead 15-PGDH activator, SW054384. 
uM, and 7 .5 uM. Y-axis is luciferase activity. Compounds
active in inducing the 15-PGDH-luciferase reporter include 
(but are not limited to): SW207997, SW207998, and 
65 SW207999. 
FIG. 91 shows activity of tested compounds in inhibiting 
enzymatic activity of 15-PGDH when tested at high con-
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centrations of 2.5 uM and 7 .5 uM. SW207997, SW207998, 
and SW207999 show lesser inhibitory activity at high con­
centration than the lead 15-PGDH activator, SW054384. 
FIG. 92 reprises structures of 15-PGDH activators 
SW054383, SW125991, SW207997, SW207998, 5 
SW207999. 
FIG. 93 shows graphical display of the activities of 
SW054383, SW125991, SW207997, SW207998, 
SW207999 in lowering PGE2 levels in medium of A549 
cells that have been treated with 2.5 µM of each compound 10 
for 24 hours, along with addition of 2.5 ng/ml ILi-beta for 
the last 16 hours of the incubation, and with then collection 
and assay of PGE2 concentration in the medium at the 24 
hour time point. Activity of compounds in lowering 
15-PGDH in the ILi-beta stimulatedA549 cells is consistent 15 
with these compounds activating intracellular 15-PGDH.
FIG. 94 shows titration curves of 15-PGDH activator 
compounds in an assay measuring effects on PGE2 levels in 
the medium of A549 cells that have been stimulated with 
ILi-beta in the same experimental design described for FIG. 20 
93. At 100 nM concentration of drug, the greatest reduction
in levels of PGE2 in the medium are achieved by treating
cells with SW207997 or with SW207998, followed by 
SW125991. SW054384 and SW207999 attain comparable
levels of reduction of PGE2 in the medium at doses of 25 
between 0.5 µM-1.0 µM.
FIG. 95 shows assessment of toxicity of SW125991 by 
testing effect of increasing doses on colony formation of 
A549 cells, Vaco9M (V9m) cells, LSI 74T cells, and 
Vaco503 (V503) cells. No reduction of colony forming 30 
activity is seen at doses up to 7.5 µM compound. 
FIG. 96 shows assessment of toxicity of SW207997 by 
testing effect of increasing doses on colony formation of 
A549 cells, Vaco9M (V9m) cells, LSI 74T cells, and 
Vaco503 (V503) cells. No reduction of colony forming 35 
activity is seen at doses up to 7.5 µM compound. 
FIG. 97 shows assessment of toxicity of SW207998 by 
testing effect of increasing doses on colony formation of 
A549 cells, Vaco9M (V9m) cells, LSI 74T cells, and 
Vaco503 (V503) cells. No reduction of colony forming 40 
activity is seen at doses up to 7.5 µM compound. 
FIG. 98 shows assessment of toxicity of SW207999 by 
testing effect of increasing doses on colony formation of 
A549 cells, Vaco9M (V9m) cells, LSI 74T cells, and 
Vaco503 (V503) cells. No reduction of colony forming 45 
activity is seen at doses up to 7.5 µM compound. 
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R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and 
which is unsubstituted or substituted; 
R6 is a thiazolyl and R7 is selected from the group 
consisting of a substituted or unsubstituted aryl, het­
eroaryl, cycloalkyl, or heterocyclyl, and pharmaceuti­
cally acceptable salts thereof; and a pharmaceutically 
acceptable excipient. 
2. The pharmaceutical composition of claim 1, wherein n
is 1. 
3. A pharmaceutical composition consisting essentially of
a compound having the formula: 
and pharmaceutically acceptable salts thereof. 
4. A pharmaceutical composition comprising a compound
having the formula: 
0 
s
�
-
and pharmaceutically acceptable salts thereof wherein the 
composition includes greater than 99% by weight of the 
R( +) isomer of the compound and less than 1 % by weight of 
the S(-) isomer of the compound. While this invention has been particularly shown and 
described with references to preferred embodiments thereof, 
it will be understood by those skilled in the art that various 
changes in form and details may be made therein without 
departing from the scope of the invention encompassed by 
the appended claims. All patents, publications and refer­
ences cited in the foregoing specification are herein incor­
porated by reference in their entirety. 
5. The pharmaceutical composition of claim 1, wherein
50 
the compound inhibits 15-PGDH enzyme activity. 
The following is claimed: 
1. A pharmaceutical composition comprising: a com­
pound having the following formula: 
wherein n is 0-2; 
55 
60 
65 
6. The pharmaceutical composition of claim 1, wherein
the compound has the formula: 
0 
s� 
and pharmaceutically acceptable salts thereof. 
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7. A pharmaceutical compos1t10n comprising: a com­
pound that inhibits 15-PGDH enzyme activity, the com­
pound having the formula: 
wherein n is 0-2; 
R1 is a C1 _8 alkyl, which is linear, branched, or cyclic and
which is unsubstituted or substituted; 
R6 is a thiazolyl and R7 is selected from the group 
consisting of a substituted or unsubstituted aryl, het­
eroaryl, cycloalkyl, or heterocyclyl, and pharmaceuti­
cally acceptable salts thereof; and a pharmaceutically 
acceptable excipient. 
8. The pharmaceutical composition of claim 7, wherein n
is 1. 
10 
15 
20 
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9. The pharmaceutical composition of claim 8, wherein
R7 is a substituted or unsubstituted aryl.
10. The composition of claim 9, wherein the compound
has the formula: 
0 
\__ \____ 
and pharmaceutically acceptable salts thereof. 
* * * * *
